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ABSTRACT 
  
Spinal cord injury (SCI) is a debilitating pathology that has increased in prevalence over 
the last few decades. Despite improvements in modern medicine leading to a normal life 
expectancy, there are limited treatment options and still no fully restorative therapies. 
Several experimental therapies have been employed to ameliorate the hostile injured 
environment, amongst which stem cell transplantation is a standout. Neural stem cell 
(NSC) transplantation has shown promising results in promoting functional recovery in 
SCI models. However, major accessibility, ethical and immunocompatibility issues 
impede their clinical translation. These barriers can be overcome through the use of 
induced neural stem cells (iNSCs), obtained by direct reprogramming of autologous 
somatic cells, leading to the possibility of fully immunocompatible transplants. 
However, stem cell transplantations in pre-clinical models of SCI showed only limited 
CNS repair and protection, likely due to limited capacity of transplanted cells to 
robustly integrate in vivo. In this perspective, we envision that a combination of 
interventions aiming to first modulate the injured microenvironment will create a more 
hospitable context for the subsequent stem cell transplantation. 
 
Expression of Lipocalin 2 (Lcn2), a siderophore-binding protein implicated in 
modulation of inflammatory response in CNS diseases, is upregulated in reactive 
astrocytes that play a major role in inhibiting regeneration in SCI. We aim to ameliorate 
the deleterious injured environment through the downregulation of Lcn2 expression by 
delivering packaging RNA (pRNA) nanostructures to create a more amenable niche for 
improving the engraftment and differentiation of transplanted iNSCs. To achieve this, 
we first established a reproducible and reliable in vitro protocol for NPC-derived 
astrocyte differentiation, a more homogeneous population compared to primary 
astrocyte cultures, subsequently employed for safety and efficacy screening of pRNA 
nanostructures. NPC-derived astrocytes showed mature astrocytic phenotype after 15 
days in vitro culture and gene expression changes upon activation, as observed in vivo. 
To silence Lcn2 expression we employed pRNA nanostructures, a bio-inspired 
construct and promising candidates amongst different nanotechnologies. Remarkably, 
pRNA transfection did not show any cytotoxicity on cultured astrocytes and we 
	observed a specific and significant decrease in the expression of target mRNA upon 
pRNA transfection, i.e. reduction of classical hallmarks of activated astrocytes (GFAP 
and vimentin upregulation) here assayed as a proof of concept, and significant reduction 
in Lcn2 expression as a new therapeutic target. Finally, before combining pRNA 
transfection and iNSC transplantation in vivo, we first aimed to characterize and 
compare the therapeutic efficacy of transplanted iNSCs with the well-described NPCs in 
a murine contusion model of SCI. Preliminary data showed a similar survival rate after 
transplantation between iNSCs and NPCs and interestingly a similar trend in 
improvements of fine locomotor recovery 7 weeks after transplantation. 
 
Therefore, transplantation of fully immunocompatible iNSCs represents an innovative 
and promising therapeutic approach for SCI and in vitro results obtained from Lcn2 
silencing showed encouraging results for a future promising combinatorial approach 
that aims at healing the injured environment and promoting functional recovery in SCI. 
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1) AIMS OF THE PROJECT 
 
Trauma to the spinal cord triggers the activation of a cascade of molecular and cellular 
events that ultimately leads to different degrees of paralysis in correlation with the 
severity and location of the initial trauma. Although it has been observed that neural 
tissue repair may spontaneously occur in patients affected by acute and chronic 
inflammatory and degenerative disorders of the nervous system, this process is not 
robust enough to promote a functional and stable recovery of the nervous system 
architecture [1]. Furthermore, despite initial surgical approaches, such as surgical 
decompression and stabilization of the spinal cord, corticosteroid administration and 
physical therapy aiming to minimize the damage to the spinal cord and optimize the 
functionality of spared connections [2], there are still no fully restorative therapies for 
SCI	[3].  
 
From this perspective, promotion of tissue repair and regeneration represents one of the 
most intriguing although challenging therapeutic approaches [4], and different 
experimental regenerative therapies have been developed in the last decades aiming to 
diminish or modulate the devastating consequences of SCIs [5]. Amongst these 
experimental therapies, stem cell transplantation has shown promising results in 
ameliorating the damaged environment and promoting functional recovery. Pluripotent 
embryonic stem cells, the recently developed induced pluripotent stem cells (iPSCs) and 
somatic neural precursor cells (NPCs) are characterized in vivo by remarkable 
intrinsically differentiation potential and potential to adapt their fate and functions to the 
specific microenvironment requirements. However, clinical translation of stem cell 
transplantation is limited by major issues of accessibility, immunocompatibility of cell 
sources, and ethical concerns; moreover, the lesion site in SCI pathology is an hostile 
and inhospitable environment that limits the survival, differentiation and engraftment of 
transplanted cells. To address the first translational issues, the use of induced neural 
stem cells (iNSCs) [6] can overcome allogeneic limits arising from transplantation of 
foetal NPCs used in clinical trials. However, the inhibitory nature of the injured site still 
represents the major impediment for a successful engraftment of transplanted cells	[7]. 
The major contributors to this hostile environment and inhibitory mechanisms are 
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represented by reactive astrocytes, thus combinations of strategies, such as stem cell 
transplantation augmented by modulation of secondary mechanisms, may lead to 
cumulative improvements in outcome after SCI [8]. Astrogliosis, as is called this 
phenomenon of reactivity observed in astrocytes, involves a broad range of mechanisms 
and its experimental modulation has yielded controversial outcomes. Indeed, it is now 
clear that complete ablation of reactive astrocytes leads to detrimental effects in SCI 
pathology [9]	[10], but on the other hand chronic astrogliosis can limit and inhibit 
axonal regeneration. Most of the approaches aimed at modulating two of the hallmarks 
of reactive astrocytes, i.e. upregulation of the intermediate filaments glial fibrillary 
acidic protein (GFAP) and vimentin, yielded controversial outcomes. The targeted 
ablation of reactive astrocytes after CNS injury, by using the mouse GFAP promoter in 
transgenic mice, showed an exacerbation of tissue degeneration [9, 11] suggesting that 
loss of astrocytes in the acute phase after CNS injury may lead to secondary 
degeneration of other cell types (Liu and others 1999; Zhao and others 2003), on the 
other hand some studies showed increased axon regeneration by deletion of GFAP and 
vimentin genes [12, 13]. More intriguingly, the application of siRNA targeting GFAP 
and vimentin in in vivo SCI models showed functional recovery and improvements in 
urinary dysfunctions, by injecting siRNA soon after the injury [14, 15]. Contrary to the 
knockout technique, the RNAi systems achieves downregulation of dysregulated 
mRNA/proteins without the loss of genomic information of the targeted gene; 
moreover, they allow for the possibility of modulating the extent and timing of gene 
regulation [16]. Thus, based on the dual role of astrogliosis in SCI, but more generally 
in CNS diseases, we strongly believe that a time-specific modulation of this 
phenomenon may lead to remarkable beneficial outcomes: while the presence of 
reactive astrocytes in acute stage of the disease would restrict the spread of secondary 
damages, their modulation in sub-acute stage would avoid the consolidation of such 
phenomena that have been shown to become detrimental, especially in the chronic 
phase. 
 
However, based on the fact that reactive astrocytes exert contradictory effects after CNS 
insults, beneficial or harmful depending o context and timing, it may be efficacious to 
look for new therapeutic targets that modulate these different activities in a controllable 
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fashion and test these mechanisms. Amongst potential candidates for modulation, 
Lipocalin 2 (Lcn2), a siderophore-binding protein implicated in the modulation of the 
inflammatory response in several CNS diseases, may represent a more promising target 
[17]. Indeed, silencing of Lcn2 in sub-acute phase may lead to a modulation of the 
inflammatory response and secondary damages upon SCI, creating a more favourable 
environment for iNSCs transplantation and engraftment.  
 
Small interfering RNA (siRNA) represents a great promise for targeted gene silencing 
in therapeutic applications, and advances in knowledge about the molecular 
mechanisms of endogenous RNA interference (RNAi) has been used to develop 
innovative nucleic-acid medicines as treatment of diseases, most commonly cancers 
[18]. However, clinical translation of RNA-based therapeutics is impeded by difficulties 
in delivery; nevertheless, over the last couple of decades nanotechnology has advanced 
the development of drug-delivery platforms, including siRNA–based drugs [19]. 
Specific to the purposes of this study, packaging RNA (pRNA) nanostructures, bio-
inspired constructs, are a promising example of this technology. Its advantageous size, 
thermodynamic stability,resistance to chemical denaturation, and modular nature make 
it a suitable candidate for translational approaches.  
 
Therefore, the overall goal of this project is to conduct preliminary investigations into a 
combinatorial approach for SCI therapy, aiming to ameliorate the deleterious injury 
environment through the downregulation of Lcn2 expression by delivering pRNA 
nanostructures, to ultimately create a more amenable niche for the engraftment and 
differentiation of therapeutically-potent transplanted iNSCs.  
 
Thus, the aims of this project have been: 
- establishment of a reproducible and reliable protocol for in vitro reactive astrocyte 
culture that would allow for screening of the safety and efficacy of pRNA 
nanostructures; 
- evaluation of the safety and efficacy of pRNA nanostructures in silencing Gfap and 
Vim genes as a proof of concept, and the evaluation of Lcn2 silencing in the perspective 
of a translational approach; and 
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- evaluation of the potential for clinical application of iNSCs compared to the most 
commonly used and characterized NPCs, by analysing the effects of subacute iNSC 
transplantation-induced functional recovery in a mouse model of moderate contusive 
spinal cord injury.  
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2) MATERIALS AND METHODS 
 
 
2.1 NEURAL PROGENITOR CELL (NPC) EXPANSION CULTURES 
Neural progenitor cells (NPCs) were isolated from the sub-ventricular zone (SVZ) of 
adult C57BL/6 mice as previously described [20]. NPCs were cultured as neurospheres 
in NPC proliferation medium: Neurocult basal medium (mouse; Stem Cell 
Technologies) containing 10% Neurocult proliferation supplement (mouse; Stem Cell 
Technologies), 2 µg/ml heparin (Stem Cell Technologies), 20 ng/ml recombinant 
human EGF (PeproTech), 10 ng/ml recombinant human FGF-basic (PeproTech), and 
100 U/ml penicillin-streptomycin (Gibco), and passaged every 3-5 days [21] in order to 
allow neurospheres to reach a diameter of 150-200 nm. To passage, NPC neurospheres 
were spun at 200 x g for 10 min and the pellet was enzymatically dissociated into single 
cells by resuspension in 200 µl Accumax (Sigma-Aldrich) and incubation for 10 min at 
37°C. Accumax was then inactivated by adding 800 µl of NPC proliferation medium at 
37°C. Cell densities were determined with a haemocytometer using Trypan Blue to 
stain for dead cells. NPCs were plated at a clonal density of 8,000 cells/cm², as 
described [22]: 200,000 in 5 mL for a T25 flask, 600,000 in 10 mL for a T75 flask, and 
1,400,000 in 15 mL for a T175 flask. All cells were cultured at 37°C in a humidified 
atmosphere of 5% CO2. All proliferating cell lines were routinely checked for 
Mycoplasma contamination. 
 
 
2.2 INDUCED NEURAL STEM CELL (INSC) EXPANSION CULTURES 
Induced neural stem cell (iNSC) lines from MEFs (mouse embryonic fibroblasts) were 
obtained from Frank Edenhofer (Stem Cell Engineering Group, Institute of 
Reconstructive Neurobiology, University Bonn). Cultures were started from a frozen 
vial of iNSCs (stored in liquid nitrogen), using iNSC proliferation medium: 1X N-2 
supplement, 100 U/ml penicillin-streptomycin, 10 ng/ml bFGF (PeproTech), and 10 
ng/ml EGF (PeproTech) in DMEM/F12 (Gibco).  
	 11	
Every other day, half of the total volume of the medium was added to the iNSCs. Cells 
were passaged every 5 days allowing neurospheres to reach a diameter of 150-200 nm. 
To passage, neurospheres were spun at 325 x g for 10 min and the pellet was 
enzymatically dissociated as for NPCs, with the difference that before counting for the 
cell density cells were spun again in order to remove Accumax and cells were 
resuspended in 1 ml of iNSC proliferation medium. Cell density was counted as for 
NPCs. iNSCs were plated at a clonal density of 10,000 cells/cm²: 250,000 in 5 mL for a 
T25 flask, 750,000 in 10 mL for a T75 flask, and 1,750,000 in 15 mL for a T175 flask. 
All cells were cultured at 37°C in a humidified atmosphere of 5% CO2. All proliferating 
cell lines were routinely checked for Mycoplasma contamination. 
 
 
2.3 NPC-DERIVED ASTROCYTE DIFFERENTIATION PROTOCOLS 
For adherent astrocyte differentiation, plastic plates or glass coverslips were coated with 
20 µg/mL poly-D-lysine (PDL) in sterile water at 37 °C for 3 h, before being washed 3 
times with sterile water and left to dry in sterile conditions. Single NPC-dissociated 
cells were plated at 80,000 cells/cm2 prior to differentiation in astrocyte media, yielding 
approximately 70-90% astrocyte confluence at the later time of analysis. 
 
NPCs were differentiated into astrocytes by using two different conditions: high-
FBS/FGF2-free condition or low-FBS/+FGF2 condition. NPC-derived astrocytes were 
cultured in high-FBS/FGF2-free conditions for 15 days; medium was refreshed every 3 
days by replacing half of the total medium volume. High-FBS/FGF2-free astrocyte 
differentiation medium was prepared by using low glucose Dulbecco’s Modified Eagle 
Medium (DMEM, 1 g/l glucose; Gibco) with 10% fetal bovine serum (FBS; Gibco), 1 
mM glutamine, and 100 U/ml penicillin-streptomycin. NPC-derived astrocytes cultured 
in low-FBS/+FGF2 conditions were first grown for 7 days in high-FBS medium: 
DMEM enriched with 10% FBS, supplemented with 50 ng/ml FGF2 (PeproTech); 
medium was refreshed every 3 days by replacing half of the total medium volume. After 
7 days, medium was completely replaced by low-FBS/+FGF2 medium: DMEM, 1% 
FBS, supplemented with 1X N-2 Supplement (Life Technologies) and 50 ng/ml FGF2.  
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NPC-derived astrocytes, both high-FBS/FGF2-free and low-FBS/+FGF2, were 
activated at day 13 (therapeutic activation) or at day 15 (preventative activation) by 
adding to the corresponding medium 2 µg/ml LPS (Sigma-Aldrich) and 3 ng/ml murine 
IFNγ (PeproTech).  
 
 
2.4 PRNA-3WJ  NANOSTRUCTURE DESIGN AND ASSEMBLY 
Packaging-RNA (pRNA)-based 3 way junction (3WJ)-siRNA were designed and 
assembled according to previously described methods[23], briefly elaborated as follows. 
pRNA 3WJs are characterized by three RNA strands: a 20-nucleotide B RNA strand 
common to each of the 3WJ structures and variable 41-nucleotide A and C RNA strands 
that contain the siRNA sequence distinct to each 3WJ. The siRNA sequences employed 
in the 3WJs described herein were derived from those used in the commercially-
obtained anti-Gfap, anti-Vim, anti-Lcn2, and non-targeting siRNA pools used as 
positive/negative controls in these experiments (Table 2.1).  
 
The common B RNA strand was purchased as a commercially-synthesised 
oligonucleotide stock (Sigma), whereas the A and C strands were generated by in vitro 
transcription of appropriate double-stranded (ds) DNA templates. These templates were 
purchased as individual, complementary DNA strands (Sigma), which were 
resuspended in Tris-EDTA (TE) buffer (10 mM Tris.HCl, 1 mM EDTA in nuclease-free 
water, pH 8.0) in order to obtain a stock concentration of 100 µM per strand. Equimolar 
amounts of each strand were annealed together in 1X Tris-Magnesium-Sodium (TMS) 
buffer (0.5 M Tris.HCl, 1 M NaCl, 100 mM MgCl2 in nuclease-free water) using a 
thermal cycler (5 minutes at 80°C before cooling by 1°C every 30 s until reaching a 
minimum of 4°C) and stored at -20°C. Each dsDNA template was designed with a 5ʹ T7 
RNA polymerase promoter sequence (TAA TAC GAC TCA CTA TTG G) to 
facilitate efficient transcription. Template concentrations were assayed using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific). 
 
Transcription of the A and C RNA strands was performed using a TranscriptAid T7 
High Yield Transcription Kit (Thermo Scientific). RNA products were isolated and 
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purified by DNase treatment and subsequent denaturing polyacrylamide gel 
electrophoresis (PAGE; 10% polyacrylamide (w/v) gel with 8 M urea in 1X Tris-
Borate-EDTA (TBE) buffer:  90 mM Tris base, 90 mM boric acid, and 2 mM EDTA in 
nuclease-free water, pH adjusted to 8.5). A 1:1 mixture of RNA transcript solution and 
2X denaturing loading buffer was loaded into the gel and electrophoresed at 120 V for 
1 h. The appropriate RNA bands were identified by UV shadowing, excised from the 
gel, and diced into small pieces that were transferred to 1.5 ml Eppendorf tubes. 
Subsequently, the gel pieces were eluted in a denaturing elution buffer (0.5 M 
ammonium acetate, 0.1 mM EDTA, 0.1% SDS) at 37°C for 2 h. The supernatant was 
collected and stored on ice while the gel pieces were subjected to a further hour of 
elution using a fresh aliquot of elution buffer. All fractions of each eluate were then 
combined into the same tube and the eluted RNA precipitated by the addition of 1/10 
equivalent volumes of 3 M sodium acetate (pH 5.2) and 2.5 equivalent volumes of 
100% ethanol. The solutions were mixed well and stored at -20°C overnight to allow 
them to precipitate. Samples were then centrifuged (16,500 g for 30 min at 4°C), 
supernatant was removed, and the pellet was washed in 500 µl of cold 75% ethanol with 
a further centrifugation (16,500 g for 15 min at 4°C). The supernatant was again 
discarded and the pellet briefly dried in a vacuum concentrator (SpeedVac, Thermo 
Scientific) prior to storage at -20°C until ready for 3WJ assembly. 
Before assembly, the transcribed A and C RNA strands and the B strand oligonucleotide 
were re-dissolved in RNase-free water and the concentration of each solution quantified 
using a NanoDrop. Where desired, RNA strands were labelled with a fluorophore (i.e. 
Cy3) using a Label IT Nucleic Acid Labeling Kit (Mirus BioScience) according to the 
supplier’s protocol, with subsequent ethanol precipitation (as above), re-dissolution and 
re-quantification. Transcription and labelling success was assayed using an additional 
denaturing PAGE gel, running approximately 500 ng of each RNA strand or complex in 
lanes alongside an Ultra Low Range DNA ladder (Thermo Scientific) to ensure the 
purity and the correct length of RNA strands. Fluorescently-labelled bands were 
identified by eye or using a ChemiDoc XRS+ system with the appropriate excitation 
wavelength, while non-labelled bands were identified by UV transillumination 
following staining with ethidium bromide or GelRed (Biotium). 
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Assembly of each 3WJ was achieved by combining equimolar amounts of the 
appropriate strands A and C with strand B in 1X TMS buffer, typically on a 50 µl scale 
in a 200 µl PCR tube. The solutions were then subjected to an annealing temperature 
profile in a thermal cycler, as follows: heating to 80°C, holding for 5 min before cooling 
1°C every 30 s until reaching a minimum temperature of 4°C. Assembled 3WJs were 
purified of excess single RNA strands or misassembled byproducts using native PAGE 
(10% polyacrylamide in 1X Tris-Borate-Magnesium (TBM) buffer: 90 mM Tris base, 
90 mM boric acid, and 5 mM MgCl2 in nuclease-free water, pH adjusted to 8.5) the gel 
was run at 100V for 2 h at 4°C to inhibit thermal denaturation. The 3WJ bands were 
identified by using UV shadowing, then cut from the gel and eluted with a non-
denaturing elution buffer: 0.5 M ammonium acetate, and 10 mM MgCl2. The assembled 
3WJs were ethanol precipitated from the collected eluate, re-dissolved in RNase-free 
water, and quantified using a NanoDrop. Success of assembly was assayed by running 
500 ng of each 3WJ in an additional non-denaturing PAGE gel alongside the Ultra Low 
Range DNA Ladder, as well as samples of single A, B, and C strands and annealed two-
strand constructs. Correctly assembled 3WJs showed lower gel mobility than did 
double- or single-stranded RNAs and were diluted to a stock concentration of 5 µM in 
1X TMS buffer solution for subsequent use. The resultant nanostructures – G10, V10, 
and L12 – possessed anti-Gfap, Vim or Lcn2 siRNA moieties, respectively, while the 
N03 negative control 3WJ possessed an siRNA sequence that does not match any 
known mammalian gene. 
 
 
RNA Sequence* Length Reference† 
3WJ Strand a 5'- GGN NNN NNN NNN NNN NNN 
NNN AAG GGU CAU GUG UAU GU 
GGG -3' 
41-nt n.a. 
3WJ Strand b 5'- CCC ACA UAC UUU GUU GAU CC -
3' 
20-nt n.a. 
3WJ Strand c 5'- GGA UCA AUC AUG GCC CAA 
NNN NNN NNN NNN NNN NN NNU 
UUU -3' 
41-nt n.a. 
Anti-GFAP moiety 5'- AGC ACG AAG CUA ACG ACU A -
3' 
19-nt J-043455-
10 
Anti-Vimentin moiety 5'- AGG AAG AGA UGG CUC GUC A -
3' 
19-nt J-061596-
10 
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Anti-Lipocalin 2 
moiety 
5'- GCG CAG AGA CCC AAU GGU U - 
3' 
19-nt J-042638-
12 
Non-Targeting moiety 5'- UGG UUU ACA UGU UUU CUG A -
3' 
19-nt D-001810-
03 
Table 2.1: Sequences of pRNA 3WJ strands.  
* Red nucleotides depict variable siRNA moiety 
† GE/Dharmacon catalogue number 
 
 
 
2.5 TRANSFECTION OF NPC-DERIVED ASTROCYTES WITH       
SIRNA/3WJS 
Intra-cellular delivery of RNAs was performed via transfection using the liposomal 
transfection agent Lipofectamine RNAiMAX (Life Technologies) on near-confluent 
astrocyte cultures. 
To compare the knock-down efficiency of 3WJs to commercial siRNAs, transfection 
was performed at day 15 on astrocytes cultured under high-FBS/FGF2-free resting 
conditions using three different concentrations of siRNA/3WJ: 5, 0.5 and 0.05 nM. 
Silencing experiments were performed under both resting and activation conditions 
(therapeutic and preventative) by transfection at day 15 of 5 nM concentrations of 
siRNA/3WJ. Immediately prior to transfection the astrocyte differentiation medium was 
replaced with low glucose (1 g/l) DMEM serum-free medium. Transfections were 
performed according to the protocol accompanying the Lipofectamine agent.  Briefly, 5 
µM stock solutions of the siRNAs or 3WJs of interest were diluted in DMEM and 
combined with an equivalent volume of DMEM containing Lipofectamine RNAiMAX 
(1:1 ratio of siRNA/3WJ to Lipofectamine solutions). The solution was mixed well and 
allowed to incubate for 10 minutes before being added to cells such that the final 
concentration of siRNA/3WJ was 5, 0.5, or 0.05 nM, as desired, in a 3 ml final volume 
of serum-free medium. Each experiment included controls for the transfection, such as 
mock transfections (Lipofectamine only, no RNA) and untreated control wells (DMEM 
only, no RNA or Lipofectamine). 6 hours after transfection the serum-free transfection 
medium in each well was replaced with the corresponding serum-containing medium. 
RNA samples were collected 48 hours post-transfection and proteins collected at 
different timepoints post-transfection (24 h and 48 h after transfection for Lcn2 
assessment, 120 h after transfection for GFAP and Vim assessment). 
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2.6 CYTOTOXICITY ASSAY 
The toxicity of siRNA-3WJ treatments were assessed by using LDH-Cytotoxicity Assay 
Kit II (Abcam), following the instructions provided. Lactate dehydrogenase (LDH) is a 
stable enzyme present in all cell types that is rapidly released upon damage of the 
plasma membrane. This assay kit is based on an enzymatic coupling reaction that allows 
for direct correlation of the intensity of a generated colour to the number of lysed cell. 
Supernatant was collected from each sample and spun at 600 x g for 10 min to 
precipitate any debris, 20 µl of each sample were transferred into an optically clear 96-
well plate as triplicates. The LDH reaction mix was reconstituted for 10 minutes and 
100 µl were added to each well, well-mixed and incubated for 30 minutes at room 
temperature. The absorbance of all wells was measured with an Infinite 200 plate reader 
(Tecan) set with a 440-490nm filter, and 650nm as reference wavelength. 
Toxicity/viability was normalised to non-transfected controls (100% viability) and 
samples lysed with a 10% v/v solution of Triton X-100 (0% viability). Assays were 
performed on the supernatant of low-FBS/+FGF2 astrocytes grown in 6-well plates, at 
timepoints of 24 h, 48 h and 120 h post-transfection. The 48 h and 120 h timepoints 
included a medium change at 6 h post-transfection. 
 
 
2.7 CONDITIONED MEDIUM EXPERIMENTS 
Confluent astrocytes were used for conditioned medium experiments. Donor astrocytes 
were transfected as described herein.  “Conditioning” astrocytes, activated with-or-
without a concomitant transfection with 5 nM L12-3WJ, were washed 2 times with PBS 
and medium was exchanged with low-glucose DMEM (containing 100 U/ml penicillin-
streptomycin) at 24 h post-transfection/activation. At 48 h post-transfection/activation 
this astrocyte conditioned medium (ACM) was collected and spun at 600 x g for 10 
minutes before 300 µl of sample was set aside for enzyme-linked immunosorbent assay 
(ELISA) experiments and the remainder (2 ml) transferred to recipient resting 
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astrocytes. After a further 24 h, the RNA of the recipient astrocytes was collected for 
qPCR analysis	
 
2.8 IMMUNOFLUORESCENCE  
Cells grown on PDL-coated glass coverslips were fixed in 4% paraformaldehyde (PFA) 
for 10 min at room temperature at the appropriate timepoint post-differentiation or post-
transfection. The coverslips were washed three times with 1X phosphate buffered saline 
(PBS) before being incubated in blocking solution (1X PBS containing 0.1% Triton X-
100 (Sigma-Aldrich) and 5% normal goat serum (NGS; Sigma) for 60 minutes at room 
temperature. Fixed cells were subsequently incubated in 60 µl of the same blocking 
solution containing the desired primary antibodies (Table 2.2) overnight at 4°C. The 
following day cells were washed 3 times in 1X PBS and incubated in 60 µl of blocking 
solution containing the species-appropriate fluorochrome-conjugated secondary 
antibodies (1:1000 dilution) for 60 minutes at room temperature. Coverslips were 
subsequently washed 3 times with PBS 1X before cell nuclei were counterstained with a 
1 µg/ml solution of 4′,6-diamidino-2-phenylindole (DAPI; Roche) in 1X PBS for 5 
minutes at room temperature. After a final wash, coverslips were mounted onto slides 
with fluorescent mounting medium (Dako). Images were acquired at 40X and 20X 
magnification using a Leica DM6000 vertical epifluorescent microscope, and images 
processed using the Fiji software package [24]. Consistent settings were used to acquire 
all images, using the appropriate filter set for each fluorophore/antibody combination. 
At least two independent coverslips were imaged for each biological replicate, each 
comprising 10 independent fields-of-view randomly distributed across distinct regions 
of the coverslip: 4 in the centre and 3 respectively in the upper and lower side of the 
coverslips. 
 
 
Antibody Supplier Dilution 
Chicken anti-GFAP Abcam 1:500 
Rabbit anti-GFAP Wako 1:500 
Chicken anti-Vimentin Abcam 1:500 
Rat anti-Lipocalin2 R&D Systems 1:250 
Mouse anti-S100B BD Bioscience 1:500 
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Mouse anti-Nestin Millipore 1:100 
Rabbit anti-β-tubulin III Covance 1:500 
Rabbit anti-cleaved Caspase III New England Biolabs 1:400 
Rabbit anti-pSTAT3 Cell Signaling 1:100 
Mouse anti-O4 R&D Systems 1:50 
Mouse anti-MAP2 Abcam 1:500 
   
AlexaFluor488 anti-chicken Invitrogen 1:500 
AlexaFluor488 anti-rabbit Invitrogen 1:500 
AlexaFluor546 anti-mouse Invitrogen 1:500 
AlexaFluor546 anti-rabbit Invitrogen 1:500 
AlexaFluor647 anti-rabbit Invitrogen 1:500 
Table 2.2: Antibodies used for ICC 
 
 
 
2.9 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
 
Levels of secreted murine Il6, Tnf and Lcn2 were quantified using sandwich ELISA 
development kits (Il6 and Tnf: BioLegend; Lcn2: R&D Systems). For Il6 and Tnf, 
2x106 NPCs were seeded in 10 ml of astrocyte medium on PDL-coated T25 plates. 
Medium was refreshed every 3 days, for which 3 mL was used for the assay. Before 
activation, medium was collected (i.e. 0 hours activation). Medium was collected at 6 h, 
12 h, 24 h, and 48 h post-activation. Collected medium was spun for 15 minutes at 
2,000 x g at 4°C and supernatant was collected and stored at -80°C. 96-well plates 
(Nunc-Thermo Scientific) were coated with 100 µL of Capture Antibody in PBS 1X 
overnight at room temperature. After 4 washes with washing buffer (PBS, 0,.05% 
Tween-20) wells were blocked with 200 µL of 1X Assay Diluent for 1 h at room 
temperature and subsequently washed 4 more times. Samples were diluted 9:10 with 
Assay Diluent and loaded in the plate in quadruplicate at 100 µL; astrocyte medium was 
loaded as blank. Antigen capturing took place for 2 h at room temperature, after which 
plates were washed 4 times, and incubated with 100 µL of Detection Antibody in for 1 
h at room temperature. After 4 more washes, 100 µL of 1:1,000 avidin-HRP in 1X 
Assay Diluent was added for 30 min at room temperature, then washed again 4 times 
before adding TMB Substrate Solution for 15 minutes in the dark at room temperature. 
Finally, 100 µL of Stop Solution was added. Using a microplate reader, optical densities 
were measured at 450 nm and 570 nm. 
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For Lcn2, pre-coated 96-well microplates (R&D Systems) were brought to room 
temperature, and 50 µL of standard, control and samples as triplicate were loaded into 
the wells and incubated for 2 hours at room temperature. After 3 washes with 400 µL of 
Wash Buffer, 100 µL of Mouse Lipocalin-2 Conjugate was added to each well and 
incubated for 2 hours at room temperature. After 3 more washes with 400 µL of Wash 
Buffer, 100 µL of Substrate Solution was added to each well for 30 minutes in the dark 
at room temperature. Then, 100 µL of Stop Solution was added to each well. Using a 
microplate reader, optical densities at were measure at 490 nm with wavelength 
correction at 570 nm. 
An eight point standard curve was generated using known concentrations of 
recombinant mouse Tnf (2 ng/ml, and a serial dilution of 1:2), recombinant mouse Il6 (4 
ng/ml, serial dilution 1:2), and recombinant mouse Lcn2 (5 ng/ml, serial dilution 1:2). 
The standard was diluted with either the supplied diluent, or with astrocyte 
differentiation medium to assess any possible interference in the detection of the 
cytokines of interest. Data analysis was performed by interpolating unknown 
concentrations with the recombinant mouse Il6, Tnf or Lcn2 standard curves after 
nonlinear regression fit, using the sigmoidal four parameter logistic dose-response 
variable slope curve on log-transformed data (as described in the GraphPad Prism 
manual). 
 
 
 
 
 
2.10 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QRT-
PCR) 
RNA extraction was performed using nuclease-free/diethyl pyrocarbonate (DEPC)-
treated water and surfaces were cleaned with RNaseZap (Thermo Fisher Scientific) to 
prevent RNase contamination. 
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Astrocytes were grown adherent to 6-well plates. At day 17, cells were aspirated and 
washed with 1X PBS (Gibco) and subsequently lysed by incubation at room 
temperature with 1 ml TRI Reagent (Sigma) per 10 cm² well for 5-10 min. TRI Reagent 
cell lysates were mixed with 20% vol. chloroform, incubated for 2-3 min and spun at 
12,000 x g for 15 min at 4 °C, allowing for phase separation. The RNA-containing 
upper aqueous phase was collected, added to an approximately equal volume of 
isopropanol, and incubated at room temperature for 10 minutes. To remove water-
soluble contaminants such as sugars and salts, RNA was precipitated by spinning 
samples at 12,000 x g for 30 min at 4 °C. Pellets were washed twice with 1 mL 75% 
EtOH, spun at 12,000 x g for 15 min at 4 °C, and decanted before being allowed to air-
dry under a fume hood and resuspended in 20 µL nuclease-free water. Samples were 
heated (55-60 °C) for 10 min, prior to quantification of concentration and purity using a 
NanoDrop spectrophotometer. RNA samples determined to have acceptable A260/A280 
and A260/A230  purity ratios were stored at -80 °C until further use.  
 
From 500 ng of total RNA, cDNA was generated using a High Capacity cDNA reverse 
transcription kit (Applied Biosciences) using random hexamer primers. Reverse 
transcription was performed using a T100 thermal cycler (Bio-Rad) and the following 
program: 10 min at 25 °C, 50 min at 50 °C, 5 min at 80 °C, and then held at 4 °C. 
qRT-PCR was subsequently performed using TaqMan reagents (TaqMan Fast Universal 
PCR Master Mix (2X) and FAM-labelled TaqMan Gene Expression Assays as listed in 
(Table 2.3) and an Applied Biosystems Quantstudio 7 real-time PCR system using the 
following program: 20 s at 95 °C, followed by 40 cycles of 3 s at 95°C – 30 s at 60°C. 
Where possible, exon-spanning TaqMan probes were used to control for possible 
genomic DNA contamination. Mouse Gapd (VIC-labelled, Life Technologies) was used 
as a reference gene for determining relative gene expression using the 2-ΔΔCt method 
[25]. Each biological sample was measured in triplicate. 
 
Target Gene TaqMan Assay 
Gfap Mm01253033_m1 
Vim Mm01333430_m1 
Lcn2 Mm01324470_m1 
Nes Mm00450205_m1 
Il6 Mm00446190_m1 
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Tnf Mm00443258_m1 
Ifnb1 Mm00439552_s1 
Nos2 Mm00440502_m1 
Ciita Mm00482914_m1 
Il1b Mm00434228_m1 
Tlr4 Mm00445273_m1 
Ifngr1 Mm00599890_m1 
Ifngr2 Mm00492626_m1 
Gapd 4352339E 
Table 2.3: TaqMan probes for qPCR  
 
 
2.11 WESTERN BLOTS 
Cells were collected from 6-well plates at appropriate time points post-transfection. 
Astrocytes, grown in adherent conditions in 6-well plates, were washed with 1X PBS (4 
°C). Cells were detached by scraping in 500 µl of 1X PBS (4°C) and transferred to a 2 
mL Eppendorf tube, to ensure the collection of all cells, wells were further washed with 
additional 500 µl of 1X PBS. Samples were spun at 500 x g for 20 min at 4°C and the 
supernatant was discarded. 
Proteins were extracted from the pellets by solubilisation in radioimmunoprecipitation 
assay (RIPA) buffer (Abcam) with the addition of Complete Protease Inhibitor Cocktail 
(Roche) and Halt Phosphatase Inhibitor Cocktail (Thermo Scientific), in addition to 1 
mM phenylmethanesulfonyl fluoride (Sigma) to inhibit serine proteases. Protein 
quantification was performed using a Pierce BCA Protein Assay kit (Thermo 
Scientific): 25 µl of diluted samples, in triplicate, and 25 µl of Diluted Albumin 
Standards were incubated with 200 µl of Working Reagent for 30 minutes at 37°C, prior 
to reading the optical density of the samples at 562 nm with a microplate reader.  
Sample volumes equivalent to 20 µg total protein were mixed with NuPAGE LDS 
Sample Buffer (Life Technologies), NuPAGE Sample Reducing Agent (Life 
Technologies), and distilled water to a final volume of 30 µl prior to being heated at 
95°C for 5 min. Proteins were separated by SDS-PAGE in a 10% gel using a Novex 
Bolt Mini Gel system and running buffer (Tris 25 mM, glycine 192 mM, SDS 10%) 
before being transferred onto Immobilon-P polyvinylidene fluoride membranes 
(Millipore, 0.45 µm pore size, methanol equilibrated) in transfer buffer (Tris 25 mM, 
glycine 192 mM, methanol 20%) for 1 h 45 min at 4°C using a Novex Bolt Mini Blot 
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Module. A SeeBlue Plus2 standard (Life Technologies) was used to estimate protein 
sizes, and transfer was confirmed by Ponceau S (Sigma) staining. For immunoblot 
analysis, membranes were blocked 1 hour at room temperature with 0.1% v/v Tween 20 
in a 5% w/v solution of dried skimmed milk powder (Marvel) in PBS (pH 7.4), and then 
incubated with primary antibodies overnight at 4°C (Table 2.4) diluted in antibody 
solution (0.1% Tween 20, 5% dried skimmed milk powder in PBS) to the appropriate 
concentration. After washing with PBS/0.1% Tween 20, the membranes were incubated 
at room temperature with the species-appropriate horseradish peroxidase-conjugated 
secondary antibodies (Thermo Scientific) for 1 hour at a 1:10,000 dilution in antibody 
solution. Immunoreactivity was revealed using Western Lightning Plus-ECL 
(PerkinElmer) and imaged using a Bio-Rad ChemiDoc XRS+ system with Image Lab 
5.1 software (Bio-Rad). Densitometry measurements were performed using Fiji 
(http://fiji.sc/Fiji) each protein band being normalised to the β-actin loading controls. 
 
Antibody Supplier Dilution 
Rabbit anti-GFAP Dako 1:10,000 
Mouse anti-VIM Abcam  1:500 
Rat anti-LCN2 R&D Systems  1:1,000 
Rabbit anti-pSTAT3 
(Tyr705) 
New England Biolabs  1:1,000 
Mouse anti-NOS2 BD Biosciences 1:2,000 
Mouse anti-ACTB Sigma 1:10,000 
Mouse anti-GAPDH Sigma 1:2,000 
Table 2.4: Antibodies for Western blot 
 
 
2.12 CONTUSION MODEL OF SPINAL CORD INJURY IN MICE 
Adult 6-to-8 week-old (20-22 g) male C57Bl/6 mice were obtained from Charles River 
(UK) and housed in specific pathogen-free conditions. Mice were deeply anesthetized 
with 2% isoflurane in oxygen (1.5 l/min). Buprenorphine (Temgesic, RB 
Pharmaceuticals) was provived pre- and post-operatively, in addition to enrofloxacin 
(Baytril, Bayer). The hair on the back of the mice was shaved and swabbed with a 
germicide prior to surgery. Under a surgery microscope, a midline incision was made 
over the thoracic vertebrae using a sterile scalpel, the muscles were separated from 
either side of the vertebral column using a spring scissor (Fine Science Tools), and 
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laminectomy was performed at T12 using Dumont #2 laminectomy forceps (Fine 
Science Tools) and spring forceps (Fine Science Tools). The lateral part of the vertebra 
at the site of laminectomy was not removed in order to maintain vertebral column 
stability. The extension of the laminectomy (approximately 1.5 mm in diameter and 2 
mm in length) was consistent between animals to allow room for the impactor tip. Small 
incisions were performed in the muscles correspondending to T11 and T13 vertebrae for 
stabilization of the vertebral column using forceps attached to the infinite horizon (IH) 
impactor clamping platform.  
 
Contusion cord injury was then induced on the exposed cord at T12 on a total of n = 55 
mice using the Infinite Horizon (IH) impactor device (Precision Systems and 
Instrumentation, Lexington, KY), as previously described [26].  
The mouse-impacting tip (∅ 1.25 mm) was aligned over the exposed cord, avoiding any 
impact on the lateral bones, and centred using the central vein as reference. A moderate 
contusion injury (70 kdyne) was then performed by using IH impactor. The IH device is 
computer-controlled that enables the application of standard-force injuries to the spinal 
cords of small rodents. It also allows the recording and monitoring of different 
parameters, such as the desired force (70 kdyne), the actual impact force, the cord 
displacement, velocity that are display for each subject concomitant with graphs 
showing force and displacement curves versus time (Fig. 2.1). The skin was 
subsequently closed with 7-mm wound clips. Mice received enrofloxacin (Baytril, 
Bayer) for two weeks to prevent infections. Urine was expelled by manual abdominal 
pressure twice a day for one week and then once a day for the duration of the 
experiment.  
 
All experimental procedures were performed in accordance with the UK Animals 
(Surgical Procedures) Act 1996. 
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Figure 2.1: Representation of IH parameters. In the red box highlighted the actual force reached with the 
impact and the corresponding displacement. Red lines in the x-y graph represents the time of the initial 
impact on the spinal cord and the respective displacement. Panel on the right shows the temporal 
development of the contusion injury. 
 
 
2.13 TRANSPLANTATION PROCEDURES 
Farnesylated green fluorescent protein (fGFP) NPCs and iNSCs, having GFP localized 
into the plasma membranes, were freshly thawed and passaged as previously described 
for NPCs and iNSCs.  
 
On the day of the transplantation 7 days after injury (subacute phase) cells were 
collected and spun as previously described, cells were resuspended in final a volume of 
ice-cold 1X PBS at a concentration of 150 x 103/µl and kept in ice prior to injection. 
Mice were anesthetized as mentioned above and the laminectomy site was re-exposed. 
Fibrotic tissue was remove by using Dumont #4 forceps (Fine Science Tools) and with 
the help of a sterile needle a small hole was created into the dura mater in order to allow 
the entrance of the injecting needle. The volume to inject (250 nl/injection site) was 
withdrawal and injected with a pump under a surgery microscope by using a 5 µl 
Hamilton syringe with a short 33G needle (Hamilton) placed onto a micromanipulator 
(World Precision Instrument). Each mouse received a total of four injection, of either 
iNSCs (150 x 103/µl), NPCs (150 x 103/µl) or an equal volume of vehicle, administered 
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bilaterally from midline at both the anterior aspect of T13 and the posterior aspect of 
T11. All cells used were at passage number  ≤ 25. 
 
 
2.14 BEHAVIOURAL ASSESSMENT 
Hind-limb locomotor recovery was evaluated by the open-field Basso mouse scale 
(BMS), a 10-point scale [27] (Fig 2.2). All the evaluations were performed in blind 
conditions by 2 observers. Locomotor activity was monitored for 4 min in an open field 
at 1, 3, 5, 7,10, 14,18, 21, 24, 28, 31, 35, 38, 45, 49, 52 days post injury (dpi). 
 
 
Figure 2.2: Basso mouse scale (BMS) to evaluate locomotor functions. Modified from Basso et al. [27] 
 
BMS subscore, assessed as previously described [27], was performed only on mice with 
a BMS score greater than or equal to 5. BMS subscore, compare to the more gross and 
generic evaluation performed by uding BMS score, allows the assessment of more fine 
locomotor capabilities, such as paw position or trunk stability (Fig. 2.3). 
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Figure 2.3: Basso mouse scale (BMS) subscore to evaluate fine locomotor functions. Modified from 
Basso et al. [27] 
 
Sensory functions were assessed by Von Frey Test. Different filaments, each with a 
corresponding force, were applied on the plantar surface of the hind paws of the mice in 
an attempt to elicit a response, following the up and down method as previously 
described [28]. Mice were placed onto an elevated grid and left to acclimatize for 15 
min prior to the test. Testing was initiated with the 1.4 g filament. A positive response 
was defined as withdrawal, or licking or shaking in the stimulated hindpwas after 3 s. In 
case of a positive response, the next weaker stimulus was presented, in case of a 
negative response, the next stronger stimulus was applied. This procedure was repeated 
until 3 positive or negative responses were achieved, for a maximum of 6 times. The 
mice were tested prior to surgery and once a week for the entire duration of the 
experiment. 
The Hargreaves apparatus (Ugo Basile) was employed to apply a thermal pain 
stimulation in order to measure hyperalgesia to thermal stimulation in unrestrained 
animals. Mice were placed onto a plexiglass surface and left to acclimatize for 15 min 
prior to testing. The Hargreaves' apparatus was set at 30% intensity and 20 sec were 
established as a cutoff time to avoid tissue damage. The mice were tested prior to 
surgery and once a week for the entire duration of the experiment. For each mouse, the 
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heat source was applied to the plantar surface of the hindpaws until the animal withdrew 
from the noxious thermal stimulus. 5 min was allowed between each session. 
Measurements were repeated 3 times for each paw. 
 
 
2.15 HISTOPATHOLOGY ASSESSMENTS 
Mice were anesthetized with ketamine/xylazine and transcardially perfused with saline 
(sodium chloride 0.9%) plus 0.5 M EDTA (Sigma) for 7 min to wash out blood, 
followed by cold 4% PFA in PBS pH 7.4 for other 7 min. The spinal cords were post-
fixed in the same solution for 12 hours at 4°C and then washed with 1X PBS. The 
dissected spinal cords were cryoprotected for at least 24 hours in 30% sucrose (Sigma) 
in 1X PBS at 4°C, then the cords were embedded in Optimal Cutting Temperature 
(OCT) (VWR Chemicals) and frozen using dry ice. Frozen cord blocks were placed in a 
cryostat (Leica) and 30 µm-thick axial sections were cut and collected onto 
SuperfrostPlus slides (ThermoScientific). Immunofluorescence was performed as 
described above (Table 2.5). 
 
Antibody Supplier Dilution 
Chicken anti-GFP Abcam 1:500 
   
AlexaFluor488 anti-chicken Invitrogen 1:500 
Table 2.5: Antibodies for immunofluorescence staining 
 
 
2.16 STATISTICAL ANALYSIS 
Statistical analyses were performed using the GraphPad Prism 6 software package. For 
multiple comparisons of three experimental groups (NPC characterization and 
differentiation data) nonparametric test Kruskal-Wallis test was used, corrected with 
Dunn’s post hoc test. One-Way analysis of variance (ANOVA) ,followed by Dunnet’s 
multiple comparison test, was used for comparison of three or more experimental 
groups (qRT-PCR data), while two-way ANOVA with Bonferroni post tests was used 
for multi-group comparisons under multiple conditions. For comparison of two 
experimental groups, Student’s t-test was applied. Results are expressed as mean ± 
	 28	
standard deviation (SD) unless otherwise stated, typically from the means of n = 3 
technical replicates from N ≥ 3 biological replicates. 
BMS, Von Frey and Hargreaves score was calculated as mean between scores attributed 
to the left and right paws, resulting in a unique score for each mouse. Data were 
analysed by using two-way ANOVA followed by Bonferroni post-hoc test correction. 
Results are expressed as mean ± standard deviation (SD) or standard error mean (SEM), 
as indicated. Statistical analysis was conducted at 95% confidence level. A P value less 
than 0.05 was considered as statistically significant. 
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3) INTRODUCTION 
 
The role of astrocytes has been reconsidered in recent decades, initially thought to be 
passive support cells, they have been shown to have crucial roles in several functions 
within the CNS, such as controlling synapse formation[29] and function[30], controlling 
of the energy supply to neurons and the turnover of neurotransmitters [31], supporting 
the blood-brain barrier [32] and regulating the flow of blood within CNS tissue [33]. 
These changes in the astrocytic-point of view has led also to an increased interest in 
understanding the functional role of astrocytes in CNS disease, since growing evidences 
showed the capability of astrocytes to respond to CNS insults by changing their 
functions and gene expression [34-37]. 
 
 
3.1 ASTROCYTES IN NEUROGENESIS 
 
Rudolf Virchow was the first to describe the central nervous system (CNS) as being 
composed of two main distinct cell populations, neurons and glial cells, where neurons 
were the real effector cells and glial cells served a simple supportive function [38]. As 
neuroscience progressed, so did our understanding of the role of glia beyond simply 
being the connective tissue of the brain. Glia were subsequently divided into two 
classes, microglia and macroglia, with the former representing the native immune 
system of the CNS and the latter including a variety of cell types, such as 
oligodendrocytes and astrocytes, that perform a multitude of integral CNS functions. 
The functional diversity and importance of astrocytes in particular has become 
increasingly prominent during recent years and, despite the common thought that 
neurons and astrocytes arise from different progenitors, more recent evidence 
suggesting that neurogenesis and gliogenesis are connected [39, 40] has highlighted the 
principal role of astrocytes in the CNS. Particularly noteworthy is the identification of 
radial glia, cells that retain similar characteristics to astrocytes while acting as 
progenitor cells able to generate cortical neurons in addition to macroglia [41, 42]. The 
name radial glia derives from the radial morphology of these cells which stretch from 
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the apical surface to the pial surface, while the adjective glial denote their shared 
characteristics with mature astrocytes [39, 43, 44], markers that distinguish them from 
their own progenitors, neuroepithelial cells. Through neurogenesis, neuroepithelial cells 
begin to acquire radial glial features at around embryonic day 9-10 (E9-E10) in the 
mouse; at this early stage radial glial still remain in contact with both pial and 
ventricular surfaces in the ventricular zone (VZ) [39] and they form adherent junctions 
to each other that help to maintain VZ integrity, similarly to neuroepithelial cells [45, 
46] (Fig 3.1). Importantly, radial glial cells showed the expression of astrocytic marker 
such as the glutamate aspartate transporter GLAST, S100 calcium-binding protein B 
(S100B), glutamine synthetase (GS), the typical intermediate filaments vimentin (Vim) 
and glial fibrillar acidic protein (GFAP), the RC1 and RC2 epitopes, and tenascin-C 
(TN-C)[42, 47]. Furthermore, radial glia maintain their radial processes during cell 
division, functioning as a precursor and guide for neural precursors, and they undergo 
asymmetric cell division to either self-renew or to generate a daughter cell	[39, 40]. 
 
 
Figure 3.1:  Representation of three different modes of neurogenesis during cortical development. Radial 
glia generate neurons through: - direct asymmetric division; - indirect generation of neurogenic 
progenitor cell and amplification; - indirect generation of neurogenic intermediate progenitor cell with 
two division rounds and amplification. CP, cortical plate; IZ, intermediate zone; MZ, marginal zone; 
nIPC, neurogenic intermediate progenitor cell; SVZ, subventricular zone; VZ, ventricular zone.  Adapted 
from Kriegstein, et al.[39] 
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Another important accomplishment in the characterization of this particular astrocytic 
precursor population of radial glial is the identification of neurogenic zones in the adult 
CNS in which glial cells act as stem cells [48-51]. In the two principal neurogenic 
niches of the adult brain, the subventricular zone (SVZ) of the lateral ventricles and the 
subgranular zone (SGZ) in the dentate gyrus, radial glial cells are well characterized 
(Fig. 3.2).  
In the SVZ, GFAP-expressing astrocytes represent the primary precursors of newly 
generated neurons	[52]. SVZ astrocytes (type B cells) (Fig. 3.2 A) showed both self-
renewal features and the capability to differentiate and generate transit-amplifying cells 
(type C cells), which subsequently generate migrating neuroblasts (type A cells) that, 
through the rostrary migratory stream, reach the olfactory bulb to differentiate into 
mature neurons [39, 50, 53]. The capability of dividing astrocytes to generate neurons in 
physiological conditions was assessed by using transgenic GFAP-TVA mice infected 
with an avian retrovirus carrying a reporter gene, showing that many labelled neurons 
migrated to the olfactory bulb [52]. Furthermore, SVZ astrocytes have been cultured as 
neurospheres in vitro to show their stem cell potential [54]. 
 
The second region that generates new neurons throughout adulthood is the SGZ of the 
hippocampus, at the interface of the granule cell layer (GCL) and the hilus of the 
dentate gyrus [50, 55]. The migration in this area is less extensive compared to the SVZ, 
nevertheless SGZ astrocytes (type B cells) (Fig. 3.2 B) show the same capability to 
generate mature neurons. The use of transgenic GFAP-TVA mice allowed for the 
tracing of the lineage of dividing SGZ astrocytes into granule neurons [55]. 
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Figure 3.2: A Schematic representation of cell types in the SVZ (orange), adiacent the lateral ventricle 
(LV). Multicilated ependymal cells (E, grey) line the LV, chains of neuroblast (A, red) migrate guided by 
SVZ astrocytes (B, blue). Rapidly dividing transit-amplifying cells (C, green) are distributed along the 
network of chains. B Schematic representation of cell types in the SGZ (orange). SGZ astrocytes (B, 
blue) give rise to intermediate precursors (D, yellow) that generate granule neurons (G, red). Modified by 
Doetsch [56] 
 
 
The affinity and the similarity observed between radial glial cells and astrocytes 
unravelled the vast heterogeneity and the different functions that astrocytes may exert in 
the CNS. Indeed, during recent years astrocytes have been distinguished based on 
different characteristics such as morphology and location. Astrocytes are therefore 
classified into two main categories:  protoplasmic and fibrous astrocytes [36]. 
Protoplasmic astrocytes characterize the grey matter; the presence of this type of 
astrocyte was first demonstrated using classical silver impregnation techniques, 
showing that they exhibit an extensive branched morphology with many finely 
branching processes leading to a uniform globoid distribution [36]. Interestingly, by 
using more fine techniques such as the injection of fluorescent intracellular tracers and 
three-dimensional (3D) confocal analysis and electron microscopy, it has been 
demonstrated that protoplasmic astrocytes in the CA1 stratum radiatum are indeed 
characterized by a spongiform nature that allows them to infiltrate distinct volumes of 
the neuropil. Furthermore, protoplasmic astrocytes vary in size and overall shape, from 
spherical to elongated (Fig. 3.3); but, contrary to what was first speculated from silver 
impregnation results, the different morphologies allow astrocytes to avoid extensive 
interdigitation, defining specific domains by astrocytes [57]. 
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Figure 3.3: A, Colocalization between adjacent astrocytes is represented by the discrete yellow zone. B, 
3D representation of colocalization of the same astrocytes reveal sheets in which neighbouring astrocytes 
interact with each other. Scale bar: 20 µm. Adapted from Bushong, et al.[57] 
 
 
The second category of astrocytes, fibrous astrocytes, are found throughout the white 
matter and exhibit a morphology characterized by many long fiber-like processes. 
Mature astrocytes exert a wide range of functions in the CNS that are maintained 
between species, nevertheless there is a main evolutionary difference between species, 
namely the size, and thus complexity, of astrocytes [58]. GFAP labelling in rodent, 
rhesus monkey and human brain has shown an increasing complexity of astrocyte 
morphology correlated to the complexity of brain functions (Fig 3.4) [59].  
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Figure 3.4: GFAP-labelled astrocytes in the cortex of mouse, rhesus monkey and human. Scale bar: 50 
µm. Adapted from Kimelberg et al. [58] 
 
 
Furthermore, two new subpopulations of astrocytes were described in human brains. A 
varicose projection astrocyte population, not observed in infraprimate species, is 
characterized by shorter, more spiny processes compared to typical protoplasmic 
astrocytes; interestingly, the domain organization is not present and their processes are 
spread in all directions crossing the domains of neighbouring protoplasmic astrocytes. 
These astrocytes may be involved in long-distance communication across cortical 
layers, or between grey and white matter. The second subpopulation is represented by 
interlaminar astrocytes; their functional role still remains unknown, but similarly to 
varicose projection astrocytes their long and tortuous processes suggest a role in long 
distance coordination of intracortical communication, and their close connection to 
vasculature suggest a role in coordinating blood flow [59]. 		
3.2 ASTROCYTIC MARKERS 
 
GFAP has been widely used as a specific marker to uniquely identify astrocytes, 
however GFAP-based identification presents a major limitation: not all astrocytes are 
immunohistochemically detectable in healthy CNS tissue since GFAP is not detectable 
in all astrocyte cell bodies, and it is absent in the finely branching astrocyte processes. 
As a consequence, GFAP-labelling can underestimate the quantity and extent of 
branching of astrocytes in the CNS [36, 60].  
 
Alternative molecular markers has been used for the identification of astrocytes, such as 
GS and S100B [61, 62], or the glutamate transporters GLT1 or GLAST[63]; 
nevertheless these molecules are not entirely exclusive to astrocytes, since some other 
neural cells like neurons or oligodendrocytes can also be positive for these markers 
[64]. 
 
New and innovative techniques, such as genome-wide transcriptional profiling, have 
provided new information about the expression profiles of subpopulations present in the 
	 35	
CNS  [65, 66]. From such studies a new and more reliable marker for astrocytes has 
been identified: aldehyde dehydrogenase family member L1 (Aldh1L1). Aldh1L1 is an 
enzyme that plays an important role in many reactions, such as the biosynthesis of 
nucleotides and the regeneration of methionine, thus playing a major role in cell 
division and growth. While GFAP remains the most commonly employed marker of 
astrocytes, Aldh1L1 provides a more representative alternative. Moreover, the 
generation of Aldh1L1- EGFP bacterial artificial chromosome (BAC) transgenic mice 
has facilitated the fluorescent labelling of the different astrocyte populations, providing 
a superior tool for visualization of astrocytes in the developing and adult mouse brain 
[65, 67]. 
 
 
3.3 PHYSIOLOGICAL ROLES 
 
Contrary to the initial limited role ascribed to astrocytes as simple supportive cells for 
neurons, it is now clear that astrocytes enact a wide variety of complex and essential 
functions in the healthy CNS. Astrocytes play an important role in CNS development. 
Although the generation of astrocytes occurs after the initial generation of neurons in 
many CNS regions, astrocytes form molecular boundaries for guiding the migration of 
developing axons and certain neuroblasts [36]. In fact, astrocytes influence synapse 
formation and maturation; in the developing CNS astrocytes, concomitant with 
microglia, play a principal role in the elimination of excess synapses in a process called 
synaptic pruning [35]. For example, it has been shown that this process, governed by 
neuronal activity, requires expression of the phagocytic receptors multiple EGF-like 
domains 10 (MEGF10) and MER proto-oncogene, tyrosine kinase (MERTK) [68]; 
synaptic pruning, in the dorsal geniculate nucleus of the thalamus, is regulated by 
transforming growth factor (TGF)-β secreted by immature astrocytes in the retina that 
activate the expression of the complement protein C1q, with subsequent elimination of 
tagged synapses by microglia [35]. However, this process of remodelling is not limited 
to development, but also takes part in adulthood, particularly upon CNS damage where 
astrocytes contribute to axonal plasticity, leading to the compensation and recovery of 
function after injury [35]. In ischemic brain lesions, for example, astrocytes contribute 
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to the synaptogenesis by stimulating the formation of new blood vessels through the 
secretion of vascular endothelial growth factor (VEGF)[69]. Moreover, astrocyte-like 
radial glial cells contribute to the formation of new neurons until adulthood [50]. 
 
Astrocytes not only promote and modulate synapse formation, but emerging evidence 
has given rise to the so-called ‘tripartite synapse’ hypothesis, describing the intimate 
involvement of astrocytes in neuronal synaptic communication [70]. Astrocytes are not 
merely passive actors in neuronal excitability, but rather it has been shown that 
bidirectional communication exists between astrocytes and neurons; astrocytes are 
characterized by a regulated release, into the synaptic environment, of a variety of 
signalling molecules including glutamate, purines (adenosine triphosphate), gamma-
aminobutyric acid (GABA), and D-serine. These gliotransmitters are released upon an 
increase in Ca2+ in response to changes in neuronal synaptic activity and this release can 
ultimately alter neuronal excitability [31, 36, 71]. Furthermore, astrocytes express high 
levels of transporters for different neurotransmitters (such as glutamate, GABA, and 
glycine) with the aim of clearing these signalling molecules from the synaptic space 
through reuptake; the neurotransmitters are subsequently converted by enzymes, such 
as GS, into precursors, such as glutamine, and recycled back to synapses for 
reconversion into active transmitters after being reuptaken [36, 72]. 
 
Vasculature plays a major part in CNS development and function, and thus it is 
important to underline that astrocytes are characterized by extensive contacts with 
blood vessels [36]. As mentioned above, astrocytes create contacts with neurons, and 
with this tight connection between synapses and blood vessels, astrocytes participate in 
the control of local metabolic demands [33]. Blood flow is regulated according to 
neuronal requirements, and recent evidences have shown that astrocytes can produce 
and release different molecular mediators, such prostaglandins (PGE), nitric oxide 
(NO), and arachidonic acid (AA), in order to modify CNS blood vessel diameter and 
blood flow in a coordinated manner [33]. It is therefore clear that astrocyte processes, 
closely related to synapses and blood vessels, exert essential functions in maintaining 
the homeostasis of the synaptic interstitial fluid. In particular, aquaporin 4 (AQP4) 
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water channels in the endfeet of astrocyte processes are responsible for creating contacts 
with the blood vessels and for regulating fluid homeostasis [73].  
 
The strategic position of astrocytes that sees them creating contacts with both blood 
vessels and neurons, axons (at nodes of Ranvier), and synapses, make them, therefore, 
an integral source for neuronal energy; glucose taken up from blood vessels by 
astrocytes is metabolised for energy by neurons in grey and white matter [36]. It is well-
established that astrocytes can store glycogen, and recent evidences have demonstrated 
that the use of glycogen, as sustenance for neuronal activity, is modulated by 
neurotransmitters. In particular, during periods of high neuronal activity glycogen is 
degraded to lactate and transferred to neurons, ensuring the maintenance of appropriate 
function and protection of neurons [74]. Furthermore, astrocytes can exchange glucose 
and its metabolites in the complex astroglial networks through gap-junctions, such as 
connexins 43 and 30 [75]. 
 
As suggested above, astrocytes are characterized by their endfeet and the creation of 
tight junctions with brain vasculature and pericytes that contributes to the maintenance 
of the blood brain barrier (BBB) [32]. While the BBB appears to be fully intact before 
astrogenesis, different neural stem cell-derived mechanisms involved in the control of 
the barrier, such as Wnt signaling, are thought to be supplanted by astrocytes after 
embryogenesis, and astrocytes are known to play an important role in sealing the barrier 
after CNS injury [37, 65]. 
 
 
3.4 REACTIVE ASTROCYTES 
 
Astrocytes not only play a major role in healthy tissue, but they also respond to CNS 
insults in a context/severity-dependent manner that leads to changes in gene expression, 
cellular structure, and functions [34, 35, 76, 77]. This heterogeneous phenomenon, 
exhibited by reactive astrocytes, is called astrogliosis and characterised by four main 
key features [34]: 
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1- Astrogliosis refers to a broad range of molecular, cellular, and functional changes in 
astrocytes in response to all forms and severities of CNS injury and disease  
 
These phenomena manifest along a gradient of intensity correlating to the magnitude of 
the insult, with milder responses yielding ostensibly reversible changes in gene 
expression, morphological changes, and increased proliferation, while more severe 
injuries can result in scar formation and permanent tissue rearrangement. Two main 
hallmarks identifying reactive astrocytes are up-regulation of GFAP and cellular 
hypertrophy (Fig. 3.5) [10], with the expression of other typical astrocytic markers, such 
as S100B, Vim, nestin (Nes), and glutamate transporters, also altered in an effort to re-
assert homeostasis [78]. 
Reactive astrocytes are common to all form of CNS injury and disease, including 
traumatic brain injury [79], spinal cord injury (SCI) [78], Alzheimer’s disease [80], 
amyotrophic lateral sclerosis (ALS)	[81], and many others, however the changes 
induced in astrocytes may vary depending on the stimulus [76]. In this regard, a recent 
study identified, through microarray gene profiling, several classes of genes 
differentially regulated upon different stimuli in cerebral astrocytes in models of 
transient ischemia (middle cerebral artery) and neuroinflammation (LPS injection). For 
example, gene ontology classification showed a prominent upregulation of categories 
such as metabolic activity, cell cycle-related genes and transcription factors in reactive 
astrocyte upon ischemia, while the antigen presentation pathway, complement pathway 
and response to inteferon classifications were more prominent in the LPS model [82]. 
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Figure 3.5: A: The left panel depicts astrocytes in the healthy mouse hippocampus, the right panel shows 
upregulation of GFAP expression and hypertrophy upon entorhinal cortex lesion . Modified from Pekny 
et al. [10] B: Table shows pathways and molecules involved in specific aspects of astrocyte reactivity. 
Modified from Sofroniew et al. [77] 
 
 
 
2 - Changes observed in reactive astrocytes depend on the severity of the insult in a 
gradient manner  
 
Mild or moderate insults of the CNS are caused by mild non-invasive trauma and 
diffuse innate immune activation, such as viral infections and systemic bacterial 
infections, and occur in areas that are some distance from focal CNS lesions [36]. Upon 
such insults, reactive astrocytes show an upregulation in expression of GFAP and 
hypertrophy without substantial overlapping of the processes (Fig. 3.6A) There is little 
or no astrocyte proliferation in mild or moderate reactive astrogliosis, but the 
upregulation of GFAP in astrocytes can lead to the detection of astrocytes that would be 
otherwise unlabelled and invisible in healthy tissue, leading to the overestimation of 
proliferation [34, 36]. 
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Severe insults result in more pronounced changes in astrocytes, including more 
substantial up-regulation of GFAP and cellular hypertrophy, resulting in the loss of 
individual astrocyte domains due to the overlapping of astrocyte processes (Fig. 3.6 A), 
as well as significant increases in proliferation [76]. These changes result in the 
reorganization of tissue to yield a dense and narrow barrier of overlapping, proliferative 
astrocytes, called a glial scar, which surrounds the lesion epicentre [36]. The nature of 
the glial scar is still under debate, yet it has appears to exert a dual role: to first 
delineate, in the acute phase of the CNS insult, the area of the damage in order to limit 
necrosis and the spreading of inflammation, and a more detrimental role during the 
chronic phase of injury as it represents an impediment to axonal regeneration, at both 
the physical and molecular levels (Fig. 3.6B)[83]. 
 
 
Figure 3.6: A: GFAP-immunohistochemically labelled astrocytes in the mouse cerebral cortex, in healthy 
tissue, moderate reactive astrocytes in response to intracerebral injection of the bacterial antigen 
lipopolysaccharide (LPS), and severe astrogliosis close to the lesion, respectively. B: Representation of 
glial scar formation: proliferative astrocytes (red nuclei), overlapping processes in astrocytes and other 
cell types such as fibromeningeal cells and other glia (gray nuclei). Modified from Sofroniew	[77] 
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3- Changes observed in reactive astrocytes are context-dependent and are regulated by 
inter and intracellular signals  
 
Astrocytes respond to all CNS insults, and while there are features common between 
reactive astrocytes across different diseases, reactive astrocytes are also characterized 
by a variety of pathology-dependent changes [81]. Interestingly, several lines of 
evidence have highlighted a new concept of astrocytopathies in which a disruption of 
normal astrocyte functions in healthy tissue is the primary cause of neurological 
dysfunction and disease [84]. For example, astrocytes in mutant SOD1 mice, a model of 
familial form of ALS, are characterized by a loss of GLT1 protein and consequently 
probably impaired glutamate transport and dysfunctional glutamate metabolism may 
drive the onset of the disease [85, 86]. In Alzheimer’s pathology astrocytes accumulate 
amyloid material resulting from local neurodegeneration, with the subsequent formation 
of GFAP+ amyloid plaques that eventually lead to astrocyte death [87]. Astrocytes in 
the context of Huntington’s disease exhibit, concomitant with an increase in GFAP 
expression, an altered expression of gap junctions, leading to a loss in their ability to 
maintain a neuronal-supportive environment [88]. 
 
Astrogliosis can be induced and regulated by a wide range of extracellular molecules 
that may initiate intracellular secondary messenger signaling cascades (Fig. 3.7). 
Transcriptome studies have demonstrated that upon different CNS insults, such as focal 
ischaemic stroke, LPS injection, or SCI, astrocytes show common changes in cell 
morphology, maintenance, growth, and proliferation [82, 89]. Signal transducer and 
activator of transcription 3 (STAT3) pathway stands out as one of the most well 
characterized instigators of astrocyte reactivity.	STAT3 is phosphorylated by Janus 
kinases (Jaks) in response to extracellular binding of various cytokines, interferons and 
growth factors produced during CNS insult, and pSTAT3 subsequently translocates to 
the nucleus where it regulates the transcription of astrogliosis-related genes [90, 91]. 
This central role was demonstrated in experiments involving the deletion of STAT3, 
with a consequent marked downregulation in hypertrophy, GFAP overexpression, and 
scar formation during astrogliosis [92]. 
 
	 42	
 
 
Figure 3.7: A,B: Representation of astrocyte receptors for different cytokines and other inflammatory 
molecules, and some of the associated intracellular signalling molecules. Modified from Sofroniew [93] 
 
 
4- Changes observed in reactive astrocytes can lead to a gain or loss of astrocyte 
functions 
 
Recent studies have shown that astrocytes exert important and beneficial roles not only 
in healthy tissue but also upon injuries; the dichotomous role of reactive astrocytes has 
become a topic of debate during recent years, particularly with the use of transgenic 
animal models [36]. In particular, these studies provided evidence that the loss of these 
functions associated with astrogliosis may lead to a worsening of the injury 
environment, since reactive astrocytes can limit the spread of inflammation and enact 
BBB repair and neural protection [9, 11, 92, 94]. Conversely, reactive astrocytes, 
especially during the chronic phase, elicit detrimental effects through inhibition of axon 
regeneration [95, 96]. Furthermore, reactive astrocytes can exacerbate the inflammatory 
response through the production of pro-inflammatory cytokines [36], or contribute to 
neurotoxicity by releasing reactive oxygen species [97], potentially excitotoxic 
glutamate [97], or by secretion of inhibitory molecules such as chondroitin sulfate 
proteoglycans (CSPGs) [83, 95]. 
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Remarkably, recent transcriptome analyses have distinguished reactive astrocytes into 
two subpopulations termed A1 and A2. This nomenclature derives from analogy with 
the nomenclature conferred upon polarised macrophages: pro-inflammatory (classically 
activated) M1 and anti-inflammatory (alternatively activated) M2 macrophages [98]. As 
mentioned above, reactive astrocytes may be helpful or harmful upon context-specific 
CNS insults and their dual role is broadly reflected in the identification of these A1 and 
A2 astrocyte subtypes. A1 astrocytes are characterized by the significant upregulation 
of many genes that have been shown to be neurotoxic, promoting the destruction of 
synapses. For example, LPS activation was found to induce A1 reactive astrocytes to 
upregulate the initial part of the classical complement cascade (C1r, C1s, C3, and C4) 
involved in synapse pruning during development and synapse loss in neurodegenerative 
disease [82]. On the contrary, animal models of middle cerebral artery occlusion 
(MCAO) have shown that alternatively-reactive A2 astrocytes express high levels of 
neurotrophic factors and cytokines, such as cardiotrophin-like cytokine factor 1 
(CLCF1), leukemia inhibitory factor (LIF), and interleukin-6 (Il6), that may aid in 
neuronal repair and protection [9, 82, 99]. 
 	
Thus, extensive evidence exists showing that astrocytes in healthy CNS are highly 
heterogeneous in their gene expression profiles, and that is in turn reflected in 
functional diversity, not only across different CNS regions, but also locally within the 
same regions [60]. This heterogeneity is also reflected upon reactivity in astrocytes, and 
indeed astrogliosis is regulated by multiple specific signalling events, leading to 
heterogeneity in the gene expression, cell morphology, CNS regions, cell signalling and 
cell function	of	reactive	astrocytes[100]. 
 
Nevertheless, heterogeneity is a crucial factor in studies aiming to screen the safety and 
efficacy of compounds in vitro, since variability between replicates may lead to 
misleading interpretation of results. For these reasons, we first aimed to establish a 
reproducible and reliable protocol for in vitro astrocytes cultures, with regards to 
expression of a canonical response of astrogliosis upon activation, to subsequently 
employ for nanotherapeutics screening 
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3.5 RESULTS 
 
3.5.1 NPC-DERIVED ASTROCYTES EXHIBIT A MATURE ASTROCYTE-LIKE 
PHENOTYPE AND MORPHOLOGY 
 
In order to evaluate the efficacy of pRNA-nanotherapeutics to modulate astrogliosis, we 
established a protocol for the in vitro differentiation of NPCs into mature astrocytes. 
Differentiation of NPCs into astrocytes was first induced by the use of a medium 
enriched with 10% fetal bovine serum (FBS), a well-established technique [101, 102]. 
NPCs were then cultured for 15 days in the differentiation medium and 
immunofluorescence staining was used to evaluate the maturation of the phenotype; 
during this time we observed an increase in cell size, acquisition of the typical astroglial 
morphology, high expression of the astrocytic intermediate filament (IF) proteins GFAP 
and Vim. S100B expression, another typical marker of mature astrocytes, increased 
during differentiation (Fig. 3.8) [103]. Purity of NPC-derived astrocyte cultures were 
previously assessed by immunostaining for microglia markers (ionised calcium-binding 
adapter 1-positive cells) and oligodendrocyte markers (O4-positive cells), with no 
expression of either marker observed, and also negligible amounts of βIII tubulin-
positive neuronal cells. 
	 45	
 
Figure 3.8: Immunofluorescence micrographs of high-FBS/FGF2-free astrocyte differentiation and 
maturation: 1, 6 and 15 DIV. Scale bar = 50 µm. 
 
 
A 15-day in vitro culture with 10% FBS therefore resulted in pure astrocyte cell cultures 
characterized by classical markers of mature astrocytes, nevertheless these cells showed 
high level of basal reactivity, marked by resting cell hypertrophy and high GFAP 
expression, and thus did not elicit a desirable phenotypic change upon subsequent 
LPS+IFNγ activation. The ineffectual nature of this protocol was indeed confirmed by 
qPCR and Western blot analyses: upon activation, qRT-PCR measurements showed that 
levels of classically activation-induced intermediate filament mRNAs were not 
significantly changed 48 h following LPS+IFNγ treatment: no induction in either Gfap 
or Vim expression levels were observed compared to non-activated control in high-
FBS/FGF2-free medium. Interestingly, in all conditions (resting and activation) high-
FBS/FGF2-free astrocytes showed a higher induction in Gfap and Vim compared to the 
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non-activated control in low-FBS/+FGF2, discussed below (Fig 3.9A), with mean Gfap 
and Vim expression levels being 20 and 4 times higher, respectively. This high basal 
expression (relative to low-FBS/+FGF2 resting), and the fact that LPS+IFNγ 
stimulation does not induce a change in expression, suggest that astrocytes grown under 
the high-FBS/FGF2-free conditions are already in a state of activation. This evidence 
was further confirmed by analysis of protein expression levels, assessed by Western 
blot, which did not show any significant changes in Vim and GFAP expression upon 
activation compared to the high-FBS/FGF2-free resting control (Fig. 3.9 B). 
 
 
Figure 3.9: A: qRT-PCR quantification of Gfap, Vim in resting and LPS+IFNγ-treated high-FBS 
astrocytes. Expression relative to low-FBS/+FGF2 resting controls (2-ΔΔCt method), Gapd reference gene. 
B: Representative Western blots showing GFAP and Vim protein expression levels in resting condition, 7 
and 5 days after activation, respectively. 
 
 
 
It has been previously described that FBS may have a stimulatory effect on astrocytes 
similar to that observed in observed in our high-FBS (10%) cultures [104], thus 
differentiation induced with low FBS media might lead to basally activated astrocytes. 
Furthermore, it has been shown that the presence of fibroblast growth factors (FGFs) in 
astrocyte differentiation media can induce a more mature quiescent state in cultured 
astrocytes [105,	106]. We therefore defined an optimised culture protocol: NPCs were 
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differentiated in a medium enriched with high (10%) FBS medium for the first 7 days of 
differentiation and then switched to low (1%) FBS medium supplemented with N2 for 
the remainder of the maturation protocol (up to 15 DIV or longer, depending on the 
experimental setting) (Fig. 3.10). Both high- and low-FBS media were enriched with 
high concentrations of FGF2 (50 ng/ml) for the duration of the experiment.  
 
 
 
Figure 3.10: Scheme for NPC-derived astrocyte experiments. NPCs were differentiated for 7 days in a 
medium enriched with high FBS, then switched to a low FBS medium supplemented with N2; both media 
are enriched in 50 ng/ml FGF2. At day 15 cells were transfected with 3WJs, while RNA and protein 
expressions were assessed at days 17 and 20, respectively. Astrocytes were activated by adding 2 µg/ml 
LPS and 3 ng/ml IFNγ to the medium for 48 h at two different timepoints: at day 13 through day 15 for 
the therapeutic treatment profile, from day 15 to day 17 for the preventative profile. 
 
  
NPCs differentiated via the low-FBS/+FGF2 protocol showed a progressive maturation 
of the astrocytic phenotype and morphology over the course of the protocol, from day 1 
to day 15. This progression was primarily observed by immunostaining for GFAP and 
Vim (Fig3.11); at 1 DIV we observed a homogenous population characterized by few 
processes (Fig. 3.11). By 6 DIV cells had started to extend processes and by 15 DIV 
near-confluent cells were characterized by typical astroglial morphology with elongated 
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processes (Fig. 3.11), notably we observed a remarkable change in cells morphology 
starting from 7 DIV, when cells are exposed to low-FBS/+FGF2 medium, indeed 6 DIV 
cells showed a morphology characterized by cell hypertrophy compared to a more thin 
and thin cell body observed 15DIV (Fig. 3.11). The acquisition of a mature astrocytic 
phenotype was confirmed by the expression of typical markers for mature astrocytes by 
immunostaining: at 15 DIV, differentiated NPC-derived astrocytes were positive for 
GFAP, Vim, S100B, ALDH1L1 and GLT1 (Fig. 3.11). 
 
 
Figure 3.11: Immunofluorescence micrographs of low-FBS/+FGF2 astrocyte differentiation and 
maturation: 1, 6 and 15 DIV. Scale bar = 50 µm. 
 
	 49	
We verified the purity of the cell population by immunostaining for neurons and 
oligodendrocytes; the absence of cells positive for βIII tubulin class (TUBB3) and 
microtubule-associate protein 2 (MAP2) for immature and mature neurons, respectively, 
excluded the differentiation of NPCs toward this lineage, and the absence of cells 
immunopositive for O4 confirmed the absence of oligodendrocytes. 
 
 
3.5.2 IN VITRO ACTIVATION OF NPC-DERIVED ASTROCYTES BY LPS AND 
IFNγ  TREATMENT  
 
After the establishment of a reproducible protocol (low-FBS/+FGF2) to differentiate 
NPCs into mature astrocytes, we aimed to activate resting astrocytes in order to mimic 
in vitro the molecular and gene expression changes observed upon in vivo activation, 
using the method described by Mor et al. [107]. Therefore, activation was induced by 
treating astrocytes with lipopolysaccharide (LPS) and interferon gamma (IFNγ): 
activation was performed by using the low-FBS/+FGF2 astrocyte differentiation 
medium enriched with 2 µg/ml LPS and 3 ng/ml IFNγ (activation medium) for 48 
hours. Activation was induced at two different timepoints during the differentiation 
protocol: at day 13 (therapeutic condition), to mimic a putative in vivo approach where 
astrocytes are first activated through injury and afterwards treated with 
nanotherapeutics; or astrocytes were exposed to the activation medium at day 15 
(preventative condition), to assess the capability of the nanotherapeutics to interfere 
with astrogliosis at the beginning of the phenomenon with the aim of a future 
combinatorial approach. Resting astrocytes (i.e. quiescent astrocytes not exposed to 
activation medium), kept in the astrocyte differentiation medium, were used as controls 
for activated astrocytes in order to evaluate the efficiency of activation protocol. 
 
When treated with LPS+IFNγ for 48 h, astrocytes exhibited an upregulation in the 
mRNA levels of their associated Toll-like receptor 4 (Tlr4) and IFNγ receptors 1 and 2 
(Ifngr1 and 2) compared to resting controls (Fig. 3.12 A,B,C), although Ifngr1 did not 
show a statistically significant increase. When medium was changed back to stimulant-
free ‘resting’ medium, expression reverted to basal levels after 48h. Astrocytes become 
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reactive in response to an infection or inflammation by inducing the expression of class 
II major histocompatibility complex, transactivator (Ciita); we observed an induction in 
Ciita mRNA (Fig. 3.12 D) in the 48h following activation, confirming the activation of 
cultured astrocytes.  
 
 
Figure 3.12:. qRT-PCR quantification of relative mRNA expression levels of low-FBS/+FGF2 cultured 
astrocytes stimulated with LPS+IFNγ. A Tlr4, B Ifngr1, C Ifngr2, D Ciita. Expression relative to resting 
controls (2-ΔΔCt method), Gapd reference gene. Data expressed as the mean of N ≥ 3 biological replicates 
± SD; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to non-activated control 
samples (one-way ANOVA with Dunnett’s multiple comparison test). 
 
 
To further confirm the reactive state of astrocytes in culture, we assessed the expression 
of the classical hallmarks of astrogliosis: both Gfap and Vim mRNA were increased at 
48h post-activation: approximately 6-fold and 2-fold, respectively (Fig. 3.13 A,B); the 
peak of activation was reached after 48 h of activation (preventative timepoint) and the 
expression of these markers decreased after a further 48 h in resting differentiation 
medium (therapeutic timepoint). Due to a large inter-experimental variation in 
expression, Gfap induction failed to achieve statistical significance. A 15,000-fold 
induction was observed for lipocalin 2 (Lcn2) expression upon 48h of activation, and as 
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observed for Gfap and Vim it came back to near-basal levels after further 48 h in resting 
differentiation medium (Fig. 3.13 C).  
 
 
Figure 3.13: qRT-PCR quantification of relative mRNA expression levels of low-FBS/+FGF2 cultured 
astrocytes stimulated with LPS+IFNγ. A Gfap, B Vim, C Lcn2. Expression relative to resting controls (2-
ΔΔCt method), Gapd reference gene. Data expressed as the mean of N ≥ 3 biological replicates ± SD; * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to non-activated control samples (one-way 
ANOVA with Dunnett’s multiple comparison test). 
 
 
Several other classical activation/pro-inflammatory genes were upregulated upon 
activation, including interleukin-6 (Il6), tumor necrosis factor (Tnf, although not 
significantly), and nitric oxide synthase 2 (Nos2) (Fig. 3.14 A,B,C); both Il6 and Tnf 
mRNA expressions revert back to near-basal levels after 48 h of exposure to resting 
medium, while Nos2 remained elevated. Notably, expression of the pro-inflammatory 
cytokine interleukin-1β (Il1b) was not significantly affected by activation in this model 
(Fig. 3.14 D). 
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Figure 3.14: qRT-PCR quantification of relative mRNA expression levels of low-FBS/+FGF2 cultured 
astrocytes stimulated with LPS+IFNγ. A Il6, B Tnf, C Nos2, D Il1b. Expression relative to resting 
controls (2-ΔΔCt method), GAPD reference gene. Data expressed as the mean of N ≥ 3 biological replicates 
± SD; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to non-activated control 
samples (one-way ANOVA with Dunnett’s multiple comparison test). 
 
 
The changes induced upon activation in our protocol, low-FBS/+FGF2 cultured 
astrocytes, were also confirmed by the analyses of protein expression by Western blot 
technique. Western blots performed at day 20, i.e. 48 h of activation medium with a 
subsequent 72 h into resting medium, confirmed the upregulation of both GFAP and 
Vim (Fig. 3.15A) relative to resting controls. Lcn2 expression could not be reliably 
ascertained by Western blot at this same time point, however a significant induction was 
evident at earlier time points: at day 16 and day 17, i.e. 24 or 48 h exposure to activation 
medium compared to resting controls (Fig. 3.15 B,C). To further investigate the reactive 
state of cultured astrocytes, the expression levels of phosphorylated signal transducer 
and activator of transcription (STAT3), a critical regular of astrogliosis, were assessed. 
The active pSTAT3, indicative of JAK/STAT3 pathway activation, was detected after 1 
h of activation and slightly decreased at 48h of activation medium exposure by Western 
blot analysis (Fig. 3.15 D). 
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Figure 3.15: Representative Western blots illustrating: A, Changes in activation markers GFAP and Vim 
in resting, therapeutic- and preventative-activation astrocytes, respectively. B, Temporal changes in Lcn2 
expression (16 DIV), red boxes highlight resting, therapeutic and preventative activated astrocytes, 
respectively. C, Temporal changes in Lcn2 expression (17 DIV), red boxes highlight resting, therapeutic 
and preventative activated astrocytes, respectively. D temporal induction of pSTAT3 upon treatment with 
LPS+IFNγ after 1 h (first two lanes) and 48 h (latter two lines). 
 
 
These findings were also confirmed by a qualitative assessment of immunofluorescence 
micrographs in which the intensity of both markers GFAP and Vim, constitutively 
expressed in resting low-FBS/+FGF2 astrocytes, increased notably upon activation at 
day 20, i.e. 48 h of activation followed by 72 h of resting medium (Fig. 3.16). Lcn2 
exhibited a remarkable upregulation in immunoreactivity, from a near-absence of 
expression in resting conditions to a strong labelling of most cells upon activation 
(Figure 3.16). Curiously, this pronounced induction of Lcn2 occurs at a timepoint (20 
DIV, 48 h of activation followed by 72 h of rest) where we were unable to observe 
expression by means of Western blot (discussed in the next section).  
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Figure 3.16: Immunofluorescence micrographs of low-FBS/+FGF2 astrocyte in resting and activated 
(LPS+IFNγ) conditions, 20DIV. Scale bar = 50 µm. 
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Therefore, both mRNA and protein levels of activation markers demonstrate the 
reliability and reproducibility of our NPC-derived astrocyte protocol and the expected 
increase in their expression upon activation. 
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3.6 DISCUSSION 
 
Astrocytes play a number of fundamental physiological roles within the CNS 
environment, ranging from the maintenance of the homeostasis through metabolite 
regulation, modulation of released neurotransmitters, and regulation of synaptic 
pruning, but they are also able to respond to pathological conditions upon CNS insults. 
In response to disease and injury astrocytes exhibit a wide spectrum of changes in gene 
expression, function and morphology, with this broad and heterogeneous reaction 
referred to as astrogliosis [34, 35, 96]. This reactive state in astrocytes is modulated by a 
diverse array of instigating stimuli and molecular signals, resulting in a complex 
phenomenon that occurs across a continuum of intensity depending	on the context, 
severity and proximity to the injury	[34, 77].  
 
For many decades astrogliosis has been considered a detrimental and harmful reaction 
to CNS insults, however more recent evidences involving transgenic loss-of-function 
models has highlighted its dichotomous nature. On one hand, astrocytes can exacerbate 
inflammation as a response to signalling pathways involved in pro-inflammatory 
activation [82], such as the nuclear factor κB (NF-kB) pathway	[108], or the astrocytic 
scar in chronic stages of injury can impede axon regeneration by	both	secretion of 
inhibiting factors and as a physicochemical barrier [83]. On the other hand, it has also 
been shown that, in acute stages of diseases, the ablation or prevention of astrogliosis or 
the inhibition of astrocyte scar formation is associated with more severe injuries, 
increased inflammation, and consequently increased tissue damage and worse 
functional outcomes [91, 92]. Astrogliosis is therefore a phenomenon characterized by a 
finely coordinated range of potential changes, and the investigation of the physiology 
and pathophysiology of astrogliosis is providing important evidence for potential 
therapeutic targets [77, 82, 109]. However, discrepancies between studies could, to 
some extent, be attributed to complete gene knockout approaches aiming to ablate 
astrogliosis, since these approaches can also inhibit the beneficial aspects of acute 
astrocyte reactivity. For example, the ablation of STAT3, a critical regulator of 
astrogliosis, resulted in a reduced induction of GFAP upregulation in reactive 
astrocytes, however STAT3 is involved in diverse aspects of astrocyte reactivity [110] 
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such as the expression of synaptogenic thrombospondins [111], neuroprotective 
oncostatin M,[112] and proliferation-mediating endothelin receptor type B[113], as well 
as the response of mitochondria in combatting oxidative stress[114]. 
  
From this perspective the overall aim of this project is to modulate astrocyte reactivity 
by using 3WJ nanoparticles as a new and promising therapeutic platform. Thus, in order 
to study the efficacy and the effect of our designed 3WJ nanoparticles, we first 
established a consistent and reproducible in vitro protocol for astrocyte culture and the 
generation of a reactive phenotype.  
 
Commonly, astrocytes cultures are obtained from primary cell derived from rodent 
brain tissues during the gliogenic stage (newborn pups). The advantages of primary 
astrocyte cultures are exemplified by a fast expansion, however astrocytes quickly tend 
towards senescence in the absence of growth factors [104]. Furthermore, primary 
cultures have been usually grown in undefined culture media, enriched with sera that 
are generally required for the maintenance of astrocytes [101]. Primary astrocyte 
cultures are also characterized by a heterogeneous astrocytic population (i.e. astrocytes 
that, in physiological conditions, differentially express the most classical astrocytic 
markers) and such cultures may be contaminated by other cell types, such as microglia, 
which can lead to confounding functional analyses of astrocytes [115]. These two 
characteristics may then represent major issues for studies that aim to screen in vitro 
compounds or potential therapies targeting astrocytes, since reproducibility between 
different primary cultures can be compromised. 
 
For these reasons, our first goal aimed to establish an in vitro protocol for the 
differentiation of murine SVZ-derived NPCs, a well-established and characterized self-
renewing population of stem cells, into a homogeneous population of mature resting 
astrocytes. We first followed already established protocols using a medium enriched 
with 10% FBS [101]; fetal bovine serum is commonly used in mammalian cell cultures 
since it contains different growth factors and is rich in metabolic substrates. We 
observed a maturation of an astroglial phenotype through 15 days of differentiation in 
high-FBS (10%) medium.	However, NPCs themselves showed high levels of expression 
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in the classical astrocytic marker GFAP [101] and it was not possible to observe an 
increase in GFAP immunoreactivity/immunofluorescence throughout the maturation 
protocol. Nevertheless, we could observe the maturation in the astrocytic phenotype in 
other regards; indeed, maturing cells acquired a larger more stellate morphology typical 
of mature astrocytes with a concomitant increase in the GFAP distribution along the 
maturing processes. Astrocytes can be characterized by different markers, and besides 
GFAP expression, S100B has been used as marker for the identification of a terminal 
maturation state for astrocytes that differentiate from NPCs [103]. Concordant with 
these previous observations, S100B expression increased during our differentiation 
protocol (maximum levels were observed at 6 DIV), and it was maintained until the 
latest timepoints for mature astrocyte differentiation (15 DIV).  Therefore, over 15 DIV 
of differentiation with a medium enriched in 10% FBS we observed a high expression 
of GFAP and S100B and the characteristic stellate morphology indicated that NPCs had 
acquired a phenotype typical of mature astrocytes, despite the observed high expression 
of IF usually associated with a reactive state. 
 
In order to mimic the reactivity state observed in vivo upon CNS damages in our NPC-
derived astrocytes, and to test consequently the efficacy of our nanoparticles as a 
modulatory tool, we employed the combined LPS and IFNγ treatment, as previously 
described by Mor et al. [107]. In that study it was shown that the exposure of primary 
cortical astrocyte cultures to LPS and IFNγ led to the secretion of pro-inflammatory 
cytokines Il6 and TNF, reaching a peak at 24-48 hours of exposure, and so we 
investigated the latter timepoint as being representative of an activated state while 
coinciding with the gene expression analysis timepoint of a typical siRNA-mediated 
knockdown experiment. The capability of mouse astrocytes to respond to LPS 
stimulation has been widely demonstrated [116-119] even though notable differences 
between human and mouse astrocytes were observed in TLR-ligand and immune 
activation [120]. In murine astrocytes LPS induces TLR4 dimerization that, through the 
activation of adaptor molecules, lead to the activation of signalling cascades through 
NF-κB, MAPK, and Jak1/STAT1 pathways, gene transcription changes, and finally 
inflammation pro-inflammatory response [117]. The direct relevance of the endotoxin 
LPS to human astrocyte reactivity in CNS injury is dubious since it has been observed 
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that human astrocytes exhibit little response to TLR4 stimulation [120], although an in 
vitro and in vivo study reported the effect of IFNγ on cultured human astrocytes as a 
potent mitogen, promoting extensive reactivity in astrocytes in vivo	[121]. 	
 
We therefore employed the LPS+IFNγ combination to induce a reactive state in NPC-
derived astrocytes, as model for astrogliosis. Nevertheless, astrocytes differentiated into 
10% FBS enriched medium showed a high reactivity in ostensibly resting basal 
conditions that hampered the further induction of a reactivity phenotype through the 
LPS+IFNγ treatment. While these cells did evoke a classical pro-inflammatory reactive 
state upon activation, inducing the expression of several pro-inflammatory cytokines 
and markers, such as Il6, TNF and Nos2 (previously established by our group), the 
canonical induction of intermediate filaments GFAP and Vim was not observed. Indeed, 
Gfap and Vim mRNA levels showed no differences upon activation. This basal reactive 
state observed in resting condition in astrocytes was attributed to the stimulatory effects 
of the high concentration of FBS (10%) present in the astrocyte differentiation medium, 
a well-described phenomenon attributed to the various cytokines, growth factors and 
hormones present in the serum that can also create variability in results due to inter-
vendor and inter-batch variability [104, 105, 122]. 
 
Thus, different conditions have been explored in order to establish an in vitro system in 
which culture conditions can induce a reactive or quiescent state in astrocyte-like cells. 
The use of serum-free conditions aimed to synchronize cultured astrocytes and allows 
astrocytes to re-enter the cell cycle from a state of quiescence (G0)	[123]; the use of 
chemically-defined media led to the induction of a multipolar stellate phenotype in 
cultured astrocytes [124, 125]; serum starvation or the withdrawal of serum from the 
medium prior to the desired assay can be used to reduce the basal activity in many 
different cell culture systems [126, 127], however the mentioned expedients may induce 
changes to cell morphology, gene expression and function	[127]. The complex 
morphology observed in astrocytes in vivo can be limited by two-dimensional culture 
systems, and while 3D matrices may provide structural support leading to the 
development of the typical astrocytic morphology and quiescent astrocytes [128, 129], it 
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has been shown that astrocytes react to different physical and mechanical characteristics 
of the substrates [130]. 
 
FGF signalling has been found to suppress astrocyte activation, in particular inhibiting 
activation while promoting proliferation, in the normal brain and after traumatic injury 
[131]. Furthermore in vitro treatment with FGF2 as been found to induce changes in 
astrocyte structure towards a resting stellate morphology combined with a significant 
decrease in GFAP mRNA and protein levels	[132]. Treatment with FGF2 has also been 
shown to facilitate the generation of mature, quiescent astrocytes characterized by low 
GFAP expression from stem cells	[105] and recent evidence suggests that FGF can 
possibly modulate the reactive state of astrocytes through regulation of TLR4/NF-κB 
pathways [133]. 
 
Therefore, to circumvent the basal activation induced by high concentrations of FBS in 
the differentiation medium, we investigated a two-phase scheme ultimately using low-
serum differentiation augmented with FGF. Astrocytic differentiation of NPCs was 
induced by using high-FBS (10%) medium during the first half of the differentiation 
protocol, while the promotion of a quiescent state was achieved by changing to low-
FBS medium (1%), N2 supplement and FGF2 (50 ng/ml) supplementation for the 
remainder of the culture. We indeed observed that NPCs differentiated in a low-
FBS/+FGF2 protocol were found to ultimately exhibit a resting astroglial phenotype. By 
6 DIV NPC-derived cells possessed a ramified morphology with numerous processes; at 
15 DIV astrocytes showed a more quiescent and mature phenotype characterized by 
stellate shape compared to hypertrophic structure of high-FBS/FGF-free cultured cells. 
Expression of astroglial markers S100B and ALDH1L1 increased over the course of the 
15-day culture confirming the maturation of NPCs towards astrocytic lineage, moreover 
cells acquired a phenotype typical of mature resting astrocytes, characterized by thin 
and elongated processes and less cell hypertrophy (opposite to what observe in high-
FBS/FGF2-free medium). Immunoreactivity and mRNA expression of GFAP, Vim and 
LCN2 were lower relative to high-FBS/FGF2-free cultured astrocytes, suggesting a 
lower level of basal activation. 
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Upon LPS+IFNγ exposure, mature (15 DIV) low-FBS/+FGF2 cultured astrocytes 
showed evidence of both a classical pro-inflammatory response and canonical astrocyte 
reactivity. In contrast to high-FBS/FGF2-free conditions, low-FBS/+FGF2 cells did 
show a response to LPS+ IFNγ-mediated activation observed by the upregulation in the 
expression of GFAP and VIM at both the mRNA and protein level. Gfap and Vim 
mRNA levels were notably higher than resting controls in the 48 h post-activation; 
while at 96 h post-activation (upon removal of the LPS+IFNγ stimulant) the expression 
of both IF genes had reduced back to a level intermediate between their resting and 48 h 
activated state. Protein levels, quantified from Western blots performed 5 days post-
activation, were likewise elevated, and, despite the density and complexity of 
intertwined astrocytes processes, increased immunoreactivity was also evident in 
fluorescence micrographs.  
 
48 h of stimulation led to an increase in the mRNA expression levels of Tlr4 and Ifngr2 
confirming the induction of a reactive state in our cultured astrocytes using the 
activation protocol. Previous studies reported an induction in Tlr4 expression upon LPS 
stimulation	[117]	and Ifngr upon IFNγ stimulation [134]. IFNγ stimulates activity of 
phagocytes by antigen presentation via Class I and Class II major histocompatibility 
complex (MHC) molecules; recent evidence from screening the transcriptome of 
astrocytes upon IFNγ activation showed an upregulation in genes involved in the 
immune response, such as expression of monocyte chemoattractant protein CCL2 and 
interferon-γ-inducible protein CXCL10 and MHC II pathway [135-137]. Our results 
confirmed the induction of a transcriptional coactivator of the class II MHC upon 
LPS+IFNγ stimulation by an increase in Ciita expression, supporting the evidence of a 
potential phagocytic role of astrocytes as immune effector cells.	Furthermore, there was 
a significant induction in Nos2 mRNA levels upon stimulation, as previously described. 
As a result of the increased expression of NOS2 by reactive astrocytes, they produce an 
excessive amount of nitric oxide (NO) in many neurodegenerative and 
neuroinflammatory conditions, and studies into in vitro stimulation with LPS and IFNγ 
showed an increase of GFAP expression as a consequence of NO production	[116, 138].  	
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Il6 has been shown to be involved in the regulation of inflammatory and immunological 
responses	[139], moreover it has been shown that human astrocytes also release Il6 
upon injury in vitro suggesting an involvement of this mechanism in post-traumatic 
cerebrovascular dysfunction [140]. A pro-inflammatory activation response was 
confirmed in our system by a significant induction in the expression of Il6 and Nos2 in 
LPS+IFNγ-treated astrocytes relative to resting controls. Amongst the different 
signalling pathways involved in astrocyte activation, STAT3 remains a critical regulator 
of astrogliosis	[90, 91]. Studies have shown that IFNγ can directly activate STAT3 
(rather than the canonical STAT1 response) upon binding to astrocytes [134]; LPS does 
not directly trigger the Jak-STAT3 pathway, and thus autocrine/paracrine stimulation by 
Il6 secreted from LPS+IFNγ-treated astrocytes might be an alternative explanation for 
STAT3 activation	[141]. We did observe pSTAT3 activation induced with LPS+IFNγ 
stimulation by quantification of protein levels via Western blot. Lcn2, further discussed 
in the section below, is also regulated via STAT3 activation and it was found 
significantly upregulated in LPS+IFNγ-treated astrocytes. A	large induction in Lcn2 
mRNA was evident 48 h post-activation, an increase reflected at the protein level as 
seen by Western blot and immunofluorescence, where negligible LCN2 expression was 
observed in resting conditions. 
 
These data confirm that our low-FBS/+FGF2-cultured astrocytes are able to undergo a 
canonical response to activation and they showed a classical pro-inflammatory 
polarisation, thus making them a convenient model system for proof-of-concept studies 
of pRNA nanotherapeutics. Indeed, both the classical markers of reactivity, GFAP and 
Vim, and the promising therapeutic target Lcn2 were upregulated in this model of 
astrogliosis, allowing for the assessment of the efficacy of siRNA-functionalised 3WJ 
nanostructures to modulate this overexpression. 
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4) INTRODUCTION 
 
The concept of nanomedicine has developed in recent decades, with the goal of 
increasing the efficacy of drug delivery through the medical application of 
nanotechnology [142]. The great improvements in the field has facilitated the 
development of nanotherapeutics based on a myriad of different materials and 
strcutures, all exploiting the key properties required for drug and gene delivery systems: 
biocompatibility, stability in circulation, negligible toxicity, minimal activation of the 
immune system, and efficiency of accumulation at a target site [143]. One material 
which has seen particular interest with regards to nanotherapeutic applications is RNA 
nanotechnology. RNA offers several advantages compare to other nanomaterials, 
possessing intrinsically defined features at the nanometer scale, being characterized by 
relatively high thermal stability and structural flexibility, and moreover the capability to 
perform a variety of different functions, such as RNA interference (RNAi)  [144, 145]. 
 
 
4.1 RNA Nanotechnology 
 
In recent years, drug delivery has become an intense field of research, with the major 
goal of overcoming the limitation that afflicts most classical medicines: an inability to 
specifically deliver a drug to its site of therapeutic action. Although pharmaceutical 
advances have led to the circumvention of many potential limitations in drug efficacy, 
including issues of poor solubility, high toxicity, an in vivo stability, specificity of 
delivery (at a specific rate and at a specific site) remains a goal yet to be substantially 
realised [146].  
 
Nanotechnology applied to medicine is often referred to as nanomedicine and it offers 
several potential benefits, such as the possibility to use submicrometer-sized tools for 
the diagnosis, prevention and treatment of diseases, that has led to a better 
understanding of the complex pathophysiology of diseases, and also allowed an 
improvements in the quality of life of patients. Significant efforts have been invested 
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and substantial progress has been made in the nanomedicine field over the last couple of 
years [142, 147]. However, the real innovation of nanomedicines over standard low-
molecular-weight drugs rely in these features: nanotherapeutics, ranging from ~30 up to 
1000 nm, reduce renal excretion and/or hepatic degradation, leading to prolonged 
circulation times; reduce the volume of distribution, with less chances of accumulation 
in healthy non-target tissues and allow site-specific delivery, thus they improve the 
ability of drugs to accumulate at pathological sites, for example by conjugating 
nanoparticle surfaces to antibodies;  [146, 148].  
Because of these features, different and multivalent nanoparticles has been developed 
that offer the possibility of an innovative tools that retains many potentials: in fact 
nanoparticles can be employed as diagnostic and imaging tools [149, 150] and 
therapeutic approaches [151-153].  
 
Amongst the diversity of nanomaterials, biological macromolecules (DNA, RNA and 
proteins) are popular building blocks for top-down approaches or bottom-up fabrication 
of nanostructures and nanodevices. RNA is particularly appealing for nanotherapeutic 
applications since it possesses several key advantages [144, 154, Guo, 2010 #1418]: 
• RNA molecules are polymers composed of a combination of four bases: adenine 
(A), uracil (U), guanine (G) and cytosine (C). Therefore, there are copious 
possibilities to create a variety of polymers; for example, a 30-nucleotide RNA 
polymer can generate as many as 430 (or 1018) different RNA molecules. 
Furthermore, the simplicity of a 4-base pool of building blocks leads to an easy 
and reliable prediction of the formation of various nanostructures by bottom-up 
assembly;  
• RNA molecules have demonstrated a variety of different functionalities. For 
example, the class of nucleic acid molecules known as aptamers function like 
protein or chemical ligands and can specifically target a definite cell population 
or cell type by binding cell-surface receptors. In this role, RNAs can serve as 
excellent targeting moieties. Another class of RNA of particular interest to 
nanotherapeutics are represented by RNA interference (RNAi) agents –powerful 
tools for targeted gene silencing, such as small interference RNA (siRNA); 
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• The high stability of RNA at lower pH, and thus its resistance to endosome 
degradation, make it an interesting and useful candidate tool for drug therapy 
since such barriers must be surmounted prior to dispersal throughout the cell 
after entry; 
• RNA structures are generally characterized by low immunogenicity and toxicity, 
owing to their biocompatibility, however it has been shown that they can 
stimulate the host immune system through the activation of members of the 
Toll-like receptor (TLR) family, specialized in the recognition of pathogen-
associated molecules. However proper modification, such as 2′-O-methyl 
modification, can easily eliminate such immune stimulation;  
• RNA nanotechnologies can be functionalised with several features, such as 
desirable chemical or biological activity including ribozymes, aptamers, 
riboswitches, and RNAi agents, and 
• RNAs possess versatile tertiary structures and catalytic functions that mimic 
some proteins. 
 
The construction of RNA nanoparticles is a multi-step process: first the desired 
properties of the nanoparticle areidentified, then computational approaches are used to 
predict the structure and folding of the RNA nanoparticles (Fig. 4.1), then the 
monomeric RNA building blocks are synthesised by enzymatic or chemical approaches, 
subsequently assembled into the desired 3D construct, assembly and functional 
capabilities are characterised, and, finally, they are employed in their 
therapeutic/diagnostic application (Fig. 4.1) [145]. 
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Figure 4.1: Schematic representation of the process for RNA nanoparticle construction. Modified from 
Guo P. [145]. 
 
 
As mentioned above, RNA molecules are characterized by different functionalities, and 
the post-transcriptional gene regulation afforded by RNAi in particular has led to the 
development of various therapeutic strategies [155, Gavrilov, 2012 #1431, Agrawal, 
2003 #1433]. RNAi utilises a mechanism of sequence-specific gene silencing based on 
short double-stranded RNAs (dsRNAs); these siRNAs or micro RNAs (miRNAs) were 
first found in plants, elaborated upon in nematodes (for which Andrew Fire and Craig 
Mello would win the 2006 Nobel Prize in Physiology or Medicine), and were later 
observed in mammalian cells [156, Hammond, 2000 #1440, Zamore, 2000 #1438], 
paving the way for research-assisting or therapeutic gene knockdown through the design 
of siRNAs for any gene of interest [157]. 
 
siRNA and miRNA shared the same machinery, they are indeed assembled into RNA-
induced silencing complexes (RISC), when loaded in the RISC complex one strand of 
the duplex is bound to Argonaute to direct silencing and the other strand is discarded. 
These strands are named guide and passenger strands, respectively, and their selection is 
a key step for silencing function. The guide strand is transient associated with 
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Argonaute, while the passenger strand will be cleaved and/or dissociated [158]. 
Therefore, activated RISC contains only single-stranded (antisense) siRNA or miRNA, 
which guides RISC to its complementary target messenger RNA. It is at this point that 
the distinction between the two types of RNAi becomes most apparent: siRNA, 
characterized by perfect sequence complementary with its target mRNA, induces site-
specific cleavage of the mRNA, whereas miRNA typically has imperfect sequence 
complementary which leads to translational repression without mRNA degradation. 
Nevertheless, both the pathways result in the inhibition of target protein synthesis [159, 
160].  
 
Inspired by this cellular mechanism, several artificial methods of RNAi have been 
developed, such as the transfection of chemically synthesized siRNA oligonucleotides 
directly into the cytosol, or the use of short hairpin RNAs (shRNAs) synthesized within 
the cell by DNA vector-mediated production, to mimic endogenous miRNAs [161, 
162]. Both techniques present advantages and disadvantages, for example the synthesis 
of siRNAs is quite fast since it does not require a cellular expression system, complex 
protein purification, or refolding schemes and a broad variety of reagents is available 
for siRNA design and synthesis. On the other hand shRNA may be used to generate 
stable knockdown cell lines, eliminating multiple rounds of transfections, but the 
creation of a stable shRNA cell line is time-consuming task and the selection of 
shRNA-positive cells requires a remarkable amount of work [163]. 
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Figure 4.2: Schematic representation of RNA-Induced Silencing Complex (RISC) assembly. On the left 
is represented the siRNA pathway, while on the right is the miRNA pathway. Briefly, Dicer’s cleavage of 
dsRNA of exogenous or nuclear origin gives rise to siRNA duplex that is loaded onto Argonaute by the 
RISC-loading complex, which comprises Dicer, a double-stranded RNA-binding protein and an 
Argonaute protein. The passenger strand (gray) is cleaved and the resulting guide strand (red) remains 
bound to Argonaute, forming the RISC. Subsequently, RISC recognizes and binds to a complementary 
mRNA target sequences (black) that are silenced via by slicing activity of Argonaute (in siRNA), or 
through translational repression (miRNA). Modified from Wilson et al. [160] 
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The increasing interest in RNAi technology and consequently the amount of data 
available has highlighted additional concerns of siRNA targeting. Indeed, unbiased 
genome-scale expression profiling studies revealed off-target activity of siRNA [164, 
165].  
The siRNA off-target effects can be divided into three main categories: siRNA-induced 
sequence-dependent regulation of unintended transcripts through partial sequence 
complementarity to their 3′ UTRs (microRNA-like off-target effects), causing the 
suppression of genes other than the desired target gene, and potentially diluting the 
anticipated silencing effect while propagating unintended physiological outcomes. 
Therefore, when designing siRNA-based therapeutics off-target silencing must be 
thoroughly investigated and testing should be undertaken for variations in normal 
protein expression profiles. Indeed, predictive bioinformatic approaches are routinely 
employed during the design of siRNAs, with the goal of reducing and preventing off-
target silencing [166]. Induction of inflammatory response represents another off-target 
effect, siRNA can trigger the activation of Toll-like receptor pathway with the 
subsequent induction of interferon-mediated responses, potentially causing cell death 
[167, Hornung, 2005 #1481], however appropriate chemical modification can rectify 
this, as discussed earlier. The third class of off-target effects is related to saturation of 
the endogenous RNAi machinery by exogenous siRNAs and widespread effects on 
microRNA processing and function, thus making the dosage of putative siRNAs an 
issue for consideration. In addition to acknowledging these off-target activities and how 
they can complicate the interpretation of siRNAs effects [168], , siRNAs, and RNAs in 
general, can be easily degraded by enzymes in serum and tissues, with the half-life of 
naked, unmodified siRNAs in serum ranging from several minutes to an hour [169, 
Gavrilov, 2012 #1431]. Again, routine chemical modifications exist which can 
minimise these potential drawbacks. 
 
To overcome these limitations, and to enhance the efficient delivery of siRNA to target 
cells, a diverse array of tools has been developed, including advances in delivery 
vehicle technology, chemical modification, and targeting moiety functionalisation 
[170]. 
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4.2 PRNA NANOPARTICLES 
 
Within the last decade an innovative bottom-up approach for the construction of RNA 
nanoparticles was developed, inspired by the molecular machinery of the DNA-
packaging motor of the phi29 bacteriophage. Linear double-stranded DNA viruses, 
including the phi29 bacteriophage, are characterized by the same mechanism: their 
genome is packaged into a procapsid during their maturation and this energetically 
unfavourable mechanism is driven by an adenosine triphosphate (ATP)-driven DNA-
packaging motor. However, the phi29 DNA packaging process is characterized by a 
unique feature: small viral RNAs called packaging RNAs (pRNAs) form a hexameric 
ring on the connector and gears the phi29 DNA packaging motor to package the viral 
genome into the preformed procapsid [171]. 
 
Each monomeric pRNA molecule contains two functional domains, specifically two 
single-stranded loops (right and left-handed loops) that interact in an intermolecular 
manner, hand-in-hand, in the assembly of the hexameric ring (Fig. 4.3). These domains 
are connected by a highly stable three-way junction (3WJ) region that can be 
manipulated and derivatised in order to obtain multi-armed, multi-functional structures. 
Since these domains fold independently around the stable 3WJ core, the arms can be 
readily functionalized by replacing the helical stem or interacting loops with, say, an 
siRNA moiety without affecting the core pRNA-3WJ structure (Fig. 4.3). 3WJs are 
common motifs in natural RNA, however the 3WJ-pRNA core is characterized by 
unique features, described below, that make it a uniquely powerful tool.  More 
importantly, multiple potential functionalities, such as aptamers, ribozymes, miRNAs, 
fluorophores and imaging moieties, or small-molecule ligands/drugs, can be 
incorporated into the 3WJs, thus these unique characteristics and the modular, highly-
functionalisable nature make pRNA nanotherapeutics promising and attractive tools for 
gene therapy  [151, Shu, 2011 #1486, Guo, 2010 #1428, Guo, 2010 #1418].  
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Figure 4.3: Structure of phi29 DNA-packaging RNA. a, Illustration of the phi29 packaging motor formed 
by six pRNAs (in different colours). b, Sequence and folding of pRNA monomer. c, 3WJ domain 
composed of three RNA oligomers in black, red and blue. d, Example of a trivalent RNA nanoparticle 
formed by three pRNA molecules bound at the 3WJ-pRNA core sequence, with AFM visualisation. 
Modified from Shu et al.[151] 		
Notably, pRNA, when compared to other RNA motifs, exhibits uncommon stability 
and, as mentioned above, can be used for a broad range of applications as its modular 
nature can give rise to a myriad of different designs. It has been shown that 3WJ RNA 
nanoparticles are resistant to denaturation in urea: dsDNA and dsRNA are usually 
denatured and dissociate in the presence of 5M or 7M urea, while the 3WJ domain 
remains stable without dissociation at concentrations of 8M. Furthermore, upon 2′-F 
chemical modifications of pyrimidine nucleotides, 3WJs are more stable in serum, 
overcoming one of the major challenges of RNA-based technology in vivo (2′-F 3WJs 
are characterized by a half-life of 2-10 hours compared to 5-30 minutes for 2′-F 
modified siRNAs), and 3WJ-based constructs remain intact at ultra-low concentrations 
[169, Shu, 2011 #1417]. 
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Three different “toolkits” have been developed for controllable and predictable 
generation of pRNA-derived nanoparticles with varying shapes and angles, exploiting 
the versatility of this platform for nanotechnological/therapeutic applications [172, 
173]: 
• Toolkit 1: Inter-molecular interactions between loop domains (R- and L-loops) 
on pRNA monomers via hand-in-hand interactions. Homo-dimers can be 
designed by using complimentary sequences in the same pRNA molecule, while 
a hetero-complex can be created through the combination of a number of 
pRNAs by matching the sequence of the R-loop and the sequence of the L-loop 
of another pRNA. These interactions between building blocks lead to the 
formation of dimers, trimers, and multimeric rings (Fig. 4.4A); 
• Toolkit 2: The 5′/3′ open region, in the helical domain of the pRNA, allows for 
the extension of sequences while maintaining the folding of the entire pRNA 
molecule. To link pRNA monomers, a palindromic sequence can be added as a 
bridge for RNA nanostructures via intermolecular interactions, denoted as foot-
to-foot interactions, and it can lead to the formation of hexamers, octamers, 
decamers, and dodecamers (Fig. 4.4B); 
• Toolkit 3: The 3WJ core of the pRNA interlocking domain can be assembled 
from three individual RNA fragments, and its structure allows the 
functionalisation of this nanoparticle by conjugation of different RNA (or other 
appropriate chemistries) moieties at each end. Importantly, the conjugation of 
functional arms does not alter the original folding, and each module maintains 
its structure and retains its functionality. The higher-order X-shaped motif is 
inspired by the interlocking domain of the pRNA; it presents a motif similar to 
3WJ with the right-hand loop on the pRNA replaced with a short, double-
stranded sequence and a final structure characterized by four RNA oligos as a 
scaffold for the conjugation of four RNA functional motifs (Fig. 4.4C).  
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Figure 4.4: Three “toolkits” used for pRNA nanoparticle construction. A: Toolkit I: pRNA hand-in-hand 
interaction. B: Toolkit II: foot-to-foot interaction. C: Toolkit III: branch extension. Adopted from Shu et 
al. [172]. 
 
The studies described herein employ proof-of-concept 3WJ-pRNA nanostructures, for 
applications in the CNS niche, bearing siRNA moieties targeting genes overexpressed 
by reactive astrocytes. 
 
4.3 LIPOCALIN-2 
 
Lipocalin-2 (Lcn2) belongs to a large family of secreted proteins with a common and 
conserved lipocalin domain that can bind various small hydrophobic macromolecules 
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including siderophore-bound iron, pheromones, fatty acids, and retinol [174]. 
Furthermore, lipocalins can bind to specific receptors and deliver ligands and growth 
factors into cells by receptor-mediated endocytosis [175]. Thus, the lipocalin-protein 
family act as transporters (some being enzymes) and are associated with a diversity of 
biological processes, such as immune responses, pheromone transport, olfaction, 
prostaglandin synthesis, retinoid binding, and cryptic coloration; more locally, they also 
regulate many cellular processes, such as cell migration, proliferation, differentiation, 
cell death and survival [174-176]. 
 
Lcn2 was first described as neutrophil gelatinase-associated lipocalin (NGAL) but it is 
also known as 24p3 or 24-kDa superinducible protein (SIP24) [175, 177]. Initially 
identified murine kidney cells [178], its presence was first described in human tissues in 
particular bronchial epithelial cells and alveolear type II pneumocytes, which showed an 
upregulation in the synthesis of Lcn2 during lung inflammation; interestingly, human 
and mouse Lcn2 showed a 62% homology in amino acid sequence [179, 180]. It has 
been shown that Lcn2 can bind two cell-surface receptors: brain type organic cation 
transporter (24p3R) and megalin [181, 182]. 24p3R is expressed constitutively and its 
presence has been shown in various cell types, such as in kidney epithelial cells [181], 
epithelia of respiratory tracts (where it is upregulated upon lung inflammation) [180], 
macrophages, neutrophils [183], microglia (where Lcn2 is constitutively expressed and 
its expression is upregulated by inflammatory stimulation) [184], astrocytes [185], and 
neurons [175]. Megalin, a multi-ligand endocytic receptor, is also expressed in different 
cell types, such as in a sub-population of epithelial cells [175], cells in brain capillaries 
and the choroid plexus, the ependymal cells of the lateral ventricles where it may 
contribute to the modulation of this microenvironment [186], and neural progenitors in 
the embryonic mouse spinal cord [187] where it may play an important role in the 
development of mature astrocytes. 
 
Lcn2 appears to play myriad roles in the CNS: a recent study focused on oesophageal 
squamous cell carcinoma employed network-based analyses of protein-protein 
interactions (PPI) to unravel the complex biological activities of Lcn2. Gene Ontology 
(GO) annotation revealed the relation of Lcn2 to a group of immunity-related terms, 
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such as ‘‘regulation of immune response’’, ‘‘activation of immune response’’, ‘‘innate 
immune response’’(Fig. 4.5 I); another pathway-cluster included ‘‘regulation of 
transforming growth factor beta receptor signaling pathway’’, ‘‘regulation of Wnt 
receptor signaling pathway’’, ‘‘immune response-regulating cell surface receptor 
signaling pathway’’ (Fig. 4.5 II); the third major identified GO term group suggested 
the enrolment of LCN2 in the regulation of the cell cycle by the discovery of GO terms, 
such as ‘‘G1 phase of mitotic cell cycle’’, ‘‘G1/S transition of mitotic cell cycle’’, 
‘‘G2/M transition of mitotic cell cycle’’ (Fig. 4.5 V) and finally Lcn2 activity was 
related two other GO terms involving ‘‘cellular response to molecule of bacterial 
origin’’ and ‘‘extracellular matrix organization’’ (Fig. 4.5 III, IV) [188]. 
 
 
 
Figure 4.5: Functional map of the total PPI sub-network. Similar GO terms were labelled in the same 
colour and the GO term group of interest related or potentially related to LCN2 function was indicated by 
a Roman numeral, magnified in the small boxes. Modified from Wu et al.  [188] 
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Another important role of Lcn2 to bind bacterial ferric siderophores was first unravelled 
by a crystallography study conducted on Lcn2 that identified its ligand. It was shown 
that Lcn2 released by neutrophils at sites of infection and inflammation was able to 
sequester bacterial ferric siderophores, thus playing a role in the antibacterial iron-
depletion strategy of the innate immune system with a specificity to sequester iron 
earmarked for bacterial use [189]. [190]. Siderophores are released by microorganisms 
under aerobic conditions to scavenge from the environment iron required for a variety 
of functions, including reduction of oxygen to synthesise ATP, reduction of 
ribonucleotide precursors of DNA, and a variety of other essential functions [191]. 
Towards this end, microbes scavenge iron that is bound to proteins in the mammalian 
host, such as haemoglobin, transferrin, lactoferrin and ferritin. In this context Lcn2 
competes with bacteria for iron by binding the siderophores [192]. To support such a 
role some evidences have shown that, upon bacterial pathogenesis, Toll-like receptors 
expressed on immune cells stimulate transcription, translation and secretion of Lcn2. 
The competition and sequestration of iron then attenuates bacterial growth and reduces 
bacterial infection [175, 192]. 
 
Another function attributed to Lcn2 regards the modulation of cell migration and 
morphology [189]. A recent study showed the capability of LCN2 to modulate the 
neuronal phenotype in primary cortical neuronal cell cultures and neuroblastoma cell 
lines as experimental models; cells exposed to Lcn2 increased their cell death rate 
related to nitric oxide, oxidative stress, and TNF and stimulate neuronal motility and 
process extension [193]. Furthermore, Lcn2 is able to induce the production of several 
chemokines, such as CXCL10, in different populations within the CNS, such as 
astrocytes, neurons and microglia, which in turn modulates their migration and 
phenotype. Two different in vivo models of CNS injury, LPS injection and cortical stab 
wound injury, showed that Lcn2 secreted mainly by astrocytes promoted the migration 
of microglia, neurons, and astrocytes themselves, likely acting through the 
JAK2/STAT3 and IKK/Nuclear fFctor κB (NF-κB) pathways [194]. 
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Lcn2 acts as a cytokine and plays a regulatory role in a broad range of inflammatory 
reactions. Indeed, its regulation is upregulated during sterile inflammation, infection, 
injury, or during autoimmune disorders	[17, 174, 175, 183, 195, 196]. In the acute phase 
of inflammation, Lcn2 is overexpressed, leading to an infiltration of granulocytes at the 
inflamed site that, in turn, synthesize and secrete further Lcn2, mediating local tissue 
injury or inflammation. Moreover, it has been shown that Lcn2 can also be released in 
systemic circulation and therefore it may represent a marker for different inflammatory 
disorders [180, 183, 197]. As part of the innate immune response, Lcn2 contributes to 
the pathogenesis of several neurodegenerative diseases, but may in fact demonstrate a 
dual functionality. It has been shown that Lcn2-deficient mice in experimental 
autoimmune encephalomyelitis (EAE) exhibit a worsened disease severity relative to 
Lcn2-expressing wildtypes, suggesting a protective role for Lcn2 through a modulation 
of the pro-inflammatory response rather than a promotion of the anti-inflammatory 
response [196]. On the contrary, the assessment of Lcn2 in a mouse model of spinal 
contusion injury revealed its detrimental effect in this condition arising from a 
promotion of neuronal loss, production of proinflammatory cytokines, and immune cell 
infiltration upon Lcn2 expression [17]. Furthermore, Lcn2 is able to modulate the 
phenotype of most of cells involved in the immune response. By using a mouse 
neuroinflammation model it has been shown that Lcn2 plays an essential role in the M1 
(pro-inflammatory) polarization of microglia. Upon LPS stimulation of primary 
microglia and LPS-induced inflammation model in vivo, Lcn2 increased M1-related 
gene expression, while inhibiting M2-related gene expression in microglia lineage 
[198]. 
 
 
4.4 THE ROLE OF LIPOCALIN-2 IN REACTIVE ASTROCYTES 
 
The important role of Lcn2 as a mediator of astrocyte reactivity was well-characterised 
with a study published by Lee et al. [185]. This study demonstrated that Lcn2 secreted 
by astrocytes has a dual role in influencing the morphology and functional fate of 
activated astrocytes. In fact, it was shown that Lcn2, secreted by astrocytes upon 
exposure to inflammatory stimuli, was able to cause cell death in activated astrocytes 
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and induce typical morphological changes, such as GFAP overexpression, associated 
with reactive astrocytosis in vivo. It was speculated that Lcn2 promoted the growth of 
astrocyte processes and motility by activating the Rho/ROCK pathway (Fig. 4.6), in 
addition to other parallel Lcn2 pathways. However, by forcing the expression of Lcn2 
and using recombinant LCN2, it was hypothesized for the first time that secreted Lcn2 
might act as a self-regulatory/feedback control mechanism, sensitizing astrocytes to cell 
death signals evident in CNS inflammation [185]. More recently these findings have 
been supported by transcriptomic analysis in models of ischemic stroke and LPS-
induced neuroinflammation in which Lcn2 expression was strongly upregulated upon 
both injuries [82]. 
 
 
 
 
Figure 4.6: Schematic representation of reactive astrocytes under inflammatory condition: secreted Lcn2 
may act as a feedback control on astrocytes to induce morphological as well as functional changes. Lcn2 
induces morphological changes and promotes migration through the Rho/ROCK pathway in reactive 
astrocytes. Parallel pathways can lead to cell death signals (BIM pathway). Adopted from Lee et al. [185] 
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Lcn2 secreted by reactive astrocytes has been shown to play a role as a mediator of 
astrocytic neurotoxicity during several disease states or neurodegenerative conditions 
(Tong et al., 2013), in fact in vitro studies showed the capability of astrocyte-secreted 
Lcn2 to induce apoptosis on neuronal cultures[199, 200]. Thus, Lcn2 may contribute to 
neuronal cell death in injury and disease in vivo. These pro-apoptotic effects of LCN2 
may be receptor-mediated and dependent on B-cell lymphoma 2 (Bcl-2) family protein 
BIM [181]. 
Expression of the Lcn2 gene under conditions related to brain injuries is controlled at 
the transcriptional level by several different transcription factors. NF-κB is described as 
one of the most important regulators of Lcn2 gene transcription; indeed, brain injury is 
inevitably related to an activation of the inflammatory response and NF-κB, as a key 
regulator in inflammatory signalling pathways, in turn regulates Lcn2 gene expression 
[201]. It has also been demonstrated that mitogen-activated protein kinase (MAPK) and 
STAT signalling pathways regulate Lcn2 expression. One particular study employing a 
mouse model of a chronic neuroinflammatory condition showed the role of astrocytic 
STAT3 in the upregulation of expression of Lcn2, and although the model does not 
imply a direct CNS injury, it still emulates the neuroinflammatory characteristic thereof 
[202]. Notably, the STAT3 pathway is a well-established central player in reactive 
astrocytosis [91, 92]. Moreover, JAK2/STAT3 and IKK/NF-κB pathways are 
downstream signalling pathways of Lcn2 and there is evidence demonstrating their 
activation by Lcn2, resulting in the modulation of chemokine release and cell migration 
in astrocytes with the likely final outcome of promoting neuroinflammation. Therefore, 
Lcn2 and the above-mentioned STAT3 and NF-κB pathways are involved in a dual 
fashion in the role of Lcn2 in reactive astrocytes both in the induction of Lcn2 
expression and in its ultimate function [174].  
The relevant role of Lcn2 in the inflammatory response has led to further investigation 
on its ability to modulate the phenotype of immune cells. By analogy to macrophage 
polarization (i.e. M1 NF-κB being categorized based on their capability to induce 
classical pro-inflammatory signals, with M2 macrophages grouped based on their anti-
inflammatory properties [98]), microglia and astrocytes can also polarise along similar 
phenotypic axes upon stimulation [82, 203]. In this regard, it has been shown that Lcn2 
promotes a classical pro-inflammatory activation in astrocytes and, by inhibiting 
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STAT6 phosphorylation, it inhibits activation of the alternative phenotype (Fig. 4.7). 
Indeed, Lcn2 can induce the expression of classical genes related to a pro-inflammatory 
response, such as IL-1β, NOS2 and TNF, while this induction was reduced in Lcn2 
knockout (KO) mice [204]. 
 
 
Figure 4.7: Schematic representation of the effect of Lcn2 on astrocytes. Lcn2 promotes classical 
proinflammatory astrocyte activation and inhibits the alternative anti-inflammatory astrocytic activation, 
acting through an autocrine mechanism. Modified from Jha et al. [175]. 
 
Despite the dual role of Lcn2 in the regulation of the injured CNS environment, its 
central role in the activation of astrocytes towards a pro-inflammatory state suggests 
this protein as a valid and promising target for the modulation of reactivity astrocytes. 
Therefore our aim is to investigate the potential efficacy of 3WJ-pRNA nanostructures 
in modulating the expression of reactive astrocyte markers, such as GFAP and Vim, 
herein employ as a proof of concept targets, and to investigate the role of astrocyte-
secreted Lcn2 in the promotion of a reactive state in astrocytes. 
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4.5 RESULTS 
4.5.1 ASSEMBLY OF SIRNA-3WJ NANOPARTICLES 
siRNA-3WJs, of the general scheme depicted in Fig. 4.8, were prepared based on the 
previously methods described by Shu, et al.[173]. The sequences of the siRNA moieties 
incorporated in the nanostructures are identical to the commercial sequences provided in 
the SMARTpool siRNA mixtures (GE Healthcare, Dharmacon), here used as controls, 
albeit without the proprietary chemical modifications. Each siRNA-3WJ was 
constructed using three RNA strands that were annealed together in equimolar amounts 
to achieve the assembly of the 3WJ nanostructure. Strands A and C, containing the 
sense and antisense siRNA sequences respectively, were prepared via in vitro 
transcription with subsequent 5′ dephosphorylation using calf intestinal phosphatase, 
while the short B strand was purchased as a pre-synthesised RNA oligonucleotide. 
Successful assembly of the siRNA-3WJs was confirmed by the decreased gel mobility 
of the multistranded structures in electrophoretic assays relative to single- and double-
stranded controls (Fig. 4.8 b). The chosen nomenclature of siRNA-3WJs refers to their 
target mRNA (G for Gfap, V for Vim, L for Lcn2, and N for non-targeted negative 
control sequences) and the identification number of their analogous SMARTpool 
siRNA analogue (see Table 2.1 in the Materials and Methods section). For uptake 
assays, Cy3-labelled analogues were prepared by labelling the constituent strands of the 
siRNA-3WJ with the Cy3 fluorophore using a Mirus Label IT kit prior to assembly. 
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Figure 4.8: Design and characterisation of pRNA 3WJs. A, Generic 3WJ scheme showing the three 
constituent RNA strands, variable siRNA moiety and 3WJ core, unpaired and wobble base pairs (●). B, 
Native polyacrylamide gel (8%) illustrating the characterisation of 3WJ assembly by gel mobility. The 
assembled 3WJ shows decreased mobility relative to a double-stranded (A+C strands) construct or the B 
strand alone. An Ultra Low Range DNA ladder is used as reference. 
 
 
4.5.2 TRANSFECTION OF NPC-DERIVED ASTROCYTES WITH SIRNA-3WJS 
Once assembled, to ensure a high transfection efficiency siRNA-3WJs were delivered to 
NPC-derived astrocytes in vitro via lipofection using Lipofectamine RNAiMAX. 
Transfections were performed at 15 DIV with subsequent RNA collection for 
assessment of mRNA levels via qPCR at 17 DIV and evaluation of protein levels via 
Western blot or immunofluorescent microscopy at 20 DIV. Transfections were 
performed in three different activation contexts: a resting profile, in which the 
astrocytes were not treated with LPS+IFNγ and therefore quiescent, and two different 
activation profiles wherein LPS+IFNγ-treatment occurs either in the 48h prior to 
transfection (i.e. 13-15 DIV) or activation and transfection are concomitant (i.e. 15-17 
DIV) (See Fig 3.10, previous section). These two activation profiles are referred to as a 
therapeutic intervention, to mimic an in vivo approach upon CNS insult, and the 
preventative intervention, exploring the utility of these putative nanotherapeutics in 
inhibiting a reactive response, respectively. 
 
4.5.3 SIRNA-3WJS UPTAKEN BY NPC-DERIVED ASTROCYTES SHOW LOW 
TOXICITY AND IMMUNOGENICITY 
To assess the uptake efficiency of the siRNA-3WJs via transfection, high-FBS/FGF2-
free astrocytes were grown on poly-D-lysine-coated glass coverslips and incubated with 
Cy3-labelled N03-3WJs in serum-free medium at a final concentration of 10 nM for 6 
hours, thereafter medium was changed and cells were incubated for further 18 hours in 
high-FBS/FGF2-free medium. 24 hours post-transfection cells were fixed and labelled 
for immunofluorescence (GFAP, DAPI), with the percentage of transfected astrocytes 
estimated by confocal microscopy to visualize the co-localisation of punctuate Cy3 
staining with GFAP+ cells. Similar high transfection efficiencies were observed across 
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the different conditions: 89%, 82% and 71% Cy3-N03-3WJ-positive cells were 
observed respectively in resting, therapeutic and preventative activated astrocytes (Fig 
4.9).  
 
Figure 4.9 A Immunofluorescence quantification of percentage of astrocytes transfected with 20 nM 
Cy3-labelled 3WJ under resting and activated conditions. Data expressed as mean ± SD; N = 3 biological 
replicates, 3 coverslips per condition for each experiment, 10 images per coverslip. No statistically 
significant difference observed between conditions. B Confocal micrograph of Cy3-3WJ (red) transfected 
astrocytes, immunostained for GFAP (green), with nuclei co-stained with DAPI (blue). Orthogonal 
projections from z-stack images show internalisation of the Cy3-3WJs.  
 
 
Prior to evaluation of the efficacy in the down-regulation of target genes, transfection of 
NPC-derived astrocytes with our siRNA-3WJ nanostructures were shown to be non-
toxic over the range of concentrations tested (0.5 to 50 nM). By using colorimetric LDH 
cytotoxicity assays we observed that the viability of cells remained >95% for all 
siRNA-3WJs (N03, G10, V10 and L12) and at all concentrations, compared to untreated 
controls (100% viability) and lysed cell samples (0% viability). No significant 
cytotoxicity relative to untreated controls or mock control, i.e. cells treated with vehicle 
only (Lipofectamine RNAiMAX), was observed, neither at 24 hours post-transfection 
when cells remained in serum-free transfection medium, nor at further timepoints 
corresponding to 48 or 120 h (timepoints of typical RNA or protein quantification) 
when cells underwent a medium change at 6 h post-transfection (restoring low-FBS 
medium) (Fig. 4.10).  
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Figure 4.10: LDH-based cytotoxicity assay. Low-FBS/+FGF2-cultured astrocytes were treated with 0.5, 
5 or 50 nM doses of anti-GFAP (G10), anti-Vim (V10), anti-Lcn2 (L12), or non-targeted negative control 
(N03) 3WJs. Viability was compared to mock-treated (Lipofectamine RNAiMAX only) or non-treated 
(control) samples at 24, 48 or 120 h post-transfection. Data presented as mean viability relative to control, 
N = 3 biological replicates ± SD. No statistically significant difference between treatments observed. 
 
 
Before analysing gene expression levels we first investigated the stability of several 
common reference genes (glyceraldehyde-3-phosphate dehydrogenase [Gapd], 18S 
ribosomal RNA [Rna18s5], and beta-actin [Actb]) via TaqMan gene expression assays 
in order to establish their suitability in subsequent qPCR assays. The expression of each 
of these reference genes at 48 h post-transfection showed little variation across 
treatments (non-transfected control vs mock-transfected control vs N03-3WJ transfected 
samples) or conditions (resting, therapeutic, or preventative activation), as determined 
by comparing mean cycle threshold CT values across experiments and using the 2-ΔCT 
method [205] to compare samples of interest to the control sample. Gapd was then 
selected as the reference to report all subsequent gene expression data.  
The potential immunogenicity was then evaluated as the capability of siRNA-3WJs to 
induce the induction of pro-inflammatory cytokines in astrocytes upon transfection. We 
first tested 3WJs assembled from in vitro transcribed ssRNAs that had not been 
subjected to dephosphorylation, i.e. presenting 5′-triphoshate transcription artefacts. 
Transfection with 5′-triphosphate N03-, G10- and V10-3WJs (5 nM) were found to 
cause significant inductions in Il6 (ca. 50-fold), Tnf (ca. 500-fold) and interferon beta 1 
(Ifnb1, ca. 100-fold) mRNA levels relative to non-transfected controls in high-
FBS/FGF2-free astrocytes (Fig. 4.11). However, this polarisation towards a pro-
inflammatory phenotype was not observed in mock-transfected astrocyte samples, or in 
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samples treated with commercial siRNA pools (chemically synthesised and modified). 
We hypothesized the involvement of retinoic acid induced gene 1 (RIG-1, also known 
as DDX58)-mediated antiviral immunity, triggered by the 5′-triphoshate transcription 
artefacts [206]. This theory was further supported by the introduction of a 
dephosphorylation step to the 3WJ synthesis that resulted in complete ablation of the 
observed cytokine induction at the mRNA level (Fig. 4.11) Thus, these data suggest that 
appropriately modified 3WJs are not immunogenic. 
 
Figure 4.11:Expression of pro-inflammatory cytokines. A Il6, B Tnf, C Il1b in high-FBS/FGF2-free 
cultured “resting” astrocytes when transfected with 3WJs with (+PPP) or without 5ʹ-triphosphate in vitro 
transcription artefacts. Results expressed as the mean mRNA expression (RT-PCR) relative to non-
transfected controls (2-ΔΔCt method) with N ≥ 3 biological replicates ± SD; Gapd reference gene; * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to control samples (one-way ANOVA with 
Dunnett’s multiple comparison test). 
 
 
4.5.4 SIRNA-3WJS EFFICIENTLY KNOCK-DOWN TARGET GENES IN 
REACTIVE ASTROCYTES 
The optimal dose of 3WJs for an efficient silencing of the siRNA-3WJs was previously 
delineated through a dose-response profile by using high-FBS/FGF2-free cultured 
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astrocytes at three dosages, 0.05, 0.5 and 5 nM, under resting conditions. A dose-
dependent knockdown of both Gfap and Vim mRNA expression levels was observed 
relative to non-treated controls, comparable to the knockdown achieved by their 
commercial siRNA SMARTpool counterparts with a statistically significant knockdown 
by each observed at 5 nM. Furthermore, neither mock transfection nor treatment with 
non-targeted siRNA (NsiR) or siRNA-3WJs (N03) had a notable effect on Gfap 
expression, nor off-target knockdown effects were observed. Moreover, trials with a 50 
nM dosage did not show any differences in silencing efficiency compared to 5 nM 
dosage (data not shown); this could be attributed to saturation of the RNAi machinery, 
sincecells indeed have a limited capacity to assemble the RISC complex on exogenous 
siRNAs [207]. These data thus suggested 5 nM as the appropriate dose sufficient to 
induce a significant (~50%) reduction in targeted mRNA. This concentration was used 
in subsequent experiments to further examine the efficacy of the treatments under 
activation conditions, and to investigate siRNA-3WJ-mediated Lcn2 knockdown. 
Transfection was then performed in our low-FBS/+FGF2-cultured astrocyte protocol, 
under resting or activated conditions. The lipofection of siRNA-3WJs yielded 
significant reductions of Gfap and Vim mRNA by the G10 and V10 3WJs, respectively. 
In particular, both in resting and activation conditions a 5 nM G10-3WJ dose decreased 
Gfap mRNA expression by ≥60% relative to non-treated controls under the same 
condition (Fig. 4.12A). Similar results were achieved by V10-3WJs, with Vim 
expression knocked down by at ≥50% in each condition (Fig. 4.12B). However, 
knockdown by L12-3WJs resulted in a stronger downregluation of the absolute 
expression levels of Lcn2 in resting astrocytes compared to activated astrocytes, with 
the most significant knockdown (80%) being observed in the resting condition. A 
significant knockdown was also observed in the therapeutic and preventative conditions 
(70% and 50% respectively) (Fig. 4.12C). Notably, no synergistic effects were evident 
in combinatorial treatments comprising 5 nM doses of both G10 and V10 
simultaneously: Gfap/Vim expression levels were comparable to those samples 
receiving individual treatments (Fig. 4.12 A,B). No indirect or off-target knockdown (or 
induction) by targeted 3WJs was observed, nor did the non-targeted N03-3WJ induce 
any significant change in the expression of the target genes (Gfap, Vim or Lcn2). 
Despite the efficaciously and specifically knockdown of 3WJs towards their target 
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mRNAs, the expression of pro-inflammatory markers was unaffected. Levels of Il6 and 
Nos2 mRNA, upregulated upon LPS+IFNγ treatment, were unaffected by 3WJ-
mediated modulation of Gfap, Vim or Lcn2. The expression of Tnf and Il1β, unchanged 
by activation, were also unaffected by these 3WJs (Fig. 4.13). 
 
 
 
 
 
 
Figure 4.12: 5 nM doses of 3WJ nanostructures induced a significant decrease in the expression of their 
target mRNA: A Gfap, B Vim, or C Lcn2 both under resting and activated conditions 48 h post-
transfection, according to RT-PCR assays. No synergistic effects were evident from a combined anti-
Gfap/anti-Vim treatment (5 nM dose of each), nor were there significant off-target modulation of 
expression. Mock (Lipofectamine-only) or non-targeted negative control 3WJs had no significant effect. 
Results expressed as the mean of N ≥ 3 biological replicates ± SD; Gapd reference gene; * P ≤ 0.05, ** P 
≤ 0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to control samples of the same activation condition 
(two-way ANOVA with Dunnett’s multiple comparison test). 
 
	 88	
 
Figure 4.13: mRNA levels of pro-inflammatory markers were not affected by none of the treatments: A 
Il6, B Tnf, and C Il1b. Results are expressed as the mean mRNA expression (RT-PCR) of N ≥ 2 
biological replicates ± SD; Gapd reference gene; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, or **** P ≤ 
0.0001 relative to control samples of the same activation state (one-way ANOVA with Dunnett’s multiple 
comparison test). 
 
 
To further confirm the knockdown efficacy of 3WJs, protein levels were quantified 5-
days post-transfection (20 DIV) in low-FBS/+FGF2 cultured astrocytes. Both G10- and 
V10-3WJs induced significant reductions in GFAP and Vim expression (>70%), in 
resting, therapeutic, and preventative conditions (Fig. 4.14). As observed for mRNA 
expression, no off-target effects were evident, and combinatorial treatments with G10 
and V10 resulted in a decreased expression of individual proteins comparable to the 
singular 3WJ treatment, excluding again the possibility of synergistic effects. 
Qualitative ICC images showed the same decreased expression of protein levels as 
observed by Western blot analysis (Fig. 4.16). Lcn2 could not be detected by Western 
blot in resting, therapeutic or preventative activation conditions at 20 DIV, even though 
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ICC assessments showed observable expression by means of immunofluorescence at 20 
DIV in reactive astrocytes (Fig. 4.15). These differences might be due to faster kinetics 
of the Lcn2 response, with an early peak and subsequent decline in expression in 
response to LPS+IFNγ exposure, and so we also performed Western blots at earlier 
timepoints. Lcn2 was detected by Western blot at both 16 and 17 DIV, with a notable 
induction in activated samples. Moreover, treatment with L12-3WJ showed a reduction 
in the amount of Lcn2 detected in each condition (Fig. 4.15), however confirmation is 
ongoing (N=2 for some conditions). This remarkable reduction in Lcn2 expression was 
mirrored by ICC results obtained at 20 DIV (Fig. 4.16).  
 
 
Figure 4.14: A Representative Western blots of Vim (54 kDa) and GFAP (50 kDa) in various controls 
and 5 nM 3WJ treated-samples 5 days post-transfection, under resting and activated conditions. B 
Densitometric analyses showing the expression of GFAP. C Densitometric analyses showing the 
expression of Vim. β-actin (42 kDa) was used as loading controls. Data represent the mean relative to 
control samples in the same activation condition-treated controls of N ≥ 3 biological replicates ± SD; * P 
≤ 0.05, ** P ≤ 0.01 (two-way ANOVA with Dunnett’s multiple comparison test). 
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Figure 4.15: A Representative Western blots of Lcn2 (24 kDa) expression at 24 h, i.e. 16 DIV. B 
Representative Western blots of Lcn2 (24 kDa) expression at 48 h, i.e. 17 DIV C Densitometric analyses 
showing the expression of Lcn2. β-actin (42 kDa) was used as loading controls. Data represent the mean 
relative to preventative untreated control at 24h, i.e. 16 DIV, N=2-3 biological replicates ± SD. (two-way 
ANOVA with Dunnett’s multiple comparison test).  
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Figure 4.16: Representative immunofluorescence micrographs of low-FBS/+FGF2 astrocytes in 
therapeutic and preventative conditions showing reduction in target genes upon 3WJ-pRNA transfection. 
Scale bar: 50 µm. 
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4.5.5 THE ABILITY OF LCN2 TO INDUCE MARKERS OF REACTIVITY IN A 
PARACRINE MANNER IS MODULATED BY 3WJ TRANSFECTION IN 
REACTIVE ASTROCYTES 
To further investigate the role of Lcn2 in the modulation of astrogliosis we assessed the 
effects of conditioned media from reactive astrocytes, with or without 3WJ treatment, 
on resting recipient astrocytes. Secreted Lcn2 has been shown to act in an autocrine 
manner on reactive astrocytes, augmenting the astrogliosis extent in those same 
astrocytes [185]. 
We employed donor astrocytes both in resting and preventative activation condition. 
Astrocytes were transfected with L12-3WJ at day 15, and we additionally tested mock 
and N03-3WJ conditions to exclude any further side-effects. Transfections were 
performed as mentioned-above. 24 h after transfection we changed media to DMEM 
which was subsequently conditioned for a further 24 h before being transferred to 
resting recipient astrocytes. mRNA levels were assessed on recipient astrocytes 24 h 
after exposure to this conditioned media (Fig. 4.17). 
 
 
Figure 4.17: Schematic representation of astrocyte-conditioned medium (ACM) experimental setting. 
 
 
Secreted levels of Lcn2 were measured by ELISA techniques, where we observed a 
significant induction in the secretion of Lcn2 upon activation: a mean concentration of 
ca. 18,000 pg/ml, compared to mean concentrations of < 50 pg/ml in resting controls. 
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These ELISA measurements confirmed results for protein levels obtained by Western 
blot and immunohistochemistry, showing a significant downregulation in secreted 
LCN2 upon transfection with L12-3WJ, while both mock and N03-3WJ conditions did 
not show any significant effect on supernatant Lcn2 levels (Fig 4.18). 
 
 
Figure 4.18: ELISA quantification of Lcn2 in the supernatant media of resting or LPS+IFNγ-stimulated 
astrocytes, as well as activated astrocytes treated with mock, N03 or L12 transfections, 48 h after 
treatment. Data represent the mean of N ≥ 3 biological replicates ± SD; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, or **** P ≤ 0.0001 relative to control samples in the same activation condition (two-way ANOVA 
with Dunnett’s multiple comparison test). 
 
 
Astrocytes exposed to conditioned medium obtained from activated astrocytes showed a 
strong and significant induction in Lcn2 mRNA levels, while a significant reduction in 
this level was observed in astrocytes exposed to medium derived from L12-3WJ-treated 
activated astrocytes, in correlation with ELISA Lcn2 measurements. Conditioned 
medium from resting donor astrocytes showed negligible induction of Lcn2 levels in 
recipient astrocytes (Fig. 4.19A). Interestingly, Nos2 was also significantly induced in 
recipient astrocytes upon treatment with non-transfected conditioned medium. But, as 
for Lcn2, Nos2 levels were found significantly downregulated when astrocytes were 
exposed to L12-3WJ conditioned medium (Fig. 4.19 B). Nevertheless, we did not 
observe any changes upon different conditions in the modulation of Gfap and Vim 
expression (Fig. 4.19 C, D). 
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Figure 4.19: qRT-PCR quantification of activation-related genes in recipient cells 24 h after transfer of 
media from treated astrocytes. A Lcn2, B Nos2, C Gfap, D Vim. Results expressed as the mean mRNA 
expression relative to those cells receiving conditioned media from activated controls (2-ΔΔCt method), 
Gapd reference gene. Data represent the mean of N ≥ 3 biological replicates ± SD; * P ≤ 0.05, ** P ≤ 
0.01, *** P ≤ 0.001, or **** P ≤ 0.0001 relative to control samples in the same activation condition (two-
way ANOVA with Dunnett’s multiple comparison test). 
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4.6  DISCUSSION 
pRNA-derived 3WJs were designed based on the technology developed in the Guo 
laboratory: a novel and efficacious RNAi-delivery platform inspired by structural and 
molecular characteristics of the phi29 bacteriophage DNA packaging motor [151]. The 
modular nature of this technology makes it versatile and nanoparticles can be 
functionalized with multiple components [208]. Recent application of the pRNA system 
have showed promising results in the targeted delivery of RNAi or small-molecule 
drugs for anti-cancer and anti-viral applications in vitro and in vivo	[209, 210]. Indeed, 
one recent application of 3WJ-pRNA nanotherapeutics in a triple negative breast cancer 
(TNBC) murine model has shown the capability of the nanoparticle to specifically bind 
and internalize into TNBC cells, efficently knocking down the target RNA, miR-21, and 
showing specificity for the target tumors with poor accumulation in healthy organs and 
tissues [210]. However, the studies reported herein represent one of the first 
applications in the CNS environment [211]. The proof-of-concept 3WJ design used for 
this project incorporate a single siRNA sequence per structure, each of which were 
selected to match the target sequences employed in commercially-validated anti-Gfap, -
Vim, -Lcn2 and non-targeting siRNA pools (which we also employed as controls in 
these studies). siRNA-3WJ mechanisms of action rely on the formation of RISCs: after 
reaching the intracellular environment, the siRNA moiety is cleaved from the 3WJ by 
the endonuclease Dicer before entering the RISC and guiding the cleavage of mRNA 
strands complementary to the target sequence	[160]. It has been suggested that Dicer-
substrate based RNAi such as this is more potent than that produced by standard 21-
nucleotide double-stranded siRNA agents since Dicer assists in loading the siRNA into 
the RISC assembly [212]. Other design considerations, such as the inclusion of two-
nucleotide overhangs on the free 3′ end of the antisense (guide) strand to promote Dicer 
recognition, and 5′ guanine residues as needed to facilitate efficient T7 RNA 
polymerase transcription of RNA strands, were addressed as previously as described by 
Shu et al [172]. 
 
The two longer RNA strands of each 3WJ (A and C strands) were prepared via in vitro 
transcription and dephosphorylated to remove 5′-triphosphate groups, an artefact of 
	 97	
transcription using nucleotide triphosphates. In mammalian cells, the innate receptors 
involved in the recognition of nucleic acid are classified in two families: the 
transmembrane Toll-like receptors (TLRs) that detect viral RNA or DNA in the 
endosomal compartment, and the cytoplasmic RIG-I receptor	[213]. RIG-I like 
receptors (RLRs) act as cytoplasmic sensors of pathogen-associated molecular patterns 
(PAMPs) for viral RNA, in particular recognising RNA sequences marked with 5′ 
triphosphorylated (5′-ppp) ends and triggering a type I interferon inflammatory response 
[206, 213-215]. It has also been shown that the activation of RIG-like receptor 
signalling is involved in the onset of astrogliosis, such as in the induction of GFAP and 
Vim upregulation, and so for our purposes we therefore aim to avoid RIG-I mediated 
interferon responses [216]. After dephosphorylation with calf intestinal phosphatase, 
transcripts were annealed together with a third, synthetic B strand to allow for the 
assembly of the construct. This process was monitored using PAGE migration assays; 
consistent with previously described characterisation of 3WJs the assembled construct 
ran as a compact band, considerably slower than single- or double-stranded assemblies. 
Targeted delivery is one of the major challenges in drug delivery; therefore, size is an 
important parameter to consider in order to allow the diffusion of therapeutics into the 
CNS. The size of siRNA-3WJs (ca. 20-40 nm) represents an optimal size to be taken up 
into cells, to avoid renal filtration or stimulation of the innate immune response or 
without being recognized by the reticuloendothelial system (RES) [154]. Moreover, 
components in a range between 35-64 nm are suitable to diffuse uniformly within the 
brain [217].  
 
siRNA-3WJs were designed and synthesised for each of the four siRNA target 
sequences found in each commercial siRNA pool (i.e. sixteen siRNA-3WJs total), but 
based on transcription yields and previously preliminary silencing assays only one 
siRNA-3WJ of each class was selected (anti-Gfap, anti-Vim, anti-Lcn2 and non-
targeting) for further characterisation. To test the uptake efficiency of transfections, 10 
nM doses of Cy3-labelled N03-3WJ were transfected using Lipofectamine RNAiMAX 
and immunostaining assays was conducted 24 hours post-transfection. The presence of 
labelled siRNA-3WJ, as punctate cytoplasmic Cy3 fluorescence, was detected in >70% 
of previous established protocol high-FBS/FGF2-free astrocytes, with no statistically 
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significant difference between resting and activated cells, and no uptake was observed 
without the use of Lipofectamine. After testing the efficiency of delivery, safety of 
siRNA-3WJ treatment in vitro was investigated by confirming that the constructs were 
both non-cytotoxic and non-immunogenic upon transfection. qRT-PCR assays were 
performed to profile the expression of genes of interest. To obtain an accurate and 
reproducible gene expression analysis, we first aimed to identify putative reference 
genes (housekeeping genes or internal control genes) with the most stable expression to 
use for normalization of gene expression data, an important validation for experiments 
utilising the 2-ΔΔCt method of assaying relative gene expression [218]. Our reference 
gene of choice, Gapd, was unaffected by activation or transfection, with or without 
3WJ-treatment. Another critical step to be investigated in siRNA knockdown techniques 
concern the cytotoxicity of the tool employed and considering the different mechanisms 
through which siRNA can interact with the immune system, the possibility to invoke 
pro-inflammatory effects is an important consideration to be addressed [219]. 
Colorimetric quantification of LDH activity in the supernatant of astrocytes treated with 
5 nM doses of G10, V10, L12 and N03 showed negligible impact on the viability of 
low-FBS/+FGF2-cultured cells for at least 120 h post-transfection, confirming 3WJs 
were non-toxic. Moreover, cytokine expression in cells transfected with 3WJs 
comprised of dephosphorylated RNA strands were compared to those using their 
phosphorylated analogues. Those siRNA-3WJs retaining their 5′-triphosphate groups 
induced a significant pro-inflammatory response in transfected astrocytes, with average 
mRNA levels of the cytokines Ifnb1, Il6 and Tnf increasing approximately 100, 50, and 
500-times, respectively. On the contrary, no such induction was evident upon 
transfection with the dephosphorylated constructs. This observation is consistent with 
previously discussed involvement of RIG-I-mediated antiviral responses upon 
triphosphate activation: this has been shown to trigger signalling cascades involving 
both interferon response factor 3 and NF-κB pathways, resulting in the upregulation 
IFN-β1 and pro-inflammatory cytokines respectively [220, 221]. Thus, these 
preliminary results suggest 3WJs as a safe therapeutic platform in a CNS context, 
however more extensive profiling would be required before any translational 
application, especially regarding potential off-target activity, due to the different 
transcript regulation across species [168]. 
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Previous results in our lab demonstrated that upon transfection, the siRNA-3WJs were 
successfully able to knockdown the expression of their target genes in high-FBS/FGF2-
free astrocytes in a dose-dependent manner, with a maximal efficacy at 5 nM. 50 nM 
did not show any increase in the knockdown efficiency, probably related to a saturation 
of RNAi machinery. Indeed it has been shown that cells are characterized by a limited 
capacity to assemble the RISC complex on exogenous siRNAs, and this might affect 
microRNA expression levels and function, although we did not observe any non-
specific effects in the few genes we examined in this proof-of-concept study [207]. 
Based on the substantial silencing observed in these preliminary studies, a 5 nM dose 
was selected as the basis for further investigation (i.e. in our reactive astrocyte model). 
At this 5 nM dose, in both resting and activated conditions, both G10- and V10-3WJ 
caused a >60% reduction in the expression of their target mRNA (Gfap and Vim, 
respectively) in low-FBS/+FGF2 cultured astrocytes relative to non-transfected 
controls. The use of siRNA-3WJs resulted in gene-specific knockdown, with each of the 
siRNA-3WJs showing no observable effect on the expression of the other analysed 
genes at any of the doses studied. Furthermore, combinatorial approaches employing 
both G10- and V10-3WJ at 5 nM doses each did not reveal any synergistic, antagonistic 
or compensatory effects, at least at the mRNA level, despite the interfunctionality of 
these two intermediate filaments	[96]. Such results are promising given the relatively 
low concentration of the siRNA-3WJs employed compared to other studies, 30-40 nM 
in one similar study, for instance [14]) which also lead to a modulation in IF expression 
by inducing a reduction, rather than complete silencing; the low-dosage may also limit 
both off-target effects and potential saturation of natural RNAi pathways	[222]. 
Moreover, while the analogous commercial siRNA pools GsiR and VsiR were capable 
of inducing similar reductions in target intermediate filaments (IF) mRNA levels (i.e. 
>60% tested in high-FBS astrocytes), this was accomplished using pools of four siRNA 
sequences targeted against each mRNA and the siRNAs themselves have unspecified 
modifications to enhance stability/activity. The possibility of inducing side effects upon 
transfection was excluded by using both the non-targeted N03-3WJ as a negative 
control that showed no effect on either Gfap or Vim expression levels at any of the 
concentrations tested, and also by showing that mock transfections showed no 
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significant effect on Gfap or Vim mRNA levels, excluding any obvious side-effects of 
Lipofection, at least with regards to IF expression. L12-3WJ, investigated in low-
FBS/+FGF2 cultured astrocytes at the 5 nM concentration, was found to significantly 
reduce the expression of Lcn2 in resting and activated astrocytes, with no effect on the 
other target genes. 
 
The increasing of number of silencing studies has led to the investigation of which 
features may influence the efficacy of siRNA, including such properties as the mRNA 
internal stability, and characteristics of the target mRNA, such as the secondary 
structure of the siRNA target site [223]. Furthermore, several studies have shown that 
the abundance of target transcripts correlate with silencing efficacy, demonstrating that 
transcripts with low expression levels are less susceptible to siRNA-mediated 
degradation [223, 224]. Nevertheless, both Gfap and Vim were expressed at relatively 
high levels in our astrocytes, even in the resting condition. Lcn2 knockdown seems to 
follow the trend (if not the magnitude) of post-activation induction. While still potent, 
the relative silencing in therapeutic (>70%; 96 h post-activation, 48 h in basal medium) 
and preventative conditions (ca. 50%; 48 h post-activation) is less than that observed in 
resting astrocytes, perhaps due to the magnitude of the induction upon LPS+IFNγ 
treatment. 
 
To further confirm the siRNA-3WJ efficacy, protein level modulation has been 
assessed. Silencing observed at the mRNA level was reflected at the protein level as 
evidenced through Western blots and immunofluorescence micrography. IF proteins, 
once synthesized, tend to be very stable [225]: GFAP and Vim are structural in nature 
and therefore expected to have a relatively long cellular half-life compared to signalling 
proteins such as cytokines. Indeed, it has been reported that these IFs exhibit biphasic 
decay kinetics in primary astrocytes, with 40% of the IF population being in a fast-
decay phase (t1/2 = 12-18 h) and 60% in a slow-decay phase (t1/2 = 8 d) [226]. 
Preliminary data conducted in the lab showed that, by comparison of several timepoints 
post-transfection, maximal silencing (ca. 90%) was observed at 4-6 days post-
transfection, therefore protein levels have been assessed 5 days post-transfection. Strong 
reductions in GFAP and Vim expression were observed in low-FBS/+FGF2 cultured 
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astrocytes at this 5 days post-transfection timepoint, in each of the different resting, 
preventative and therapeutic conditions. Significant reductions of GFAP and Vim were 
observed upon transfection with 5 nM doses of G10- and V10-3WJs, respectively, by 
Western blot assay, while a combined treatment of G10- and V10-3WJs efficiently 
reduced their expression simultaneously, supporting results obtained for mRNA levels. 
Qualitative assessment by ICC techniques showed a decrease in the GFAP and Vim 
intensity upon transfection in activated astrocytes as compared to controls. Substantial 
Lcn2 knockdown was also evident in immunofluorescence images of activated 
astrocytes at 20 DIV (i.e. 5 days post-transfection). However, as mentioned earlier, 
Lcn2 could not be detected by Western blot assay at this timepoint. Results suggest that 
Lcn2 expression might reach a peak between 24h and 48h and decreases throughout 
time, as observed between 16 DIV and 17 DIV by Western blots. Although its 
expression remains higher compared to control, as observed in immunofluorescent 
images, it is possible that the high sensitivity of immunofluorescence techniques could 
detect its cellular expression while such signal could be not enough to be detected in 
Western blot, likely Lcn2 protein quantity in the total 20 µg protein loaded for Western 
blot assay might be insufficient to be detected as such later timepoints.  Results 
obtained from Western blots performed on reactive astrocytes at 16 and 17 DIV showed 
a substantial upregulation in Lcn2 expression compared to resting condition, and, upon 
L12-3WJ transfection, a strong decreases in Lcn2 expression was observed. 
 
Thus, it is evident that low doses of siRNA-3WJs are capable of downregulating 
astrogliosis-associated molecular markers at both the mRNA and protein levels in 
astrocytes, however potential therapeutic approaches require more substantial 
investigation. For this purpose, we examined the effect of 3WJ treatments on the 
expression of several pro-inflammatory cytokines and markers. Il6, Tnf, and Nos2 
expression levels, each found to be elevated in LPS+IFNγ-treated low-FBS/+FGF2 
astrocytes, both at mRNA and protein levels (from ELISA data), were unaffected by the 
substantial reductions in Gfap, Vim, or Lcn2 afforded by our siRNA-3WJs, at least at 
the 17 DIV (48 h post-transfection) timepoint at which qRT-PCR experiments were 
performed. The inability to modulate pro-inflammatory signals upon siRNA-3WJ 
treatment may be due to a differential kinetics between protein knockdown and 
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subsequent secondary effects on cytokine/chemokine mRNA expression at the assayed 
timepoint. However, considering that Il6 and NO synthesis (by NOS2) are upstream 
pathways in the induction of IFs	[91, 116], an effect on the expression of these 
signalling mediators is not necessarily a certainty following the knockdown of our 
selected targets. Therefore, downregulation of GFAP/Vim is likely to be too late an 
intervention in the astrogliosis response to modulate the pro-inflammatory polarisation 
of astrocytes. Lcn2, however, is known to be a secreted autocrine/paracrine mediator of 
astrogliosis, playing a dual role in STAT3 and NF-κB pathways, both being induced via 
activation of these signalling pathways but also by activating those same pathways upon 
secretion and subsequent binding to the 24p3R receptor on recipient astrocytes	[174, 
185, 194]. Despite this dual relationship between Lcn2 induction and astrocyte 
reactivity, we did not observe changes in cytokine or IF expression, by qRT-PCR, 
Western blot, or immunofluorescence upon L12-siRNA-3WJ transfection. This might 
be related to a strong induction in reactivity via stimulation with a large LPS+IFNγ dose 
that may consequently mask or inhibit therapeutic actions resulting from siRNA-3WJ 
treatment. 
 
To further investigate this hypothesis, we aimed to unravel the paracrine effects induced 
by reactive astrocyte-secreted Lcn2 on recipient resting astrocytes, by transferring 
media conditioned by the activated astrocytes (with or without L12-3WJ treatment) to 
non-reactive astrocytes, and characterising the extent of the induced secondary 
reactivity. ELISA measurements performed on the supernatant/conditioned media of 
reactive astrocytes confirmed the presence of secreted Lcn2 in conditioned media, 
showing a significant upregulation in the secretion of pro-inflammatory Lcn2 upon 
activation, while treatment with L12-3WJ was able to downregulate this Lcn2 secretion. 
ACM obtained from LPS+IFNγ-stimulated astrocytes was found to induce a significant 
induction in Lcn2 and Nos2 expression in recipient resting astrocytes. Remarkably, both 
upregulated genes were reverted back to levels comparable to resting ACM controls 
when exposed to media obtained from L12-3WJ activated astrocytes (in which secreted 
Lcn2 levels were downregulated), confirming the capability of Lcn2 to act as a 
paracrine mediator in regulating itself and its capability to regulate pro-inflammatory 
signals, such as NO production. Further investigations are currently being undertaken 
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by us in order to elucidate the interconnected roles of these genes in the modulation of 
reactive state in astrocytes. Nevertheless, both genes are indeed crucial in astrogliosis 
and these results confirmed the significant role of Lcn2-mediated reactivity as Lcn2 is 
known to upregulate NO production (via NOS2 induction), which in turn may drive 
astrogliosis-associated GFAP overexpression [116, 185].  
 
Therefore these proof-of-concept studies confirmed the powerful potential of siRNA-
3WJ constructs. 3WJ nanotherapeutics did not show any cytotoxic or immunogenic 
effects and in particular their employment showed an efficacious knockdown of 
astrogliosis-associated genes (Gfap, Vim and Lcn2), confirmed by a significant 
reductions in mRNA and protein expression using relatively small doses of siRNA-
3WJ. Moreover, no off-target effects were observed in our limited study. Furthermore, 
we confirmed the key role of Lcn2, as protein secreted by reactive astrocytes, as a 
potentially significant contributor to the propagation of inflammation and astrogliosis, 
and consequently the potential of therapeutic intervention employing anti-Lcn2 3WJs to 
ameliorate astrocyte reactivity. 
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5) INTRODUCTION 
 
Spinal cord injury (SCI) is a devastating neurological disorder that affects thousands of 
individuals each year. During the last few decades enormous progress has been made in 
understanding the molecular and cellular events initiated by SCI, leading to a better 
knowledge of crucial mechanisms that contribute to tissue damage and regenerative 
failure of injured neurons. Surgical procedures soon after the injury aim to stabilize and 
decompress the spinal cord to reduce secondary complications and rehabilitative care 
[227], however fully restorative treatments are not yet available. Due to the multifaceted 
nature of SCI, different therapeutic approaches have been investigated, amongst which 
stem cell transplantation has emerged as a promising tool [8]. Stem cells retain the 
capability to differentiate into different cell types, an appealing approach for cell 
replacement in the injured CNS; neural precursor cells (NPCs) in particular have 
received considerable attention for their committed nature to differentiate towards the 
neural lineage. Intriguingly, recent evidence pointed out bystander mechanisms 
alternative to cell replacement [228]. 
 
 
5.1 SPINAL CORD INJURY 
 
SCI can be defined as a damage or trauma to the spinal cord that results in impairment 
in sensory, motor or autonomic functions, leading to a devastating and debilitating 
condition that adversely affects a patient’s quality of life. In 2013 the World Health 
Organization reported a global estimation for SCI incidence at around 40 to 80 new 
cases per million population per year, based on quality country-level incidence studies 
of spinal cord injury from all causes, meaning that every year, between 250 000 and 500 
000 people become spinal cord injured [229]. Traumatic injuries (i.e. caused by trauma 
or damage resulting from the application of an external force of any magnitude, such as 
in the event of road traffic crashes, falls or acts of violence) have a higher rate of 
incidence compare to non-traumatic injuries (i.e. congenital/genetic malformations, 
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damage caused by infection, loss of blood supply (infarction), compression by a cancer 
or tumour, or by slow degeneration of the vertebrae because of osteoarthritis) (Fig 5.1) 
[229, 230]. Demographic distribution of SCI also influence the etiology of spinal cord 
injuries -- traumatic spinal cord injuries, for example, affect predominatly young people 
between 18-32 years, and while life expectancy of people with SCI has greatly 
improved over time as a result of advances in medicine and improved access to medical 
care, rehabilitation and systems of support, this leads to a noteworthy cost in terms of 
medical and support resources [227]. 	
	
 
Figure 5.1: Traumatic spinal cord injury causes from 1959-2011, WHO global regions. Adopted from 
Lee et al. [231] 
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Spinal cord injury in humans has been classified into 4 different categories based on 
gross findings [232, 233]: 
• Solid cord injury (representing 10% of cases) – despite the normal appearance of 
the spinal cord by a gross evaluation, without signs of softening or cavity 
formation, a clear damage in the spinal cord is evident by deeper histological 
examinations compared to normal appearing spinal cord (Fig. 5.2 A,B); 
• Contusion/cavity (representing 49% of cases) – this type of injury develops from 
a haemorrhagic event and subsequent necrotic area, eventually forming a cyst 
into the cord developing from the rostral to the caudal side of the cord, along the 
ventral parts of the posterior columns. However, the surface of the cord does not 
show any disruption (Fig. 5.2C); 
• Laceration (representing 21% of cases) – this is the result of a disruption of 
meningeal layer and underlying parenchyma by a sharp object. Compared to 
contusion, formation of cavity in this type of injury is minimal and the lesion is 
mostly characterized by the deposition of collagenous connective tissue (Fig. 
5.2D). Notably, complete transection of the spinal cord is a rare condition in 
patients, with most of the cases still presenting small amount of residual tissue 
traversing the cord, although complete transection is a common paradigm in 
experimental research; 
• Compression (representing 20% of cases) – with this type of injury the spinal 
cord appears macerated and the degree of the damage depends on the severity of 
the compression. This lesion presents characteristics similar to contusion, with 
the development of extensive scarring over time and similarities with laceration 
(often as consequence of vertebral body fractures) (Fig. 5.2E). 
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Figure 5.2: Pathophysiology and histopathology of SCI. A, Coronal section of normal appearing spinal 
cord. B, Solid cord injury with loss of the normal architecture and myelin loss. C, Contusion/cavity with 
cyst. D, Laceration injury and disruption of the pial surface. E Massive compression showing 
haemorrhagic area. Bar = 2 mm. Modified from Norenberg et al. [233] 
 
 
Spinal cord injury develops in different phases (Fig. 5.3). The initial trauma, as a 
consequence of any of the above-mentioned causes, leads to the primary injury, damage 
of blood vessels, disruption of axons, and breakage of neural-cell membranes; however, 
in most of the cases no abnormalities are observed during this early phase  (unless 
resulting from a consistent compression or laceration) suggesting that secondary 
phenomena contributes to a significant extent to the pathology [1, 233, 234]. 
 
This initial injury is followed by acute and sub-acute phases, lasting for days and weeks, 
respectively, which are characterized by the activation of a cascade of biological events, 
referred as “secondary injury”, that exacerbate the pathology throughout the time	(Fig. 
5.3). Finally, in the chronic phase, occurring from days to years after the injury, 
neurological impairments in both orthograde and retrograde directions are observed, 
including in the brain [235]. 
 
The relevant role of the secondary injury in the development of the pathology has 
underlined the need for a better understanding of the biochemical and cellular events 
driving these phenomena in order to provide significant information for the 
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development of promising therapies to minimize the injury and to improve regeneration. 
Towards this goal, several studies have unravelled the complexity of these secondary 
events, highlighting a number of key contributory mechanisms (Fig. 5.3): 
 
 
Figure 5.3: Schematic representation of the pathophysiology of the secondary damages in SCI. The 
illustration on the left depicts a neuron represented with the cascade of secondary damages. Modified 
from Schwab, et al.[5]. On the right, a schematic representation of the temporal progression of secondary 
damages after SCI. Modified from Bareyre et al. [236]. 
 
− Vascular changes: these are characterize by haemorrhage, breakage of the blood 
brain barrier and infiltration of inflammatory cells, which leads to oedema, 
necrosis and a period of ischemia followed by reperfusion which increases the 
production of oxygen-derived free radicals that further exacerbate the secondary 
damage [234, 236, 237]; 
− Free radical formation and lipid peroxidation: these biochemical events lead to 
hypoperfusion, oedema, failures in axon conduction and energy metabolism, and 
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Wallerian degeneration	[238]. Peroxidation of phospholipids results from 
degradation of the cell membranes of damaged cells by the enzyme 
phospholipase A2, which in turn releases arachidonic acid. The metabolisation 
of this acid by cyclooxygenases produces pro-inflammatory prostaglandins, such 
as PGE2. As a consequence, free radicals are produced and trigger the 
progression of inflammation and apoptosis [5]; 
− Disruption of the ionic balance of K+, Na+, Ca2+, and glutamate excitotoxicity: 
following injury, extracellular levels of glutamate rise rapidly. Glutamate 
excitotoxicity has been shown to play a key role in neuronal cell death and in 
delayed post-traumatic spinal cord white matter degeneration. Indeed, 
oligodendrocytes are particularly vulnerable since they express a variety of 
glutamate receptors, such as the alpha-amino-3-hydroxy-5-methyl-4-
isoxazoleproprionate (AMPA) receptors	[239]. AMPA receptors present on the 
myelin sheets in turn activate Ca2+-sensitive proteases that lead to cytoskeleton 
degradation and myelin disruption [240].  
Finally, impairment in calcium and sodium regulation induces a depletion of 
potassium and magnesium, with subsequent depolarization and interference with 
metabolic processes [241]; 
− Apoptosis: morphological and biochemical evidence has showed the presence of 
apoptosis after SCI, occurring in neurons, oligodendrocytes, microglia and likely 
astrocytes [242]. The activation of caspases, proteases with a crucial role in the 
apoptotic programme, occurs in neurons at the injury site within hours and it 
extends to oligodendrocytes. The widespread nature of this phenomenon may 
lead to long-term deficits after the injury, and to the damage of cells unaffected 
by the initial trauma [243], as observed in several different animal model, as 
well as in humans[244, 245]; 
− Inflammatory response: this includes different cellular components, such as 
neutrophils, macrophages and T cells, and the release of cytokines, 
prostaglandins and complement factors [236]. After the injury, infiltrating 
neutrophils rapidly increase in the tissue and start to release cytokines [246] to 
recruit other inflammatory cells and to further promote activation of resident 
microglia and astrocytes [247]. However, it is now clear that inflammation can 
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play a dual role, both exacerbating the damage and promoting neural tissue 
repair.Therefore, therapeutic modulation of the immune system, as well as of the 
injured environment, is still a challenge for pre-clinical research [248]. For 
instance, TNF, a central player in inflammation signalling, is significantly 
upregulated in neurons, glia, and endothelial cells within hours of SCI [249]. 
Yet, while the reduction of TNF signalling has been demonstrated to improve 
functional neurological recovery following SCI [250], the use of TNF-deficient 
mice led to an increase in apoptotic cell numbers, increased lesion size, and 
worsened functional recovery when compared with wild-type mice after SCI 
[251]; 
− Glial scar: it is well known that astrocytes react to CNS injury, and reactive 
astrocytes can lead to the formation of a glial scar that surround the injured 
environment, incorporating newly proliferated cells and in which astrocyte 
processes overlap in ways not seen in healthy tissue [34, 77]. Furthermore, it has 
been observed that the glial scar is characterized by a gradient of severity, with 
astroglial proliferation and density of astroglial cells diminishing with distance 
from the SCI lesion, gradually assuming a density similar to that seen in healthy 
tissue [252]. Traditionally, it was thought that this structure represented only a 
simple mechanical barrier, later studies suggested that regeneration was 
inhibited even when a dense glial scar does not form, unravelling the production 
of inhibitory molecules by astrocytes and the molecular composition of the scar 
as contributing factors for regenerative failure [83, 95, 253]. Reactive astrocytes, 
concomitant with other cells present in the scar, exert inhibitory effects due to 
the secretion of three main axon growth inhibitory molecules in the extracellular 
matrix such as Semaphorin 3, ephrins and chondroitin sulfate proteoglycans 
(CSPGs) [95, 254-256]. Semaphorin 3 is mainly secreted by meningeal cells that 
enter CNS lesions and contribute to the lesion core, which are highly inhibitory 
to axons that express the relevant receptors and they may therefore represent an 
important cause of regenerative failure [257]. Axon regeneration is affected also 
by the upregulation of members of the eph/ephrin family of tyrosine kinases and 
their ligands, mainly by astrocytes in SCI [258]. Finally, reactive astrocytes 
secret several of the inhibitory CSPGs major factor in blocking axon 
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regeneration, in particular neurocan, NG2, versican and brevican	[95]. The 
mechanisms by which the GAGs inhibit axon growth are not well understood, 
probably related to the small GTPase Rho, however hey also bind to other 
extracellular matrix molecules such as laminin and tenascin, masking their 
growth-promoting properties [259, 260]; 
− As with inflammation, the experimental ablation of the glial scar in animal 
models of SCI has shown that this structure plays a dual role in the pathology 
(Fig. 5.4)	[261]. The enzymatic removal of scar-associated molecules has shown 
to lead to a restoration of post-synaptic activity and the promotion of functional 
recovery of locomotor and proprioceptive behaviours [262, 263]. Nevertheless, 
the manipulation of some the hallmarks for astrocyte reactivity, and thus glial 
scarring, have shown detrimental effects on locomotor recovery. The ablation of 
reactive astrocytes from the injury site during acute phase in a moderate 
contusion injury model showed increased tissue disruption, pronounced cellular 
degeneration, and worsened motor deficits [9]. Moreover, (STAT3-CKO)  mice, 
i.e. presenting conditional deletion of STAT3 from astrocytes, showed similar 
results with marked widespread inflammation, demyelination and neural 
disruption, increased lesion volume, and attenuated motor recovery [91, 92]. 
Thus, these evidences emphasize the dichotomous functions of reactive 
astrocytes, during the early phase of the injury they can preserve and protect the 
tissue from spreading of the damage, while a persisting presence of glial scar in 
the chronic phase can inhibit the axonal regrowth and neuronal survival [261]. 
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Figure 5.4: Representation of the roles of the glial scar in the development of SCI. Green boxes and 
arrows show the beneficial effects of the scar tissue, red box show the harmful growth-inhibitory 
properties of the scar tissue on axon regrowth in the chronic phases of the repair process. Adopted from 
Rolls, et al.[261]. 
 
 
 
Animal models have been developed in order to mimic the aspects that characterise the 
different types of human SCI. The use of animals has facilitated a deeper understanding 
of the anatomical, biological, and functional consequences of the injury [264] and, in 
fact, great advances have been made in the comprehension of the cellular and molecular 
reactions involved in acute and chronic SCI. Animal models can also offer advantages 
over clinical observations, especially for testing new therapeutic approaches, in that 
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they are characterised by reproducibility, relatively low-costs allowing for the 
employment of large numbers of deep histological and molecular analyses [265], and 
they lend themselves to standardized functional outcomes [266].  
 
The choice and the design of models is usually dictated by the following characteristics: 
similarities to clinical conditions, reproducibility and reliability, and the desire for the 
use of a simple technique [267]. Certainly, rodents are the most common models 
employed in SCI research. Indeed, compared to other species they more readily allow 
for the generation of a reproducible injury model, one of the more crucial points for 
screening therapeutic approaches and treatments; the rapid availability of mice and rats 
of specified age, weight and sex, combined with the relative low cost and ease-of-care 
(a distinct advantage for chronic studies), have also increased their value for SCI. For 
these reasons a vast array of SCI-induction techniques have been modified to their size 
[268]. 
 
Despite their universal adoption, rodent models present some limits for translational 
applications, such as the substantial difference in size of the spinal cord compared to 
humans [269]. Indeed, most studies that aim to investigate potentially regenerative 
approaches targeting axons deal with very small distances in the rodent spinal cords, 
typically millimetres, while longer fiber distances are instead required to reinnervate 
injured areas in humans [270]. Another important limit of rodent models is represented 
by corticospinal tract (CST) organization. CST location, as result of evolution, differs 
between species and these differences are also reflected in the responses to SCI, since 
CST damage does not completely compromise stepping in rodents [271, 272]. 
 
As mentioned above, human SCI can be classified in different categories and so animal 
models aimed to mimic the pathology of these SCI are likewise categorised: 
 
• Contusion: contusion and compression are the most common injuries in human. 
For recapitulation in animal models, a controlled weight-drop contusion model 
was developed by Allen in 1911. This device is based on the kinetic energy 
released when a set weight falls from a measured height onto the exposed 
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surface of the spinal cord, resulting in compression and displacement of the 
tissue [273]. Different types of injuries (mild, moderate or severe) are obtained 
by changing the combination of weight and height. The major advantage of this 
model relies in the close similarity between pathology developed in the most 
common animal models, such as rodents, and human pathology. In fact, starting 
from the acute stage arising from the first initial mechanical damage, secondary 
reactions develop into chronic stage comparable to that observed in human SCI 
patients in the chronic stage. The original impact device has been improved 
during recent decades and various models has been developed, nowadays the 
most commonly used device is the Infinite Horizon (IH) impactor; it is based on 
a force-controlled impact, in which a sensor measures the force inflicted to the 
tissue and, when the established force is reached, a stepping motor automatically 
and immediately withdraws the tip. This excludes the weight-bounce 
phenomena, and consequently the introduction of errors encountered with the 
other devices [274]. Similar in nature to the IH impactor, the Ohio State 
University (OSU) impactor is a computer feedback-controlled electromagnetic 
impactor. 
 
• Compression: this model resembles the contusion as both apply a pressure on 
the spinal cord, however this model allows prolonged compression of the cord, 
mimicking the residual compression after column displacement observed in 
patients. Compression can be obtained by using clips, calibrated forceps or 
balloon compression	[275]. 
 
• Transection: this model consists of complete or partial transection of the spinal 
cord performed with spring scissors, making it a suitable and reproducible 
model for evaluation of the effectiveness of interventions aimed at axonal 
regeneration, tissue engineering, plasticity or implantation of specific devices, 
therefore for assessment of axonal regeneration and subsequent functional 
recovery [276, 277], although spinal cord transections are not common in 
clinical settings. 
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• Photochemical: photochemical injury is based on the reaction between a 
photosensitive dye with light source, resulting in the production of singlet 
oxygen molecules on the spinal cord vessel surface and subsequent ischemia in 
the tissue. This model technique may provide an appropriate milieu to better 
understand the aspects of the vexing problem of post-traumatic syringomyelia in 
the human [278]. 
 
• Excitotoxic model: this model is obtained with intraspinal or intrathecal 
injection of some excitotoxins, such as quisqualic acid or other amino acids 
[278]. The employment of chemicals is aimed to mimic a specific aspect of the 
secondary injury cascade in traumatic SCI, their investigation and the effect of 
various therapies on specific pathways. 
 
• Canal stenosis: canal stenosis is obtained by compression of the cauda equina 
and/or lumbar nerve roots and models a clinical problem derived from 
impairment of walking [278]. 
 
It is important to remember that both species and models for SCI are relevant for the 
design of an experimental study, in particular the type of the approach and the potential 
therapeutic interventions (aim of the study) are the most relevant and essential factors 
that should influence the choice of a model. The correct choice of a model could 
improve the translational value of a treatment, whereas the non-appropriate model could 
underestimate the potential of a treatment or lead to negative results when translating 
into humans [267].  
 
 
5.2 THERAPEUTIC APPROACHES FOR SCI 
The first intervention for SCI patients consists of early spinal decompression and 
stabilization surgery [279], with subsequent therapeutic approaches being divided into 
neuroprotective or neuroregenerative treatments. Neuroprotective therapies aim to 
interfere with or prevent the progression of the secondary injury, while 
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neuroregenerative therapies aim to repair neuronal circuitry of the spinal cord [234]. 
However, due to the complexity of the pathology, a combination of multiple therapeutic 
modalities (Fig. 5.5) should be considered, including: (i) limiting secondary damage by 
surgery, (ii) re-myelination of axons or replacement of oligodendrocytes, (iii) 
elimination of inhibitory factors, (iv) enhancement and support of neuronal growth and 
axonal regeneration by delivering neurotrophins or growth factors, (v) employing cell 
grafts as a replacement approach and as a source for creating bridges, (vi) implanting 
biomaterials to create bridges, and finally, (vii) the removal of dead cells [227]. 
 
Figure 5.5: Schematic representation of different therapeutic strategies in conjunction with the 
progression of the spinal cord injury pathology. Modified from Kabu et al. [280]. 	
Therapies focused on preventing the progression of the secondary injury target 
mechanisms such as apoptosis, oxidative stress or inflammation. For instance, 
immunomodulatory therapies aim to modulate the inflammatory response to SCI, an 
extremely complex phenomenon that has been shown to have both beneficial and 
detrimental roles in the recovery process [281]. Clinically, the glucocorticoid 
methylprednisolone (MP) was thought to yield neuroprotection by suppressing 
secondary inflammation and lipid peroxidation, however its safety and efficacy for 
acute SCI is controversial [282-284]. In fact, beneficial effects depend on the type of 
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injury and the time of intervention (3-8 hours after injury), with prolonged or delayed 
treatment, or treatment applied in penetrating SCI having been shown to be detrimental 
[283]. The employment of the glycolytic enzyme chrondroitinase ABC (ChABC) to 
degrade the CSPG inhibitory activity in the glial scar has shown significant restoration 
of neuronal regeneration and plasticity in both small and large animal models [262, 
285]. In fact, ChABC gene therapy led to significantly reduced secondary injury and 
showed immunomodulatory properties through the modulation of macrophage 
phenotype towards the anti-inflammatory M2 polarisation [286]. However, ChABC has 
different disadvantages as clinical treatment: a single injection is insufficient since 
CSPGs are continuously synthetized and it ChABC has a short functional half-life, and 
also it is a biological product (synthesised by the bacterium Proteus vulgaris) and so 
repeated injections could induce a potential immune reaction [287]. 
 
One of the most attractive approaches for translational medicine and clinical trials in 
SCI research is cellular transplantation. Indeed, cellular transplantation aims to bridge 
cysts or cavities at the injury site, replace dead cells (such as neurons or myelinating 
cells), and create a more amenable environment for axon regeneration [8, 280]. 
Amongst the different cell types that can be transplanted in order to promote recovery, 
stem cell-based therapy is one of the most promising treatments, although some 
concerns arise about potential side effects and safety, including potential immunological 
rejection or tumour formation, as well as ethical issues regarding the acquisition of the 
cells [288]. 
 
One promising cell candidate is neural stem/precursor cells (NPCs): multipotent cells 
capable of self-renewal, readily expandable in vitro, and committed to the neural 
lineage. During recent decades it has been shown that both fetal and adult brains contain 
NPCs [50, 289], with the cells residing within specific niches – the subventricular zone 
lining the lateral ventricles of the forebrain	[52], the dentate gyrus of the hippocampus 
[55], and the periventricular region of the spinal cord [48]. Reynolds and Weiss 
demonstrated for the first time the possibility to isolate neural stem cells from the adult 
mouse brain and their culture protocol, now widely used, is known as the neurosphere 
assay. Neurospheres are obtained by culturing NPCs in a chemically defined serum-free 
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medium enriched with specific mitogenic growth factors, such as epidermal growth 
factor (EGF) and FGF2 [290].  
 
A systematic review published in 2011 summarized the application of NPCs as a 
treatment for SCI, both in mice and rats. These studies showed that significant clinical 
improvements could be attained upon transplantation, even though in some of these 
studies co-treatments were applied, such as myelin vaccination or infusion of trophic 
factors cocktails [291-294]. Indeed, our current interest in stem cell transplantation 
arose from remarkable outcomes observed in sub-acute transplantation of NPCs into a 
murine model of moderate contusive SCI. A number of noteworthy outcomes were 
observed including a survival capacity in vivo of up to 2 months after transplantation, 
the localisation of transplanted NPCs to clusters in very close proximity to 
macrophage/microglial cells and blood vessels, highly reminiscent of the ‘atypical 
ectopic perivascular niche-like areas’, as previously described [22, 295, 296], and the 
ability of transplanted NPCs to significantly skew the polarisation of inflammatory 
infiltrates of the injured spinal cord segment towards a tissue remodelling/repair (M2-
like) phenotype leading to the promotion of tissue healing [26]. Interestingly, it has also 
been shown that transplanted undifferentiated NPCs exert a long-term bystander effect. 
Studies in rodents and non-human primates with experimental autoimmune 
encephalomyelitis (EAE, an experimental model of multiple sclerosis) demonstrate the 
accumulation of systemically injected NPCs around the perivascular space in the 
proximity of reactive astrocytes, inflamed endothelial cells and blood-borne infiltrating 
T cells [22, 297, 298]. These areas, called ‘CNS atypical ectopic niches’, display a 
molecular cross talk between the different constituents of the atypical niche where 
undifferentiated stem cells promote neuroprotection by in situ release of 
immunomodulatory molecules and neurotrophic factors [228]  
 
Therefore, NPCs constitute an attractive option for transplantation because they can be 
readily expanded and are committed along the neural lineage; however, transplanted 
embryonic stem cell-derived neural cells may give rise to ethical issues for the use of 
these cells,	as	well	as	immunocompatibility concerns and accessibility limitations [291, 
299]. These limits have been overcome by the generation of induced pluripotent stem 
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cells (iPSCs); through the administration of four key transcription factors mature 
somatic cells can be reprogrammed into pluripotent stem cells that in turn can be 
differentiate into neural-lineage cells [300]. Other new and alternative methods have 
been developed for reprogramming, such as zinc-finger nucleases (ZFN), transcription 
activator-like effector nucleases (TALENs) and the CRISPR–Cas9 system	[301]. 
However, iPSCs do present some limits, such as the possibility of tumorigenesis upon 
transplantation [302], and, although this issue is often understated, individual iPSC lines 
may show variability in their potential to differentiate into functional cells of a given 
lineage [301]. 
 
 
5.3 INDUCED NEURAL STEM CELLS (INSCS) 
 
Advances in iPSC methods led to new approaches allowing for the generation of 
neurons by direct induction of fully mature neurons from somatic cells by using forced 
expression of various key neuronal transcription factors [303, 304]. The major 
advantage of this technology is the more rapid and easy induction of the neuronal 
phenotype compared to iPSC generation. However, these techniques showed some 
disadvantages, especially for clinical applications, such as the limited rate of expansion 
of these derived cells. Therefore, new induction processes have to be started for every 
experiment and mature-differentiated cells are more difficult to transplant due to their 
increased sensitivity to manipulation [305]. To overcome these limitations, an 
alternative approach has been developed to derive induced neural stem cells (iNSCs) 
from somatic cells as an expandable cell type, retaining the potential to differentiate into 
all neuroectodermal lineages. This novel approach is based on a combination of various 
key fate-determining transcription factors and has shown success in generating stable 
and expandable iNSCs from somatic cells which exhibit the major properties of primary 
NSCs [6, 306]. 
Indeed, it has been demonstrated that it is possible to obtain stably expandable NSCs, 
forming neurosphere-like clusters, from fibroblasts through a curtailed version of 
reprogramming toward pluripotency. The innovation of this protocol resides in the 
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limited induction (up to 5 days) of the expression of Oct4 (which would rather favour 
iPSC induction), based on the observation that NSCs endogenously express a subset of 
iPSC reprogramming factors, namely transcription factors Sox2 (Sry-box containing 
gene 2), Klf4 (Krüppel-like factor 4), and c-Myc, but not Oct4	(Pou5f1 - POU domain, 
class 5, transcription factor 1) (Fig. 5.6). iNSCs exhibit similar morphological and 
molecular features of NSCs such as the expression of Nestin, Olig2 (oligodendrocyte 
transcription factor 2), Sox2, Blbp (brain lipid binding protein), and Pax6 (paired box 6) 
(Fig. 5.6), and all the three transgenes employed were determined to be silenced in all 
iNSC-derived lines analyzed, confirming that a stable conversion had been achieved.  
Concomitantly, endogenous Sox2 has been shown to be upregulated in iNSCs, 
demonstrating that self-renewal capability of iNSCs is not dependent on sustained 
transgene expression, but triggered by activation of the intrinsic NSC transcriptional 
program. Furthermore, when exposed to appropriate culture media, iNSCs showed the 
capability to differentiate into the three main neural lineages: astrocytes, 
oligodendrocytes and neurons [6]. 	
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Figure 5.6: A, Schematic representation of the experimental protocol to derive induced neural stem cells 
(iNSCs). B, Phase contrast micrograph of neurosphere-like colony at day 25 and axonal structures 
processing out of the sphere. C, Immunofluorescence analysis using a specific antibody directed against 
the neuronal marker b-III-tubulin performed on neurosphere-like colony at day 27. F, A phase contrast 
micrograph of iNSCs. Immunofluorescence analysis of the NSC marker proteins in iNSCs: Nestin and 
Olig2 (G), Sox2 and BLBP (H), and mesenchymal marker Vimentin (I). J and K: Phase contrast pictures 
of iNSCs in neurosphere propagation medium at passage 5 (J) and 31 (K). L and M: iNSCs at passage 12 
(L) and passage 31 (M) were stained for NSC markers Nestin and Pax6. Modified from Thier et al. [6]. 
 
Therefore, considering the promising results obtained from NSCs transplantation in SCI 
models, and the translational potential inherent to iNSCs as a potential source for 
autologous transplantation, our aim is to assess the therapeutic potentiality of sub-acute 
iNSC transplantation in a murine contusion model of SCI. In particular, with the overall 
aim of a combined approached using reactive astrocyte-ameliorating pRNA-3WJs 
nanotherapeutics and stem cells, our first goal is to verify the potential of iNSC 
transplantation compared to the already well-characterized NSC approach. 
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5.4 RESULTS 
 
5.4.1 TRANSPLANTATION IN A MURINE MODEL OF CONTUSIVE SPINAL 
CORD INJURY  
The therapeutic potential of sub-acute transplantation of iNSCs was assessed in a 
moderate contusive model of SCI, 70 kDyne (IH Horizon impactor), applied in a total 
of n = 55 C57Bl/6 mice at day 0. Locomotor activity of SCI mice was assessed at day 1, 
3 and 5 by using the Basso Mouse Scale (BMS) score in the open field arena; SCI mice 
presenting an abnormal (asymmetric) BMS score (10/55; 18.2 %) were excluded from 
further studies, in line with previously described methods [27], while 4 mice were 
excluded based on the force/displacement outcomes from initial impactor treatment 
(force above 75 kDyne, displacement above 900 µm). Deficits in bladder functions, 
such as cystitis or inflammation of the bladder, are common in both human SCI and 
rodent SCI models	[307]; in our experiments 5 mice were sacrificed due to bladder 
infections. 
 
7 days after SCI, mice were randomized into a total of three different treatment groups 
based on individual BMS scores assessed on the same day: 
• Control group - PBS group: SCI mice received sterile PBS 1X at 7 days post 
injury (dpi) in a total of n = 4 injection sites (250 nl/site) bilaterally from 
midline at both the anterior aspect of T13 and the posterior aspect of T11 (fig. 
5.7)  (n = 4 for 28 days post transplantation (dpt) evaluation; n = 9 for 49 dpt 
evaluation);  
• NPCs group: SCI mice received single cell-dissociated 150 x 103 farnesylated-
GFP+-NPCs at 7 dpi in a total of n = 4 injection sites (250 nl/site), as described 
above (n = 6 for 49 dpt evaluation);  
• iNSCs group: SCI mice received single cell-dissociated 150 x 103 farnesylated-
GFP+-iNSCs at 7 dpi in a total of n = 4 injection sites (250 nl/site), as described 
above (n = 3 for 28 dpt evaluation; n = 10 for 49 dpt evaluation). 
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Figure 5.7: Schematic representation of the transplantation setup. 4 injections were performed bilaterally 
from midline at both the anterior aspect of T13 and the posterior aspect of T11, 250 nl/injection, a total of 
150 x 103 farnesylated-GFP+ NPCs/ iNSCs were injected.
 
 
 
Functional performances were then tested 1 and 3 days after transplantation, and then 
weekly for the entire duration of the experiment by using BMS score and, upon 
reaching a BMS score of 5, BMS subscores. Mechanical allodynia was tested weekly by 
using Von Frey testing on the hind limbs; the lowest filament associated with an 
animal’s withdrawal was assigned as a threshold the day before the injury. Thermal 
nociception was assessed weekly by using Hargreaves’ method on the hind limbs, 
withdrawal response observed the day before the injury was assigned as the threshold. 
 
Tissue samples obtained 35 dpi (28 days after transplantation) and 56 dpi (49 days after 
transplantation) were analysed for preliminary data on the localisation and survival of 
transplanted cells. 
 
The evaluation of hind limb-locomotor recovery by using BMS scores for the 
transplanted groups, both NPCs and iNSCs, did not reveal any significant differences 
compared to control group (Figure 5.8).  
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Figure 5.8: BMS score evaluation of the three different SCI treatment groups. No statistically significant 
differences were observed. N = 9 PBS group; n = 6 NPC group; n = 9 iNSC group (mean ± SEM). Two-
way ANOVA and Bonferroni post-hoc test, p < 0.05. dpt = days post transplantation. 
 
 
However, significant spontaneous recovery occurs in moderate injury and the use of the 
BMS scale, a gross evaluation of locomotion, may not allow one to appreciate the 
recovery in more fine locomotor capabilities. For this reason, we also performed BMS 
subscore analyses on mice that reached a 5/9 score with BMS (Figure 5.9). The small 
number of subjects for each group only allowed us to observe a trend in the 
improvement of NPC and iNSC-treated groups compared to the control group (Figure 
5.10). 
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Figure 5.9: Representative images of BMS appraisal. BMS subscore was evaluated as previously 
described by [27]. Mouse belonging to PBS group in A, NPC group in B. Paw position is evaluated by 
the orientation of the middle digits of the paw (blue line) compared to the long axis of the body (white 
line).  
 
 
 
Figure 5.10: BMS subscore evaluation of the three different SCI treatment groups. No statistically 
significant differences were observed. n = 9 PBS group; n = 6 NPC group; n = 9 iNSC group (mean ± 
SEM). Two-way ANOVA and Bonferroni post-hoc test, p<0,05. dpt = days post transplantation. 
 
 
5.4.2 MECHANICAL ALLODYNIA AND THERMAL STIMULUS TEST 
ASSESSMENTS 
 
In order to evaluate the possibility of development of hind limb allodynia upon 
transplantation or an increased sensitivity to noxious thermal stimulus applied to the 
hind limbs, Von Frey hair test and Hargreaves' test were assessed the day before the 
surgeries in order to establish a threshold for each mouse, and then weekly for the entire 
duration of the experiment. 
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Von Frey’s hair test was applied to the hind limbs following the up and down approach, 
as previously described [28]. Transplantation of both NPCs and iNSCs did not show 
any decrease in the threshold of response to mechanical allodynia or statistically 
significant differences between groups (Figure 5.11). 
 
  
Figure 5.11: von Frey analysis of mechanical allodynia in the hind limbs. Data are normalized to the 
threshold measured the day before the spinal cord injury surgeries (mean±SEM). Two-way ANOVA and 
Bonferroni post-hoc test, p < 0.05. dpi = days post injury. 
 
 
 
The Hargreaves method measures cutaneous pain thresholds in rodents [308]. Pain 
thresholds are evaluated as hind limb withdrawal latencies from a painful stimulus, a 
standard baseline temperature applied to the skin in unrestrained rodents. As observed 
with the Von Frey test, no induction in pain sensitivity was recorded upon 
transplantation in both NPC and iNSC-transplantation groups, with no statistically 
significant differences between groups (Figure 5.12). 
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Figure 5.12: Hargreaves’ method for thermal pain sensitivity in the hind limbs. Data are normalized to 
the threshold measured the day before the spinal cord injury surgeries (mean ± SEM). Two-way ANOVA 
and Bonferroni post-hoc test, p < 0.05. dpi = days post injury. 
 
 
 
5.4.3 CELL SURVIVAL AND MIGRATION EVALUATION 
 
To investigate the survival of transplanted cells, mice from iNSCs were sacrificed 4 and 
7 weeks after transplantation. We observed successful cell engraftment in all 
transplanted mice; specifically, quantification at 4 weeks (n = 3) revealed the presence 
of an absolute number of 2057.67 ± 357.39 GFP+-engrafted iNSCs (Fig 5.15), 
decreasing to an average of 350.83 ± 78.32 at 7 weeks after transplantation (n = 6), 
corresponding to a percentage of surviving cells on the total number of transplanted 
cells of 5.23 ± 1.34 % and 1.94 ± 0.43 %, respectively (Fig. 5.13). Nevertheless, limited 
graft survival has previously been reported in SCI models, with less than 10% of grafted 
NPCs usually observed upon transplantation [26]. Further evaluations are being 
assessed to compare iNSC and NPC survival upon transplantation. 
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	 	Figure 5.13: Preliminary evaluation of survival percentage of grafted iNSCs. Percentage of surviving 
cells decreased during over time reaching a percentage of 1.94% of the total amount of transplanted cells 
that survive in the host parenchyma at 7 weeks after transplantation (mean ± SEM). 	
 
Additionally, we estimated the migration capabilities of transplanted iNSCs into the 
parenchyma. It has been shown that transplanted cells migrate both toward rostral and 
caudal direction [26, 309], and while we found that transplanted cells did not migrate 
extensively, we did observed an increased accumulation of cells around the lesion site 7 
weeks after transplantation (Figure 5.14). 
 
 
Figure 5.14: Evaluation of migrational properties of GFP+-transplanted iNSCs 4 weeks (A) and 7 weeks 
(B) after transplantation. Percentage of grafted-cells are represented (± SEM). 
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Figure 5.15: representative image of grafted-GFP+ iNSCs 28 dpt. Coronal section of spinal cord, 30 µm 
thickness. DAPI is represented in blue, GFP in green. Scale bar = 50 µm. 
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5.5 DISCUSSION 
 
Spinal cord injuries (SCI) are highly debilitating pathologies characterized by an initial 
mechanical insult that is subsequently exacerbated by secondary damages such as 
inflammatory responses, continuous cell death, demyelination, Wallerian degeneration, 
astrogliosis and glial scarring [235].   
 
Despite the observation that spontaneous repair of neural environment may occur in 
patients affected by acute and/or chronic inflammatory and degenerative disorders of 
the nervous system, including SCI patients, this process is usually not sufficient to 
promote a functional and stable recovery of the highly compromised nervous system 
architecture [1]. Among a number of innovative therapeutics aiming at CNS repair 
and/or regeneration, cell-based therapies represent the most promising approaches. In 
particular, stem cell-based therapies have shown remarkable evidences in their 
capability to protect the CNS from chronic inflammation-driven degeneration, such as 
that occurring in EAE/MS, stroke and SCI. Interestingly, it has been demonstrated that 
non-hematopoietic somatic stem cells, such as NPCs, can promote the protection of the 
damaged nervous system through mechanisms other than cell replacement	[228]. 
Evidences from transplanted NPCs in immune-mediated experimental demyelination 
and stroke showed the capability of transplanted cells to mediate efficient bystander 
myelin repair and axonal protection/rescue [22, 26, 297, 298]. A new concept has been 
therefore proposed to describe the capability of NPCs to adapt fate and functions to 
specific microenvironments, named therapeutic plasticity [310]. Several studies have 
shown that transplantation of NPCs in SCI rodent models resulted in a functional 
integration of transplanted cells into the host perilesional cord tissue, differentiation into 
oligodendrocytes, and improvement in locomotor recovery [7, 26, 291, 309]. Moreover, 
sub-acute transplantation with NPCs showed a reduced volume of the lesion site, 
decreased volume of macrophage/microglial infiltration at lesion site, and decreased 
volumes of demyelination, compared to controls, suggesting that delayed (sub acute) 
NPC transplantation may significantly interfere with the development of main 
secondary events after SCIs [26]. Additionally, the route of cell administration may 
impact on the therapeutic outcome. Direct intraparechymal injection represents is one of 
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the most used route of cellular transplantation in animal models of SCI. This invasive 
method allows, through direct access to the site of injury via laminectomy, multiple 
injections into the injury epicentre and/or into the parenchyma adjacent to the injury [7, 
26]. Despite the invasiveness of this technique, augmenting the risk of causing further 
trauma to the injured tissue during surgery, some clinical trials showed promising 
outcomes with no remarkable complications [311, 312].  
 
While NPCs have elicited promising results, the last few decades have seen the 
development of novel technologies for the generation of iPSCs, leading to the 
possibility of an easily accessible cell source, such as the skin, and the possibility of 
autologous transplantation [305]. In this regard, iNSCs represent an even more 
promising technology, with the direct reprogramming of skin fibroblasts into neural 
precursor cells being faster compared to iPSC technology and involving less 
manipulation and therefore less chance to develop teratomas [305]. The use of 
constitutively expressed Yamanaka factors (Sox2, Klf4, and c-Myc) [300] and a 
regulated expression of Oct4 that reduces the induction of pluripotency, has allowed for 
the possibility of generating a stably expandable (more than 50 passages) iNSCs which 
ultimately can be induced to efficiently differentiate into cells of each of the neural 
lineages [6]. 
 
Therefore, considering the remarkable therapeutic potential of iNSCs, we are aiming to 
characterize their capability of exerting beneficial roles upon transplantation compared 
to the well-described effects of NPCs. For this purpose, we employed a moderate 
contusive model of SCI; due to their similarity to the majority of human injuries, and 
the great incidence of this type of injury in humans, contusion and compression models 
are the most employed animal models of SCI [313].  
 
Preliminary data showed no differences in the BMS scores between a PBS-injected 
control group and transplanted groups, either with NPCs or iNSCs. In explaining this 
apparent non-outcome, it is important to remember that evidence shows that motor and 
locomotor-like movements are observed in the hind limbs of even complete paraplegic 
mice without intervention, i.e. as spontaneous regeneration. Mice subject to complete 
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spinal cord transection showed signs of locomotor activity [314], as was previously 
observed in adult cat [315]. Cellular mechanisms responsible for the motor and 
locomotor-like recovery in complete spinal animals remain largely unknown. The 
progressive return of hind limb movements over time observed in complete spinal 
transection animals could be attributed to time-dependent plastic changes in networks of 
the lumbo-sacral spinal cord that can generate walking in the absence of supraspinal 
input (i.e. central pattern generators) [316].  
 
CST organization represents another limit to rodent models. CST is characterized by a 
main common function conserved through species, the cortical modulation of spinal 
cord activity, although it performs also other functions, such as descending control of 
afferent inputs, selection, gating and gain control of spinal reflexes, direct and indirect 
excitation of motoneurons, inhibition of motoneurons, autonomic control and long-term 
plasticity of spinal cord circuits. It is deducible how evolutionary changes have lead to 
remarkable differences. In fact, in human and primate the CST has increased in the size 
of the neocortex and consequently in the amount of the neocortex giving rise to the CST	
[271]. Therefore, the CST location, as a result of evolution, differs between species: in 
rodents, the CST projects mainly in the dorsal horn neurons and premotor spinal 
circuits, whereas human and non-human primate CST projects mainly to ventral horn, 
with soma axons creating direct synapses into motor neurons, in particular axons 
innervating hand muscles [270]. Differences in location are also reflected in the 
responses to SCI, CST damage does not completely compromise stepping in rodents, 
underlying the importance of other nervous pathways, such as the rubrospinal tract 
[271]. Therefore, the considerable spontaneous recovery observed in control mice may 
mask some effects of treatments, even though these still represent preliminary data and 
number of employed mice has to be increased to be relevant. 
 
Finally, BMS evaluation, as adaptation of the Basso Beattie Bresnahan (BBB) score for 
rats, represents a gross measurement of locomotor functions, lacking the specificity and 
sensitivity for the detection of smaller and finer changes in motor behaviour	[317]. For 
this reason, a more detailed scale was introduced, called BMS subscore, that evaluates 
improvements in stepping frequency, coordination, paw position, trunk stability, and tail 
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position. A cumulative score can be calculated over time to discriminate differences in 
the fine details of locomotion that BMS score may not reveal. In addition, each attribute 
of the subscore, such as paw position, can be used to compare different groups as 
individual locomotor features [27]. We therefore applied BMS subscore on mice that 
reached a score of 5 on the BMS scale (i.e frequent or consistent plantar stepping, no 
coordination -OR- frequent or consistent plantar stepping, some coordination, paws 
rotated at initial contact and lift off (R/R)) and we observed a trend in the improvement 
of fine locomotor capabilities of transplanted groups compared to control group. 
Nevertheless, these are still preliminary data and the number of subjects for each group 
has to be increased in order to evaluate effects from transplantation and to attain 
statistically significant results. We are aiming to improve the assessment of accuracy, 
and therefore the evaluation of proper connections between functional sensory and 
motor systems, by using foot slip test through horizontal ladder walking test on which 
animal can walk along variable rung spacing [318].  
Cell transplantation may lead to the development of allodynia, defined as hyperalgesic 
responses to normally innocuous stimuli, due to nociceptive fiber sprouting in the dorsal 
horn regions rostral to the injury site or associated to astrocytic differentiation of grafted 
NSPCs as observed in SCI rodents [319, 320]. Von Frey hair test was assessed weekly 
after injury and after transplantation by applying up and down approach as previously 
described [28]; animals transplanted with either NPCs or iNSCs did not show any signs 
of allodynia, confirming the safety of grafted cells in this sense. To further confirm 
these results, thermal nociception was assessed by Hargreaves’ test, by measuring 
withdrawal latency following thermal stimulation to the paw, allowing the measuring of 
cutaneous pain thresholds [308, 321]. Transplantation of NPCs or iNSCs did not induce 
any hyperalgesia in the present study. 
Another important result to be assessed upon transplantation are represented by the 
survival rate of cells upon transplantation. Subacute transplantations have been shown 
to be more effective rather than acute or chronic; in fact inflammatory responses 
immediately after injury create a cytotoxic environment, unfavourable for NPC 
transplantation. On the contrary, during the subacute phase (1 to 2 weeks post-injury) 
the inflammatory response is reduced and the glial scar is starting to form, therefore 
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NPC transplantation has the potential to modulate the development of secondary injury 
mechanisms [288, 322]. However, poor graft survival after NPC transplantation has 
been reported in SCI models, with usually less than 10% of grafted NPCs surviving [26, 
323, 324]. Preliminary data upon local transplantation of iNSCs showed similar results 
as previously seen for NPCs: 4 weeks after transplantation 5.54 ± 0.94 % of 
transplanted cells survived in the host environment, while 7 weeks after transplantation 
only 1.94 ± 0.43 % survived, in line with evidence from the literature. Further 
quantifications are being assessed to characterize better comparisons between NPCs and 
iNSCs transplantation, as well as the differentiation of grafted cells. 
Finally, the injured microenvironment could alter both the engraftment dynamics and 
the availability of differentiation cues since it is well-known that niches provide 
extrinsic cues that influence many aspects of stem cell biology [325, 326]. Therefore, 
the damaged environment may influence both the fate and migration of transplanted 
cells. Previous evidences showed a great migratory capability of NPCs upon 
transplantation, in particular grafted-cells migrate both in the rostral and caudal portion 
of the injured spinal cord [26], however they also migrate toward the lesion site 
surrounding it [326, 327]. In the present experiment we saw negligible iNSC migration 
from the injection site at 4 weeks post-transplantation, however we did observe a 
migration towards the lesion site at 7 weeks.  
Although these represent preliminary data, transplantation of iNSCs retains the potential 
to ameliorate the hostile injured environment upon SCI. Improvement in fine locomotor 
capabilities may suggest a modulation of the secondary mechanism involved in the 
pathology that further investigations are aimed at elucidating, such as a reduction in 
lesion volume, promotion of remyelination or modulation of inflammatory response. 
Ultimately, iNSCs have a greater latent translational value compared to the most 
commonly used NPCs, since their employment may overcome the ethical and practical 
barrier to translation faced in using fetal NSCs or the teratogenic potential of autologous 
induced pluripotent stem cells (iPSCs). 
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6) CONCLUSIONS 
 
 
Spinal cord injury (SCI) is a highly debilitating pathology characterized by different 
mechanisms that take part in the worsening of the pathology [1]. Of particular interest is 
the role of reactive astrocytes in SCI as, in recent decades, their dual role in the 
pathology has been unravelled: while they play a beneficial role in the acute stages by, 
for example, limiting the spreading of the inflammatory response, in the chronic phase 
they can exert inhibitory functions limiting axonal regeneration [256].  This 
dichotomous nature has led to controversial results in pre-clinical studies. Indeed, the 
ablation of canonical markers, i.e. the upregulation of GFAP and vimentin, in reactive 
astrocytes using transgenic mice has shown both a worsening of the pathology [9] and 
an increased axon regeneration [12] in different studies. Moreover, improvements in 
functional outcomes have been observed by the application of siRNA targeted against 
Gfap and vimentin in rodent models of SCI [14, 15]. siRNA technologies allow for the 
possibility of modulating the extent and timing of gene regulation, a subtler alternative 
to the knockout technique in which target mRNA/proteins, and thus the effects in which 
they play a role, are severely ablated [16]. Thus, the possibility of finely regulating the 
expression of target genes might be a promising approach for modulating reactive 
astrocytes in CNS disease since they have showed both beneficial and detrimental roles 
depending of the time window. For this reason, we envision that a time-specific 
modulation of this phenomenon may lead to remarkable beneficial outcomes: the 
presence of reactive astrocytes in the acute phase of the pathology might limit the 
spreading of secondary damages, such as the inflammatory response, preserving the 
spared tissue from further damage, while the modulation of astrocyte reactivity in the 
sub-acute phase might prevent the formation of the glial scar at later stages and 
consequently diminish the detrimental effects of astrogliosis. Nevertheless, astrogliosis 
is finely regulated by several mechanisms, and the identification of new therapeutic 
targets that modulate these different activities may lead to more efficacious treatments 
compared to the most classical markers, such as intermediate filament upregulation; 
hence the interest in targeting Lcn2. Lcn2 has been shown to play several functions in 
the CNS upon damage or infection, such as regulation of cell cycle and apoptosis in 
different cell types, it can also acts as cytokine in the promotion of the inflammatory 
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response, but more intriguingly it has been observed that Lcn2 is mainly secreted in 
reactive astrocytes in the CNS[82, 185]. Moreover, it has been shown that astrocyte-
secreted Lcn2 is able to perpetuate this reactive state in an autocrine manner [185]. 
Therefore, silencing of Lcn2 in the sub-acute phase may lead to a modulation of the 
inflammatory response and secondary damage upon SCI.  
 
Small interfering RNA (siRNA) holds great promise for targeted gene silencing in 
therapeutic applications and the advances in nanotechnology have allowed for the 
development of several nanomaterials, amongst which RNA nanotechnology is the 
highly promising [144, 145]. In fact, RNA-based technology possesses several 
advantages over other materials, such as structural and functional versatility and high 
stability in vivo [172]. In particular, 3WJ-pRNA showed a remarkable potential as a 
powerful therapeutic platform. 
 
Nevertheless, due to the complexity of SCI pathology, a single approach is unlikely to 
be sufficient for promoting recovery, whereas a combination of approaches may 
augment the therapeutic potential. Stem cell transplantation, having the capability of 
both influencing bystander mechanisms to promote regeneration in the CNS and the 
possibility of cell replacement by cell differentiation upon transplantation, make it one 
of the most promising approaches in SCI research. Furthermore, the development of 
innovative techniques for reprogramming somatic cells into neuronal precursors, such 
as iNSCs, paved the way for the possibility of autologous transplants. For these reasons, 
our ultimate goal is to employ 3WJ-pRNA nanotherapeutics targeting Lcn2 in order to 
modulate astrogliosis and increase the potential of subsequent iNSC transplantation in a 
murine model of moderate SCI. 
 
To screen the efficacy of our 3WJ-pRNA we first developed and optimised a 
differentiation protocol for in vitro differentiation of NPC-derived astrocytes. Thus, we 
showed the reproducibility of our protocol and homogeneity of our astrocyte cultures 
compared to the most commonly employed astrocyte-differentiation protocols or 
primary astrocyte cultures. Reproducibility and homogeneity are indeed essential 
aspects for studies that aim to assess the efficacy of compounds, since they avoid 
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variability between replicate that can finally lead to misleading interpretation of 
knockdown results. 3WJ-pRNA nanotherapeutics use, previously having shown great 
potential, primarily in cancer-therapeutic approaches	[210], showed non-cytotoxicity 
and non-immunogenic effects in this first study employing the technology in a CNS 
environment [211]. Moreover, we showed the efficacious knockdown of different 
astrogliosis-associated genes (Gfap, Vim and Lcn2), by significant reductions in their 
mRNA and protein expression using relatively small doses of siRNA-3WJ (5 nM). 
Furthermore, knockdown was target-specific without off-target effects. 
 
Gfap and Vim knockdown were employed herein as a proof of concept, while Lcn2 
knockdown has been investigated as a putative therapeutic target. Indeed, the 
knockdown of Lcn2 resulted in a concomitant decrease in the secretion of this 
neuroinflammatogen and greatly reduced the induction of pro-inflammatory genes in 
astrocytes exposed to astrocyte-conditioned media from activated donor astrocytes with 
or without treatment with Lcn2-3WJ, suggesting the important role of secreted Lcn2 to 
induce a pro-inflammatory phenotype in recipient astrocytes. These results therefore 
suggest the possibility to modulate astrocytic phenotype toward a less pro-inflammatory 
phenotype through RNA nanotechnology-mediated regulation of Lcn2. 
 
Before combining 3WJ-pRNA treatment and subacute transplantation of iNSCs we 
aimed to characterize engrafted iNSCs in a murine model of moderate SCI. Preliminary 
data showed the potential of transplanted cells to promote improvements in fine 
locomotor functions, without inducing any allodynia or nociceptive effects. Moreover, 
we observed the capability of cells to integrate into the host tissue, although only a 
limited percentage survived upon transplantation.  
 
In conclusion, based on the availability of a reliable in vitro model of astrocytes that we 
developed, we were able to assess the efficiency of 3WJ-pRNA in downregulating the 
expression of markers and propagators of astrogliosis. Additionally, preliminary data on 
iNSC transplantation suggests a potential role of grafted-cells in promoting recovery, 
with greater latent translational value over NPCs since their employment may overcome 
the ethical and practical barrier to translation faced in using fetal NPCs or the 
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teratogenic potential of autologous induced pluripotent stem cells (iPSCs). We therefore 
envision that RNA nanotechnology-mediated modulation of secondary mechanisms, 
such as astrogliosis, upon SCI may enhance the survival of iNSCs by favouring a more 
amenable environment for transplantation and integration, promoting cellular survival 
and leading to enhanced anatomical and functional recovery after SCI. 
 
 
6.1 FUTURE AIMS 
 
The 3WJ constructs that we employed in thus study was functionalised with siRNA, 
however a key characteristic of 3WJ-pRNA nanotechnology if the possibility to 
incorporate multiple different functionalities. Thus, future goals aim to 
multifunctionalization such constructs to optimise them for in vivo application. 
Chemical modifications will be included to enhance in vivo stability and promote 
intracellular delivery. Ultimately, our aim is to incorporate an astrocyte-specific 
aptamer in order to maximize the uptake by target cells and minimize off-target loss.  
 
Lcn2, a novel marker in CNS diseases, will be further investigated. The involvement of 
astrocyte-secreted Lcn2 in different mechanisms, such as in promotion of inflammatory 
response, will drive further investigations on its effect on microglia and macrophage 
polarization, influences that we attend to address by employing astrocyte-condition 
medium experiments. Astrocyte-conditioned medium transfer, as key experiment in 
revealing the capability of secreted Lcn2 to propagate detrimental effects, will be also 
employed to explore the effect of the secreted protein on neuronal fate, since Lcn2 may 
lead to neural death [199] and the capability of 3WJ-pRNA capability to revert this 
process will be then assessed.  
 
Modulation of Lcn2 expression will be assessed in vivo prior to cells transplantation in 
order to evaluate the beneficial role of Lcn2 downregulation in promoting regeneration, 
with a particular attention to the chronic phase of injury. Indeed, modulation of Lcn2 as 
pro-inflammatory actor in the central nervous system may also lead to an extended 
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therapeutic window for treatments of chronic phase, still the most challenging situation 
in SCI research.  
 
Transplanted iNSCs will be further characterized, by evaluation of fine locomotor 
movements by using different behavioural assessment, such as the use of horizontal 
ladder to discriminate the increased capability of controlling paw placement in 
transplanted mice compared to controls. Differentiation of grafted-iNSCs will be further 
evaluate as well as modulation of secondary mechanism upon SCI and transplantation, 
such as quantification of lesion volume, analysis of the peri-lesional inflammatory 
infiltrate and secondary tissue damage axons and myelin.  
Finally, combinations of 3WJ-pRNA nanotherapeutics and iNSCs transplantation, in 
different therapeutic time windows (chronic phase modulation represent an intriguing 
although challenging scenario), will be applied to our murine model of SCI to evaluate 
the therapeutic potential of this combinatorial approach.  
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